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Nasal polyposis (NP) is a chronic inflammatory airway disease, which represents 
severe infiltration of inflammatory cells (e.g. eosinophils and neutrophils), epithelial 
damage, and stromal edema. Although glucocorticosteroid (GC) treatment is effective 
in relieving NP inflammation, the high recurrence rate makes the etiology and 
pathogenesis of NP complicated. The results from our research group reported profiles 
of cellular infiltration in Asian NP. In this respect, this thesis focuses on the molecular 
mechanisms underlying the pathogenesis of Asian (especially Chinese) NP and its 
response to GC treatment. 
 
At first, we started to test the hypothesis of Staphylococcus aureus (S. aureus) and its 
superantigens in Asian NP. A low incidence rate of S. aureus was found in the studied 
NP and superantigens could not be found in all NP tissues, indicating no significant 
effects of S.aureus related superantigens in Asian NP.  
 
Secondly, we tried to find if some cancer related mechanism (methylation) would be 
involved in NP pathogenesis. This is based on the assumption that NP pathological 
features are somewhat similar to tumor growth, such as tissue hyperplasia and high 
recurrence rate. Although methylation of common tumor suppressor genes (TSGs) 
(CDH1, TSLC1, DAPK1, and PTPN6) was detected in NP, the frequency of gene 
methylation did not differ between NP and nasal mucosal controls, indicating the role 
of methylation of these TSGs appears to be minimal in NP. 
 
The first two studies came out with negative results which were not anticipated 
initially. For this reason, a systemic microarray analysis was used to identify novel 
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gene markers and molecular pathways which underlie the NP pathogenesis and its 
response to GC treatment. Two sets of NP biopsies, i.e., before the initiation and after 
oral GC treatment, were taken from the same patient with bilateral NP. The inferior 
turbinate from patients with nasal septal deviation served as a nasal mucosal control. 
All subjects were Chinese. Histological results demonstrated that GCs had potent 
effects on epithelial repair and suppression of eosinophils. Pathway analysis revealed 
that alteration of AP-1 network, anti-inflammatory gene network, apoptosis signaling, 
complement system, EGF/EGFR signaling, Leukotriene signaling, PGE2 signaling, 
ERK/MAPK signaling, IL-6 signaling, and NF-kappaB signaling would be involved 
in the NP pathogenesis. AP-1/AP-1 related genes and their interactive networks were 
considered to be the central molecular evidence for the epithelial healing effect by 
GCs. GCs also regulated the expression of several important pro-/anti-inflammatory 
genes (e.g., MMPs, DUSPs, and SPRYs) and then performed the anti-inflammatory 
effects to control the inflammatory responses in NP. In addition, eosinophil- and 
neutrophil-associated genes were reviewed in array data based on literature reports 
and they were able to differentiate eosinophilia and neutrophilia in nasal samples. The 
pathological features of NP were also attributed to the change of other genes/gene 
families in NP, such as oxidant/antioxidant related genes, edema related genes, and 
mucin genes. 
 
In conclusion, we demonstrate the molecular profiles underlying the beneficial effects 
of GCs on NP and the histopathological patterns of NP. Identification of these genes 
and gene networks ultimately contributes to the knowledge of NP pathogenesis and 
improvement of NP therapy. 
 
 xii
List of Tables 
Table 3.1 Primers for the detection of S.aureus related superantigens  
and nuc gene …………………………………………………………... 40 
Table 3.2 MSP and BGS primers ………………………………………………… 43 
Table 3.3 Identity for human Taqman Gene Expression Assays-On-Demand™ … 62 
Table 5.1 Patient clinical and histological characters (for Study Subject 1) …….. 76 
Table 5.2 Summary of TSGs methylation status (by MSP analysis)  
of different groups …………………………………………………….. 80 
Table 5.3 Correlation between CDH1 expression and methylation status of     
CDH1 in nasal tissues (both NP and IT) ………………………………. 83 
Table 6.1 Clinical and histological characteristics of NP patients and         
control (for Study Subject 2) …………………………………………... 90 
Table 6.2 Comparison of histopathological patterns between GC-naïve NP  
and control ……………………………………………………………... 92 
Table 6.3 Parameters for assessing assay performance …………………………... 99 
Table 6.4 Signficant GC-responsive genes in NP ………………………………… 107 
Table 6.5 Functional network analysis for GC-responsive genes ……………….... 119 
Table 6.6 Microarray expression profiles of eosinophil-associated genes in  
GC-naïve NP as compared to control …………………………………... 142 
Table 6.7 Microarray expression profiles of neutrophil associated genes in   
GC-naïve NP as compared to control …………………………………... 145 
Table 6.8 Comparisons of c-Jun immunohistochemistry in NP epithelium from GC 
naïve and GC treated subjects ………………………………………….. 153 
Table 6.9 Summary of functional network pathways in NP ………………………. 159 
 
 xiii
List of Figures 
Figure 1.1 Gross view of nasal polyps……………………………………………. 1 
Figure 1.2 Lateral wall of the nose ……………………………………………….. 5 
Figure 3.1 Flowchart of affymetrix gene chip experiment ………………………… 46 
Figure 4.1 PCR product of S.aureus specific nuc gene …………………………... 70 
Figure 4.2 Direct sequencing results of nuc gene ………………………………… 71 
Figure 5.1 Histological patterns of epithelium with squamous metaplasia ………. 78 
Figure 5.2 Representative samples of MSP analyses of DNA samples from          
NP, IT, and PBMC ……………………………………………………. 79 
Figure 5.3 Detailed methylation analysis in promoter of selected genes       
(PTPN6, DAPK1, TSLC1, and CDH1) by using BGS ………………... 81 
Figure 5.4 Immunohistochemical staining of CDH1 in NP samples ……………... 83 
Figure 5.5 Gross view of nasal polyps and nasal inverted papilloma …………….. 85 
Figure 6.1 Representative staining pictures of nasal tissues ………………............ 91 
Figure 6.2 Correlation between infiltration of eosinophils and neutrophils         
in nasal tissues (GC-naïve NP and control) …………………………... 92 
Figure 6.3 Flow chart for identification of GC-responsive genes and NP    
associated genes ……………………………………………………..... 95 
Figure 6.4 Gel electrophoresis of RNA samples ………………………………….. 97 
Figure 6.5 Gel electrophoresis of fragmented/unfragmented cRNA ……………… 98 
Figure 6.6 Visualization of array raw data ………………………………………... 101 
Figure 6.7 Chip pseudo-images of normalized array data …………………………103 
Figure 6.8 RLE and NUSE single summary plots of normalized array data ………104 
Figure 6.9 Overlapping genes in three datasets ……………………………………106 
Figure 6.10 Cluster pictures generated from the results of significance       
 xiv
analysis of microarrays (SAM) identified genes ……………………… 111 
Figure 6.11 Principal component analysis (PCA) plots generated from the results   
of significance analysis of microarrays (SAM) identified genes ………113 
Figure 6.12 Functional comparison among the datasets ………………………….. 117 
Figure 6.13 Network pathways of GC-responsive genes ………………………… 122 
Figure 6.14 Merged network of GC-responsive genes …………………………… 124 
Figure 6.15 Canonical pathways in NP …………………………………………… 127 
Figure 6.16 Cluster view of eosinophil associated genes in nasal tissues ………... 143 
Figure 6.17 Correlation of gene expression levels between Real-time RT PCR     
and microarray assays ………………………………………………… 148 
Figure 6.18 Relationship between mRNA level (by real-time PCR) of AP-1     
genes versus AP-1 related genes ……………………………………… 150 
Figure 6.19 Expression of c-Jun and c-Fos protein in nasal tissues ……………… 152 
Figure 6.20 Schematic diagram of AP-1 and AP-1 related genes in epithelial    
repair in NP after GC treatment ………………………………………. 179 
Figure 6.21 Schematic representation of the epithelial repair process as well       









List of Abbreviations 
AA arachidonic acid  
ADAM8 ADAM metallopeptidase domain 8 
AIF apoptosis-inducing factor 
ALOX5AP arachidonate 5-lipoxygenase-activating protein 
ANGPT1 angiopoietin 1 
ANGPT2 angiopoietin 2 
ANXA1 annexin A1 
AP-1 activation protein 1 
APCs antigen presenting cells 
AREG Amphiregulin 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 
BGS bisulfite genomic sequencing 
Bid BH3 interacting domain death agonist 
C1QB complement component 1, q subcomponent, B chain 
C3 complement component 3 
C4A complement component 4A  
CASP3 caspase 3 
CASP7 caspase 7 
CCL11 chemokine (C-C motif) ligand 11,(known as eotaxin) 
CCL15 chemokine (C-C motif) ligand 15 
CCL28 chemokine (C-C motif) ligand 28 
CCRs chemokine receptors 
CDH1 cadherin 1, type 1,(known as E-cadherin) 
CDKN2A cyclin-dependent kinase inhibitor 2A (known as p16) 
CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1 
CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 
CF cystic fibrosis 
CFH complement factor H, (known as HF1) 
c-Fos v-fos FBJ murine osteosarcoma viral oncogene homolog 
c-Jun jun oncogene 
CLIC3 chloride intracellular channel 3 
CLIC5 chloride intracellular channel 5 
CLIC6 chloride intracellular channel 6 
CRISP3 cysteine-rich secretory protein 3 
CRS chronic rhinosinusitis 
CT computed tomography 
Ct threshold cycle 
CXCL11 chemokine (C-X-C motif) ligand 11 
CXCL12 chemokine (C-X-C motif) ligand 12,(known as SDF-1) 
CXCL2 chemokine (C-X-C motif) ligand 2 
CXCL6 chemokine (C-X-C motif) ligand 6, (known as GCP2) 
CXCL9 chemokine (C-X-C motif) ligand 9 
 xvi
CYSLTR1 cysteinyl leukotriene receptor 1 
CYSLTs cystinyl-leukotrienes 
DAPK1 death-associated protein kinase 1 
DEFB1 defensin, beta 1 
DUOX1 dual oxidase 1 
DUSP1 dual specificity phosphatase 1 
DUSP2 dual specificity phosphatase 2 
DUSP4 dual specificity phosphatase 4 
DUSP5 dual specificity phosphatase 5 
DUSP6 dual specificity phosphatase 6 
ECM extracellular matrix 
ECP eosinophilic cationic protein 
EGF epidermal growth factor  
EGR1 early growth response 1 
EPO eosinophil peroxidase 
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 
ERK extracellular-signal-regulated kinase 
FDR false discovery rate 
FGF fibroblast growth factors 
FosB FBJ murine osteosarcoma viral oncogene homolog B 
GC Glucocorticosteroid 
GCLM glutamate-cysteine ligase, modifier subunit 
GM-CSF granulocyte-macrophage-colony stimulating factor 
GPX3 glutathione peroxidase 3  
GR glucocorticoid receptor 
GRE glucocorticoid response element 
GRα   glucocorticoid receptor alpha 
GRβ  glucocorticoid receptor beta 
HBEGF heparin-binding EGF-like growth factor 
HETEs hydroxyeicosatetraenoic acids 
ICAMs intercellular adhesion molecules 
IFNAR1 interferon alpha receptor 1 
IL Interleukins 
IL13RA2 interleukin 13 receptor, alpha 2 
IL18 interleukin 18 
IL5Ra interleukin 5 receptor, alpha 
IL-6 interleukin 6 
IL6ST interleukin 6 signal transducer (known as gp130) 
IP inverted papilloma 
IPA Ingenuity Pathways Analysis 
IPKB Ingenuity Pathway Knowledge Base 
IT inferior turbinate 
ITGB2 integrin, beta 2 
JAK Janus Kinase 
 xvii
JNK Jun N-terminal kinase 
JunB jun B proto-oncogene 
LGALS8 lectin, galactoside-binding, soluble, 8 (known as galectin 8) 
LGALS9 lectin, galactoside-binding, soluble, 9 (known as galectin 9) 
LPO Lactoperoxidase 
LT Leukotriene 
LTA4H leukotriene A4 hydrolase 
LTB4R leukotriene B4 receptor 
LX Lipoxins 
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
MAPKs mitogen-activated protein kinases 
MEKs mitogen-activated protein kinase kinase 
MBP major basic protein 
MHC II major histocompatibility complex class II 
MIF macrophage migration inhibitory factor 
MMP7 matrix metallopeptidase 7 
MMP9 matrix metallopeptidase 9 
MSP methylation specific PCR 
MUC16 mucin 16 
MUC20 mucin 20 
MUC4 mucin 4 
MUC7 mucin 7 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta 
NO nitric oxide 
NOS2A nitric oxide synthase 2A 
NOX4 NADPH oxidase 4 
NP nasal polyposis 
NPC nasopharyngeal carcinoma 
NR4A1 nuclear receptor subfamily 4, group A, member 1 
NR4A2 nuclear receptor subfamily 4, group A, member 2 
NR4A3 nuclear receptor subfamily 4, group A, member 3 
NRG3 neuregulin 3 
NUSE normalized unscaled standard errors 
OMC ostiomeatal complex 
OXR1 oxidation resistance 1 
PBMC peripheral blood mononuclear cell 
PCA principal component analysis 
PGs Prostaglandins 
PLA2 phospholipase A2  
PLA2G10 phospholipase A2, group X 
PLA2G4A phospholipase A2, group IVA 
 xviii
PLM probe-level model 
PM perfect match 
PRDX1 peroxiredoxin 1 
PRDX5 peroxiredoxin 5 
PTGER2 prostaglandin E receptor 2 (subtype EP2) 
PTGER3 prostaglandin E receptor 3 (subtype EP3) 
PTGIS prostaglandin I2 synthase 
PTGS2 prostaglandin-endoperoxide synthase 2,(known as COX-2) 
PTPN6 protein tyrosine phosphatase, non-receptor type 6 (known as SHP-1) 
PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 
QC quality control  
RASSF1A Ras association domain family member 1 
RBC red blood cell 
RLE relative log expression 
RMA robust multichip average 
RNS reactive nitrogen species 
ROS reactive oxygen 
RT PCR reverse transcription PCR 
RTK receptor tyrosine kinases 
S.aureus Staphylococcus aureus 
SAM significant analysis of microrarray 
SCGB1A1 secretoglobin, family 1A, member 1 (known as uteroglobin) 
SCNN1A sodium channel, nonvoltage-gated 1 alpha 
SCNN1B sodium channel, nonvoltage-gated 1 beta 
SCNN1G sodium channel, nonvoltage-gated 1 gamma 
SEA Staphylococcus aureus enterotoxin A 
SEB Staphylococcus aureus enterotoxin B 
SEC Staphylococcus aureus enterotoxin C 
SED Staphylococcus aureus enterotoxin D 
SEE Staphylococcus aureus enterotoxin E 
SEG Staphylococcus aureus enterotoxin G 
SEI Staphylococcus aureus enterotoxin I 
SELPLG selectin P ligand 
SERPINA1 serpin peptidase inhibitor, clade A, member 1 
SHE Staphylococcus aureus enterotoxin H 
sIgE specific IgE 
SOCS3 suppressor of cytokine signaling 3 
SOD3 superoxide dismutase 3, extracellular 
SPRY1 sprouty homolog 1 
SPRY2 sprouty homolog 2 
SPRY4 sprouty homolog 4 
STAT3 signal transducer and activator of transcription 3 
TAE tris-acetate EDTA 
TEK TEK tyrosine kinase, endothelial 
 xix
TGF transforming growth factor 
THBD thrombomodulin 
TSGs tumor suppressor genes 
TSLC1 tumor suppressor in lung cancer 1  
TSTT-1 toxic shock syndrome toxin-1 
TXN thioredoxin 
VCAMs vascular cell adhesion molecules 
VEGF vascular endothelial growth factor 



















Chapter 1. Nasal Polyposis – a Multifactorial Chronic Inflammatory 
Disease (Literature review) 
 
1.1 Histopathology 
Nasal polyposis (NP) is a common inflammatory disease in upper airway. Nasal 
polyps are generally regarded as a benign mucosal swelling that arises from the 
middle meatus and ethmoid sinus and prolepses into the nasal cavity. In some cases, 
polyps also arise from the maxillary sinuses and from the middle and superior 
turbinates.  
 
In macroscopical appearance (Figure 1.1), nasal polyps are usually soft, lobular and 
mobile swellings, and have a smooth and shiny surface with a bluish-grey or pink 
translucent color. The cut surface is moist and pale but appears more pink or red if the 
polyp is more vascular. The polyp often has an elongated stalk and the polyp size 
varies from 2 to 3 cm in diameter.  
 
Figure 1.1 Gross view of nasal polyps. Picture was taken from the patient with NP under endoscope 
examination. 
 
The characteristic features of nasal polyps are large quantities of extracellular edema 
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and an inflammatory cell infiltrate consisting of mast cells, eosinophils, lymphocytes, 
neutrophils and plasma cells, with eosinophils often dominant. The epithelium of 
polyps is often damaged followed by aberrant remodeling (such as squamous 
metaplasia). Other characteristics of nasal polyps include proliferation of stromal 
elements, a thickening of the basement membrane, sparse blood vessels and few 
mucous glands lacking normal innervation.   
 
NP is categorized into four types based on the different histological patterns [Hellquist, 
1997]. The most common one is the edematous, eosinophilic polyp, which is 
characterized by edema, goblet cell hyperplasia of the epithelium, thickening of the 
basement membrane, and infiltration of numerous leukocytes, predominantly 
eosinophils. The second common type is the fibro-inflammatory polyp, which is 
characterized by squamous metaplasia of epithelium and intensive infiltration of 
lymphocytes, but lack of stromal edema and goblet cell hyperplasia. The less common 
polyp presents with pronounced hyperplasia of seromucinous glands but also shows 
extensive edema. The rarest type is a polyp with stromal atypia which contains 
atypical fibroblast-like cells without mitoses.  
 
1.2 Epidemiology 
In the general population, the prevalence of nasal polyposis (NP) ranges from 0.2% to 
4.3%, making it one of the most common chronic diseases of the upper respiratory 
system [Falliers, 1974; Hedman et al., 1999; Larsen and Tos, 1991; Mygind et al., 2000]. A far 
higher prevalence of NP was found at 32% from an autopsy study [Larsen & Tos, 2004]. 
The incidence of NP is higher in men than in women and increases with age [Larsen & 
Tos, 2002], while the frequency of NP is rare (about 0.1%) in children [Triglia & Nicollas, 
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1997]. There is lack of epidemiology data in Asian populations, and only one Korean 
group reported that the incidence of NP in Korea was 0.5%, based on a nationwide 
survey of 10,054 subjects [Min et al., 1996]. Whether there is any difference in the 
prevalence among various population groups is not clear.  
 
NP is usually associated with chronic rhinosinusitis, aspirin intolerance, asthma, and 
cystic fibrosis:  
 
(1) NP and chronic rhinosinusitis (CRS) 
Chronic rhinosinusitis (CRS) is a common disease closely associated with NP. The 
percentage of CRS in patients with NP has been reported to range from 65% to 90% 
[Bunnag et al., 1983; Slavin, 1988]. In addition, a higher incidence rate of CRS in patients 
with NP was reported in Asians, compared to Caucasians [Tan et al., 1998]. Although 
CRS almost always coexists with NP, only about 20% of the patients with CRS 
develop NP [Settipane, 1996]. Accumulated evidence has shown that CRS with NP and 
CRS without NP actually are two different disease entities [Polzehl et al., 2006; Van Zele et 
al., 2006], while it is still not clear whether CRS predisposes for NP or results from it.  
 
(2) NP and aspirin intolerance 
NP is commonly found in aspirin intolerant patients, who are manifested by acute 
bronchospasm and rhinorrhea within 3 hours after injection of aspirin. The reported 
incidence rate of NP in patients with aspirin intolerance varies from 36% to 95% 
[Larsen, 1996]. Samter described the triad of NP, aspirin intolerance and asthma, which 
was so called “Samter’s syndrome” [Samter & Beers, 1968]. The triad seems to develop 
in a time sequence: asthma usually occurs first followed by aspirin intolerance within 
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one year, while NP occurs within the next 10 years of asthma onset [Settipane, 1986].  
 
(3) NP and asthma 
Asthma is a chronic respiratory disease which is characterized by bronchoconstriction 
in response to various stimuli, including allergen, cold air, moist air, exercise and 
emotional stress. NP was found in 13% of non allergic asthma and only 5% of allergic 
asthma [Settipane, 1977], suggesting that non allergic asthma was most commonly 
associated with NP. In addition, one French study reported that the prevalence of 
asthma in patients with NP was as high as 45% in 224 cases without relevant sex 
difference [Rugina et al., 2002].  
 
(4) NP and cystic fibrosis (CF) 
Cystic fibrosis (CF) is a hereditary disease that mainly affects the respiratory and 
digestive system, causing progressive disability and early death. CF is one of the most 
common life-shortening, childhood-onset inherited diseases, especially in Caucasians. 
Patients with CF have a high frequency of NP, ranging from 20% to 37% [Settipane, 
1996; Hadfield et al., 2000]. In addition, it has been reported that 50% of the patients with 
nasal polyps aged 16 or younger had CF [Schramm, 1980], indicating children with 
nasal polyps need to be evaluated for CF.  
 
1.3 Anatomy 
The nasal cavity and nasal sinuses have important physiological functions: airflow 
ventilation, olfaction, sensation, filtration, warming and humidifying, and immunity 
[Jones, 2001]. The nasal cavity is divided sagittally into left and right halves by the 
nasal septum. The roof of the nasal cavity is the cribriform plate, separating it from 
 5
the anterior cranial cavity. The inferior wall is the palate which separates the nasal 
cavity from the oral cavity. The superior, middle, and inferior turbinates (also called 
concha) form the lateral wall as horizontal projections, where the superior, middle and 
inferior meatus line below the respective turbinate (Figure 1.2). They are considered 
to be the main nasal passages.   
 
Figure 1.2 Lateral wall of the nose. Superior, middle and inferior turbinates are shown. (Picture source: 
http://training.seer.cancer.gov/ module_anatomy/ images/ illu_nose_nasal_cavities.jpg) 
 
There are four nasal sinuses: the frontal, sphenoidal, maxillary and ethmoidal sinuses. 
The maxillary sinus, anterior ethmoidal and frontal sinuses all drain into the middle 
meatus via the ostiomeatal complex (OMC). OMC is important, because obstruction 
here by inflammation and swelling due to some pathological conditions (e.g. allergy, 
infection, anatomical variants and nasal polyps) will interfere with the drainage and 
aeration of these three sinuses.  
 
The middle meatus and ethmoids have been considered the important region where 
most NP and sinusitis develop. Messerklinger described his nasal endoscopic findings 
on the pathophysiologic roles of this area: when the mucosal surfaces from middle 
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meatus and ethmoids contact directly, localized disruption of the mucociliary 
clearance occurs, resulting in retention of secretions in the surface contact, preventing 
or slowing drainage, predisposing the patient to infection and leading to inflammation 
and edema [Messerklinger, 1978].  
 
From the ultrastructure view: (i) the nasal lining consists of a pseudostratified 
columnar ciliated mucous membrane which is continuous with the sinuses and 
pharynx; (ii) one third of the anterior nasal cavity is covered by epithelium which has 
a typical airway structure. The normal nasal epithelium comprises the columnar 
ciliated cells, goblet cells and basal cells. Under the epithelium is the basement 
membrane which is a layer of collagen fibrils. The nasal submucosa (lamina propria) 
is a loose connective tissue, containing blood vessels, submucosal glands and various 
cell types, such as macrophage, fibroblast, lymphocyte and plasma cell. In the 
pathological condition, the number and status of the host cells in nasal 
mucosa/submucosa may change, and increase of the infiltration of some inflammatory 
cells (e.g. neutrophils and eosinophils) will occur.  
 
1.4 Pathogenesis 
Although the pathogenesis of NP is poorly understood, several hypotheses underlying 
the mechanisms of NP have been proposed in recent decades, including 
environmental factors, genetic predisposition, allergy, local nasal allergy, 
microorganisms, chemical mediators, deregulation of fluid and electrolyte transport, 
and epithelial rupture theory. 
 
1.4.1 Environmental factors 
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Since nasal mucosa is exposed to a variety of environmental allergen, pollutants, and 
microbes, the role of environmental factors in the etiology of NP have been proposed. 
NP has been suggested to be associated with aeroallergen hypersensitivity [Asero & 
Bottazzi, 2001]. NP patients exposed to noxious inhalant pollutants were significantly 
associated with NP occurrence [Pimentel, 1995]. Moreover, an association between the 
use of a woodstove as a primary source of heating and the development of NP was 
also reported [Hanley and Kim, 2002]. 
 
1.4.2 Genetic predisposition 
Some epidemiological evidence supports the genetic factors on NP: (i) Drake-Lee 
reported the development of NP in identical twins [Drake-Lee, 1992]; (ii) high rates of 
NP (52.6%) and asthma (43.6%) have been reported in the family history of patients 
affected with NP [Rugina, 2002]. However, evidence is still lacking for a genetic basis 
for this. 
 
Human leukocyte antigen (HLA) genetic patterns have been reported in NP: (i) 
Moloney et al. reported a higher incidence of HLA-A1/B8 in 29 patients with NP and 
asthma, but not the patients with NP alone [Moloney & Oliver, 1980]; (ii) a significant 
association was found between HLA-A74 and NP [Luxenberger et al., 2000]; (iii) 
Molnar-Gabor et al. showed that HLA-DR7-DQAI*0201 and –DQBI*0202 haplotype 
had two to three times higher odd ratios in patients with NP compared to controls 
[Molnar-Gabor et al., 2000]. Moreover, the mutation of the cystic fibrosis transmembrane 
regulator (CFTR) gene was reported in few patients with NP but without cystic 
fibrosis, however the vast majority of patients with NP do not have inactivation of the 
CFTR gene [Irving, 1997].  
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In the recent literature, some studies were able to show linkage of certain phenotypes 
of NP to candidate gene polymorphisms. Karjalainen et al. reported that subjects with 
a single G-to-T polymorphism in exon 5 at +4845 of the gene encoding IL-1alpha 
(IL-1A) were found to have less risk of developing NP as compared to subjects with 
common G/G genotype [Karjalainen et al., 2003]. In another study, polymorphism of IL-4 
(IL-4/-590 C-T), a potential determinant of IgE mediated allergic disease, was also 
found to be associated with a protective mechanism against NPs in the Korean 
populations [Yea et al., 2006]. In addition, asthma-related Argl6gly polymorphism of the 
beta2-adrenoceptor gene (ADRBeta2) was found to be associated with an increased 
risk of nasal polyposis [Bussu et al., 2007]. 
 
1.4.3 Allergy 
Allergy has been assumed to be the underlying cause of NP because of three factors: 
(i) presence of eosinophilia; (ii) association with asthma; (iii) allergic symptoms and 
signs, such as high levels of IgE, mast cell degranulation, and high recurrence rate.  
 
However, there is still much evidence to support the association between allergy and 
NP. Park et al. found that allergen-induced in vitro release of 
granulocyte-macrophage-colony stimulating factor (GM-CSF) and interleukin (IL)-8 
from NP tissue in atopic subjects and these mediators were associated with increased 
eosinophil survival [Park et al., 1997]. In Thailand, Pumhirun et al. reported that the 
incidence rate of positive skin prick test was 40% (24 out of 40) in patients with NP, 
while 20% (6 out of 30) in the control group [Pumhirun et al., 1999]. Asero and Bottazzi 
found 40% (8 out of 20) of patients with NP showed skin reaction to Candida 
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albicans, a common commensal mold of the upper airway tract [Asero and Bottazzi, 
2000]. Asero et al. also found that 70% (30 out of 43) of the patients with NP who 
were tested positive in the skin prick test seemed to be sensitive to perennial airborne, 
compared to 19% (215 out of 1128) of the controls with respiratory allergy, 
suggesting that perennial airborne allergens may play a relevant role in the NP [Asero 
and Bottazzi, 2001].  
 
It has been suggested that food allergy may have a possible role in the pathogenesis of 
NP although evidence for this is limited. Pang et al. reported that 81% (65 out of 80) 
of NP patients showed positive intradermal test results relating to food allergy, while 
only 11% (4 out of 36) of control subjects were positive to food allergy test [Pang, 
2000]. Another study showed that 31% of NP patients gave a history of food or drug 
allergy [Rugina et al., 2002]. Because the food allergy studies in NP are mostly based on 
clinical trials, its role need to be further investigated in molecular and cellular levels.  
 
1.4.4 Microorganisms 
Several types of microorganisms have been investigated to determine their role in NP. 
Some old studies have found that the nasal cavity is normally colonized with some 
non-pathogenic bacteria: (i) Calenoff et al. showed that 59 out of 61 NP patients 
exhibited positive serum IgE to at least one out of 11 bacteria tested [Calenoff et al., 
1983]; (ii) Dunnette et al. reported that multiple aerobic bacterial species occurred in 
NP from patients with asthma more frequently than in those from patients without 
asthma, and the number of bacteria was related to the number of infiltrating 
neutrophils [Dunnette et al., 1986]; (iii) Daws et al. showed that pus cells and bacteria 
were found in 16% of sinus irrigations [Dawes et al., 1989].  
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Recent studies have suggested the role of superantigens secreted by Staphylococcus 
aureus (S. aureus), which may contribute to the pathogenesis of NP [Bachert et al., 2008]. 
Superantigens are defined as toxins of bacterial or viral origin that are able to 
cross-link antigen presenting cells (APCs) and T-lymphocytes by binding to the major 
histocompatibility complex class II (MHC II) on APCs and the TCRs on 
T-lymphocytes. The recognition of superantigens is generally not MHC restricted and 
unprocessed superantigens directly bind to the conserved amino acid residues that are 
outside the peptide-antigen binding groove. Such special cross-inking characters 
results in an extreme polyclonal activation of CD4 and CD8+ T cells. S. aureus 
produces a large variety of enterotoxins, including S. aureus enterotoxins (SEs) A to E, 
G to I, and TSST-1 (toxic shock syndrome toxin-1), which act as superantigen 
function and activate large subpopulations of T cells, B cells, and other 
pro-inflammatory cells.  
 
Van Zele et al. presented some interesting results about superantigens in NP [Van Zele 
et al., 2004]: (i) coagulase-positive S. aureus colonization in the middle meatus is 
higher in patients with NP (64%) compared to patients with chronic sinusitis (27%) 
and healthy controls (33%); (ii) the potential to produce enterotoxins was also parallel 
with the S. aureus colonization rates in NP; (iii) tissue concentrations of specific IgE 
against S. aureus enterotoxins were higher in the NP patients with aspirin intolerance 
and asthma, compared to those with NP only; (iv) the infiltration of eosinophils and 
concentration of total IgE in tissues were also significantly increased in samples with 
the presence of specific IgE to enterotoxins. Moreover, there is also some evidence 
that S. aureus superantigens play a role in the induction of Th2 cytokines like IL-4 
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and IL-5 [Bachert et al., 2008]. These results indicate that NP with local overproduction 
of IgE, eosinophilia, and Th2 shift may represent an allergic phenomenon originated 
from S. aureus derived superantigens. 
 
Other than bacteria, it has been suggested that viruses may be involved in the 
pathogenesis of NP, such as the Influenza A virus [Ginzburg et al., 1982] and the 
Epstein-Barr virus [Tao et al., 1996]. However, these opinions are not of any interest, 
mostly because viruses were found in both healthy individuals and NP patients.  
 
1.4.5 Cellular components 
Two major cell types have been determined in NP: infiltrated inflammatory cells and 
structure-related cells. Traditionally, the inflammatory cells including eosinophils, 
lymphocytes, mast cells, plasma cells and neutrophils were considered the major 
sources of inflammatory chemical mediators. However, there is a growing awareness 
that structure-related cells including epithelial cells, endothelial cells and fibroblasts 
have also been seen as active participants in the interaction with other inflammatory 
cells as well as the release of various mediators, but not just passive barrier lining. 
The crosstalk between these different cell populations and various mediators 
ultimately contribute to the complicated pathogenesis of NP. 
 
1.4.5.1 Lymphocytes 
Lymphocytes play a central role in adaptive immunity. T helper 1 (Th1) cells 
stimulate phagocyte-mediated defense against infections, T helper 2 (Th2) cells 
stimulate IgE and eosinophil/mast cell-mediated immune reactions, and cytotoxic T 
cells recognize and kill target cells expressing foreign peptide antigen in association 
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with class І MHC molecules. T lymphocytes were often prominent over B 
lymphocytes [Liu et al., 1994]. Bernstein et al. reported that nasal polyps were found to 
have more lymphocytes than the inferior turbinates [Bernstein et al., 1997]. In contrast, 
Linder et al. reported that the relative proportion and spatial distribution of T and B 
lymphocytes were similar with regards to both NP and normal mucosa from 
disease-free controls [Linder et al., 1993]. The findings of helper T cells (CD4+) and 
cytotoxic T cells (CD8+) were also controversial. Liu et al. demonstrated that staining 
of CD4+ T cells were present in greater numbers than CD8+ T cells in NP [Liu et al., 
1994]. However, Stoop et al. reported that more CD8+ T cells than CD4+ T cells were 
found in the NP [Stoop et al., 1989]. In addition, our previous study showed significantly 
higher levels of CD8+ T cells and an inverse median ratio of CD4+/CD8+ T cells 
were found in nasal polyps compared to the middle turbinates from controls [Hao et al., 
2006]. It has been suggested that the cytokine pattern in NP assumes neither a Th1 nor 
Th2 type predominance, because IL-5, IL-5 and IFN-gamma have all been shown to 
be up-regulated in NP, without influence of the atopic status [Bachert et al., 2002]. One 
most recent study has indicated that a dysfunction of T regulatory cells may contribute 
to severe inflammation in NP tissues due to a decreased expression of forkhead box 
P3 (FOXP3) [Van Bruaene et al., 2008]. 
 
1.4.5.2 Eosinophils 
The activated infiltrating eosinophils produce a large amount of granule-associated 
toxic proteins, such as eosinophilic cationic protein (ECP), major basic protein (MBP) 
and eosinophil peroxidase (EPO), causing cellular injury and tissue damage. There is 
recognition that the accumulation of eosinophils into a tissue site involves a number 
of events, including (i) differentiation of bone marrow progenitors into functionally 
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mature cells; (ii) rolling, adhesion and migration through the endothelium; (iii) 
chemotaxis, activation and survival within the tissue [Rothenberg, 1998]. Several studies 
have indicated that cytokines (e.g. IL-3, IL-5, and IL-13) [Allen et al., 1997], 
chemokines (e.g. eotaxin, RANTES and CCL24) [Olze et al., 2006], growth factors (e.g. 
GM-CSF) [Allen et al., 1997], leukotrienes [Parnes et al., 2002], adhesion molecules (e.g. 
integrins, VCAM1 and ICAM1) [Kupczyk et al., 2006] and other regulatory factors may 
participate in the eosinophil infiltration in NP.  
 
It is widely accepted that eosinophils are a hallmark of allergy. Bachert et al. found 
significantly more eosinophilic infiltration in NP containing high total IgE tissue 
concentrations and these high total IgE levels were more frequently found in 
asthmatic and aspirin-intolerant NP patients [Bachert et al., 2001]. However, in 
non-asthmatic and aspirin tolerant NP patients, the resulting eosinophilic infiltration 
appears to be the same for both atopic and non-atopic NP. Therefore, it remains 
unknown what causes the primary recruitment of eosinophils to the site of nasal 
polyps; to investigate the cellular sources of those inflammatory mediators should be 
helpful to clarify the mechanism of eosinophilia in NP. 
 
1.4.5.3 Neutrophils 
Increase of neutrophils has been commonly found in bacterial infectious disease. 
Studies of neutrophil infiltration in NP remain controversial, i.e., high infiltration in 
NP [Takasaka et al., 1986] as opposed to lack of difference between NP and controls 
[Fujisawa et al., 1990]. The correlation between neutrophil infiltration and bacteria count 
in NP has been reported [Dunnette et al., 1986]. Some mediators (e.g. IL-8, GM-CSF and 
ICAM) have been reported to regulate the recruitment and survival of neutrophils in 
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NP [Demoly et al., 1998; Takeuchi et al., 1995; Vancheri et al., 1991]. Furthermore, the 
relationship between neutrophils and other inflammatory cells in nasal polyps has also 
been documented. A significant correlation was identified between neutrophil 
elastase+ cells and activated mast cells or eosinophils [Park et al., 1997]. Neutrophil 
elastase may contribute to tissue inflammation and remodeling by inducing the 
expression of secretory leukocyte protease inhibitor [Marchand et al., 1997]. 
 
1.4.5.4 Mast cells 
Mast cells are known to play a key role in IgE-mediated diseases, but they are also 
involved in non-IgE-mediated inflammatory diseases. Mast cells can be detected in 
the stroma as well as the epithelium of nasal polyps. The level of mast cells in NP was 
higher than that in the sinus mucosa from patients with sinusitis and the middle 
turbinate mucosa from patients with allergic rhinitis [Otsuka et al., 1993]. Mast cells in 
NP produce a variety of cytokines such as Il-4, IL-5, Il-6, Il-13, GM-CSF and IL-8 
[Pawankar, 2003]. In addition, mast cell mediators like histamine and tryptase are able to 
up-regulate the release of RANTES and GM-CSF from epithelial cells and fibroblasts 
in NP, indicating a vicious cycle that further promote eosinophilia in NP [Pawankar, 
2003].  
 
1.4.5.5 Epithelial cells 
In NP, epithelium is both an active player and a “passive” target in the pathology. It 
plays a central role in the interaction with eosinophils and myfibroblasts. Epithelial 
damage caused by inflammatory mediators can trigger aberrant epithelial remodeling 
processes in NP, causing hyperproliferation of epithelial cells and squamous 
metaplasia. During this process, epithelial cells would release various molecules (e.g. 
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TGF-beta, EGF, VEGF, GM-CSF, eotaxin and RANTES) which are related to growth, 
differentiation, migration, and activation, and then such anti-apoptotic 
microenvironment further promote the infiltration of eosinophils and survival of 
myofibroblasts [Devalia & Davies, 1993; Mullol et al., 1995; Shin et al., 2003]. 
 
1.4.5.6 Fibroblasts/Myofibroblasts 
Myofibroblasts are an activated phenotype of fibroblasts and are involved in wound 
repair and tissue differentiation in non-pathological circumstances [Serpero et al., 2006]. 
Myofibroblasts are atypical stromal cells that play a crucial role in the pathological 
tissue changes seen in both NP and asthma. In NP, myofibroblasts produce large 
amounts of extracellular matrix molecules, such as collagens (type I, III, IV and VIII) 
and fibronectin, which would contribute to the stromal fibrosis [Beju et al., 2004]. The 
fibrosis in NP seems to represent an unchecked and deranged tissue repair since the 
myofibroblasts do not go into apoptosis [Zhang et al., 1999], and consequently it may 
promote the growth of NP. It has been suggested that some growth molecules secreted 
by eosinophils or epithelial cells may cause uncontrolled proliferation and survival of 
myofibroblasts [Elovic et al., 1994].  
 
1.4.6 Molecular and chemical mediators  
The molecular and chemical mediators (e.g., peptides, proteins, amines, or lipids) 
released from the inflammatory/structural cells contribute to the complicated 
inflammatory signaling networks and appear to be important in the development of 





Histamine is released primarily by mast cells after activation by IgE or other 
histamine releasing factors. Recent study showed that histamine content in NP and 
normal nasal mucosa did not differ, but histidine decarboxylase (histamine 
biosynthesis enzyme) was elevated in NP tissue and histamine-N-methyltransferase 
(histamine degradative enzyme) activity was enhanced in NP compared to the control; 
hence, histamine metabolism seems to be increased in NP [Jokuti et al., 2004]. Another 
report showed that histamine H4 receptor was elevated in NP and associated with the 
eosinophil infiltration [Jokuti et al., 2007]. In addition, former study showed that the 
level of histamine was higher in NP patients with allergy than in those with aspirin 
intolerance, due to the difference in histamine-N-methyltransferase activity [Ogino et al., 
1993].  
 
1.4.6.2 Arachidonic acid metabolites 
Arachidonic acid (AA) is the precursor of a family of chemical mediators. Two main 
pathways exist: the lipoxygenase pathway synthesizing hydroxyeicosatetraenoic acids 
(HETEs), lipoxins (LX), and cystinyl-leukotrienes (cysLTs); the cyclooxygenase 
pathway producing prostaglandins (PGs), thromboxanes, and prostacyclin.  
 
Abnormalities of AA metabolism may be related to the chronic inflammation of NP, 
especially those with aspirin intolerance. The major AA metabolite in NP is 15-HETE, 
which was found in a higher level in NP compared to normal nasal mucosa [Jung et al., 
1987]. 5-Lipoxygenase (5-LO) is the key enzyme which can convert 15-HETE to 
Lipoxin A4 and Lipoxin B4, and consequently perform vasodilation effects during 
inflammatory progression. Both 5-LO and Lipoxin A4 were increased in NP 
 17
[Perez-Novo et al., 2005].  
 
cysLTs have profound effects on airway function by inducing airway smooth muscle 
contraction, vasodilatation, and vascular permeability and altering the remodeling 
process in asthma [Funk et al., 2001; Holgate et al., 2003]. All of the cysLTs have been 
found in NP tissue: LTE4 was frequently identified in nasal lavage [Salari et al., 1986]; 
both LTB4 and LTC4 was found in higher concentration in NP [Jung et al., 1987], and the 
level of LTB4 is higher in NP from allergic patients than non-allergic ones [Ogino et al., 
1993]; LTC4 and LTD4 are predominant in NP patients with aspirin intolerant asthma 
[Yamashita et al., 1989].  
 
NP contains detectable levels of PGD2 and PGE2. PGE2 has been proposed to reduce 
cysLTs synthesis [Szczeklik et al., 1997], and its production has been found lower in NP 
[Mullol et al., 2002], especially in aspirin intolerant patients [Picado et al., 1999]. PGD2 has 
been proposed to prolong eosinophil survival [Monneret et al., 2001], and its production 
was increased in NP and was positively correlated with eosinophil accumulation [Hyo 
et al., 2007].  
 
1.4.6.3 Granular proteins 
The non-enzymatic, performed granular proteins of eosinophils include eosinophil 
cationic protein (ECP) and major basic protein (MBP). Two types of ECP have been 
identified: non-secretory form and secretory form, and both have been found in 
greater amounts in NP tissues than in healthy nasal mucosa [Stoop et al., 1993]. Nasal 
lavage from patients with NP contained more ECP than that from patients without NP, 
but levels did not change with seasonal allergen exposure [Keith et al., 1994]. MBP has 
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also been found in mast cells in NP, suggesting the sequestration of MBP in mast cells 
[Butterfield et al., 1990]. The amount of MBP present in NP tissues has been positively 
correlated with the degree of epithelial damage [Fujisawa et al., 1990].  
 
1.4.6.4 Interleukins 
Interleukins (ILs) are a family of mediators released by a number of inflammatory and 
non-inflammatory cells. IL-1 (alpha and beta) was found primarily in mononuclear 
leukocytes, but not commonly in polymorphonuclear cells [Liu et al., 1993]. IL-3 
expression was elevated in NP tissues compared to controls, and the level of IL-3 was 
associated with eosinophil infiltration [Allen et al., 1997]. IL-4 was localized in 
eosinophils[Nonaka et al., 1995], and it regulated eotaxin-2/CCL24 (potent eosinophil 
attractant) production in a dose-dependent manner [Lezcano-Meza et al., 2003], 
suggesting IL-4 perform an indirect effect on eosinophil infiltration in NP.  
 
IL-5, a key cytokine for the maturation and activation of eosinophils, was found to be 
significantly increased in NP compared to controls [Bachert et al., 1997]. IL-5 expression 
was correlated with the degree of eosinophilic inflammation in NP [Allen et al., 1997] 
and anti-IL-5 treatment induced eosinophil apoptosis in NP tissue homogenates in 
vitro [Simon et al., 1997]. In addition, IL-5 receptor alpha subunit, which transduces IL-5 
signal to the nucleus of the target cells, was significantly up-regulated in NP versus 
the control [Gevaert et al., 2003].  
 
IL-8 is a chemokine produced by macrophages and other cell types such as epithelial 
cells. Mullol et al. showed that epithelial cells from NP released more IL-8 than those 
from healthy nasal mucosa, and IL-8 was reduced in NP after dexamethasone 
 19
treatment [Mullol et al., 1995]. Furthermore, allergen-induced in vitro release of IL-8 
from NP tissue in atopic individuals was associated with increase of eosinophil 
survival [Park et al., 1997]. IL-13 is an important mediator of allergic inflammation and 
GC treatment can reduce IL-13 expression in NP [Hamilos et al., 1999]. However, there 
is no evidence to support the up-regulation of IL-13 in NP.  
 
1.4.6.5 Growth factors 
Several growth factors appear to be involved in the pathogenesis of NP. Colony 
stimulating factors (CSFs) have been found to be important in proliferation and 
differentiation of granulocyte precursors. They are classified depending on different 
stimulated cells: macrophages (M-CSF), granulocytes (G-CSF), and both granulocyte 
and macrophages (GM-CSF). They are released from macrophages and lymphocytes, 
as well as from epithelial cells, endothelial cells, eosinophils, and fibroblasts in NP 
tissues. 
 
GM-CSF is supposed to be the primary growth factor in NP. GM-CSF staining was 
stronger in NP subepithelium than in normal mucosa and the number of GM-CSF 
staining cells was correlated strongly with the number of activated eosinophils [Ohno 
et al., 1991]. Both non-allergic and allergic NP presented large numbers of GM-CSF 
immunoreactive cells, but healthy nasal mucosa did not [Hamilos et al., 1998]. Fibroblast 
and epithelial cells cultured from NP tissues produced significantly higher levels of 
GM-CSF in their supernatants compared to those from inferior turbinate tissues 
[Ohtoshi et al., 1991; Vancheri et al., 1991]. In addition, conditioned media from NP derived 
cell lines has been used to study the roles of GM-CSF. Epithelial cells from NP tissue 
survived and proliferated better than normal tissue in vitro [Otsuka et al., 1987]. The 
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conditioned media from NP tissues induced differentiation of monocytes and 
neutrophils to a greater level than media from controls [Ohtoshi et al., 1991]. 
Supernatants of epithelial cells and fibroblasts increased eosinophil survival and 
activation, and this effect was abrogated by antibody to GM-CSF [Gauldie et al., 1994; 
Xaubet et al., 1994]. 
 
Transforming growth factor beta (TGF-beta) is another growth factor important for 
inducing fibroblast proliferation, and the increased stromal fibrosis seen in NP may be 
due to the increased expression of TGF-beta [Elovic et al., 1994]. Eosinophils are an 
important source of TGF-beta, suggesting that eosinophils could enhance their 
infiltration via TGF-beta regulation [Elovic et al., 1994]. Vascular endothelial growth 
factor (VEGF) which is important for inducing angiogenesis and edema was reported 
to be increased in NP and was further up-regulated by TGF-beta [Coste et al., 2000]. 
However, other studies showed that TGF-beta could inhibit the synthesis of IL-5 and 
abrogate the survival of eosinophils [Alam et al., 1994], and the expression of TGF-beta 
was higher in chronic rhinosinusitis than in NP [Watelet et al., 2004].  
 
Fibroblast growth factors (FGF) constitute a family of at least nine heparin-binding 
polypeptide growth factors, which may promote stromal fibrosis and the proliferation 
of endothelial and epithelial cells. Up-regulation of both acidic FGF (aFGF) and basic 
FGF (bFGF) was found in NP compared to nasal turbinates [Kim et al., 2006], and GCs 
may decrease bFGF levels in NP [Yariktas et al., 2005]. However, the mRNA level of 
aFGF and bFGF was lower in NP than healthy nasal mucosa, while mRNA level of 
keratinocyte growth factor (KGF or FGF-7) was higher in NP compared to nasal 
mucosa [Ishibashi et al., 1998].  
 21
 
Other growth factors have been reported to be involved in the cellular proliferation in 
NP. Insulin-like growth factor I (IGF-I) was present in high concentrations in NP 
tissues, but in low level in adjacent control nasal mucosa [Petruson et al., 1988]. 
Platelet-derived growth factor (PDGF) and proliferating cell nuclear antigen (PCNA) 
were also up-regulated in NP compared with controls [Coste et al., 1996].  
 
1.4.6.6 Chemokines 
Chemokines are a family of low molecular weight cytokines that stimulate leukocyte 
movement and regulate the migration of leukocytes from the blood to tissues. Some 
inflammatory chemokines are important in recruiting monocytes, neutrophils, and 
eosinophils into NP tissues.  
 
The CC-chemokine eotaxin has been considered to play a key role in tissue 
eosinophilia in NP [Bartels et al., 1997; Shin et al., 2000]. Olze et al. showed that not only 
eotaxin, but also eotaxin-2 and eotaxin-3 were increased in NP tissues compared to 
healthy turbinate tissues, and all eotaxin family members were positively correlated 
with eosinophil infiltration [Olze et al., 2006]. Another CC-chemokine, RANTES was 
found to be stained more intensively in NP than in healthy controls [Beck et al., 1996], 
and was found to be increased in eosinophilia NP tissues compared to those without 
tissue eosinophilia [Meyer et al., 2005]. Some monocyte chemotatctic proteins (MCP-3 
and MCP-4) have been also considered potent eosinophil chemoattractants [Bartels et 
al., 1997; Woodworth et al., 2004]. These chemokines bind to chemokine receptor 3 (CCR3) 
and then recruit eosinophils in NP, therefore, antagonism of CCR3 could have a 
therapeutic role in this disease.  
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1.4.6.7 Adhesion molecules 
Adhesion molecules are membrane proteins which regulate cell to cell interaction. An 
early study demonstrated that intercellular adhesion molecule 1 (ICAM-1), E-selectin 
and P-selectin were expressed in NP endothelium and contributed to eosinophil 
adhering and rolling through the endothelium [Symon et al., 1994]. Jahnsen et al. 
reported that both the number of eosinophils and the proportion of vessels positive for 
vascular cell adhesion molecule 1 (VCAM-1) were significantly increased in NP 
compared with the turbinate mucosa of the same patients [Jahnsen et al., 1995]. 
Moreover, the ligand of VCAM-1 on the peripheral blood eosinophils is very late 
antigen 4 (VLA-4), and both VCAM-1 and VLA-4 were significantly increased in NP 
patients with aspirin intolerance than those with aspirin tolerance [Kupczyk et al., 2006].  
 
1.4.6.8 Neurotransmitters 
Neurotransmitters, released from autonomic and sensory nerves, may contribute to 
airway inflammation via their effects on the immune system and respiratory glands, 
particularly if their metabolism is impaired. Neuropeptide Y (NPY) and vasoactive 
intestinal peptide (VIP) were predominantly found around the thick wall vessels and 
in close proximity to the submucosal glands in NP tissues, respectively [Fang et al., 
1994]. Substance P was not found in NP [Fang et al., 1994] and poor response of 
substance P to capsaicin stimulation was present in nasal secretions of the patients 
with NP [Gungor et al., 1999]. A recent study showed that brain derived neurotrophic 
factor (BDNF), a neurotrophin which up-regulates neuropeptide production, was 
expressed at a higher level in epithelial cell cultures from NP than those from middle 
turbinates and BDNF was increased in response to pro-inflammatory cytokine 
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stimulation [Jornot et al., 2007]. However, dipeptidyl peptidase (DPPIV), the enzyme 
which degrades neuropeptides, was expressed at a similar level between NP and 
control [Jornot et al., 2007].  
 
1.4.7 Deregulation of fluid and electrolyte transport 
The large quantity of extracellular fluid (edema) in NP may suggest the abnormal 
regulation of fluid and ion channel properties. This mechanism has been supported by 
several studies: (i) increased expression of VEGFs would promote the vascular 
permeability and angiogenesis in NP [Coste et al., 2000]; (ii) the CFTR protein is an 
active chloride pump that plays a crucial role in fluid homeostasis, and evidence has 
been shown that this protein was mutated in NP with cystic fibrosis (CF) [Noone et al., 
2001], and it was also expressed in a low level or located abnormally in epithelium of 
non-CF NP [Jang et al., 2001]; (iii) increased voltage and short circuit current was found 
in cell cultures from NP as compared to those from turbinate tissues, indicating a 
significant increase in absorption of sodium ion [Bernstein et al., 1997]. These interesting 
findings suggest that the micro inflammatory environment in NP would cause 
abnormal bioelectric properties, and then result in the increased movement of water 
into the interstitial fluid in NP.  
 
1.4.8 Epithelial rupture theory 
Larsen et al. proposed the epithelial rupture theory which may explain the early stages 
of NP formation [Larsen et al., 1991; Larsen et al., 1992]: (i) polyp formation starts with 
epithelial damage, necrosis, and rupture due to tissue pressure by inflammatory edema 
and infiltrated lamina propria; (ii) lamina propria protrudes through the epithelial 
defect and the mucosa tends to cover it by migration of the epithelium from the edges 
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of the defect; (iii) the prolapse of the lamina propria undergoes epithelialization, and 
the vessel stalk will be established; (iv) tubulous glands are formed; (v) polyp 
enlarges due to gravity with elongation of the glands; (iv) the epithelium and stroma 
are changed (such as transformation of pseudostratified to stratified epithelium, 
changes of density of goblet cells, changes of cell infiltration) and polyp is 
well-developed.  
 
1.5 Clinical symptoms, diagnosis and treatment 
1.5.1 Symptoms 
The nasal symptoms of NP are described as follows: (i) constant non-periodic nasal 
blockage and stuffiness, which can have a valve-like sensation allowing better airflow 
in only one direction; (ii) nasal congestion, which can be a feeling of pressure and 
fullness in the nose and paranasal cavities (“full-head”); (iii) perennial clear 
rhinorrhea and sneezing; (iv) white or yellow postnasal drip, which represents the 
sinusitis symptoms; (v) facial pain and headache, which are exacerbated when 
infection in sinuses; (vi) hyposmia or anosmia. About one third of patients who are 
often accompanying asthma have chest symptoms, including wheezing and chronic 
cough. Diet may induce exacerbations if the patient has aspirin intolerance.  
 
The recurrence of NP is common. About 40% of patients with surgical polypectomy 
have recurrences [Settpiane et al., 1987]. It was reported that those patients with positive 
response of allergy skin test had a higher recurrence rate compare to those with 




The diagnosis of NP is based on the patient’s history, symptoms, and clinical 
examination. When taking the history, the typical symptoms of the patient should be 
recorded during spontaneous conversation and followed by questions on most 
important individual symptom. Some specific techniques and scoring systems have 
been developed to validate the symptoms: (i) validation of nasal obstruction by 
rhinomanometric or nasal peak flow evaluations; (ii) validation of facial pain and 
pressure by maxillary antral aspiration or paranasal sinus radiographs; (iii) validation 
of smell abnormalities by subjective scoring of olfaction.  
 
Endoscopic examination should be the most helpful technique to assess the severity of 
NP in clinics. Staging systems for NP under endoscopy view have been proposed 
[Malm, 1997; Fokkens et al., 2007]: (i) score “0” means absence of nasal polyps; (ii) score 
“1” means polyps in middle meatus only; (iii) score “2” means polyps beyond middle 
meatus but not blocking the nose completely; (iv) score “3” means polyps completely 
obstructing the nose.  
 
Computed tomography (CT) scanning is the imaging modality of choice confirming 
the extent of pathology and the anatomy in paranasal sinuses. It is also helpful to aid 
the sinus surgery by providing information on anatomy. The Lund-Mackay system 
relies on a score of 0-2 depending upon the absence (score = 0), partial (score = 1) 
and complete opacification (score = 2) of each sinus system and of the ostiomeatal 
complex, deriving a maximum score of 12 per side [Lund et al., 1993].  
 
In addition, routine pathological examination of nasal biopsy is the gold standard to 
confirm NP diagnosis at the histopathological level and helpful to differentiate 
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neoplasia and vasculitides.  
 
1.5.3 Treatment 
The management of NP includes: drug treatment, which is traditionally based on the 
use of topical or systemic glucocorticosteroids (GCs); and surgical operation, which is 
trying to eradicate all polyp tissues from the nasal lumen and sinuses. The aims of 
treatments are to relieve nasal blockage, restore olfaction, and improve sinus drainage.  
 
1.5.3.1 Topical and systemic glucocorticosteroids 
GCs can suppress many phases of the inflammatory process, which may explain their 
strong effect on inflammation. As NP represents intensive infiltration of various 
inflammatory cells, especially eosinophils, GC treatment is the first-choice approach. 
This can range from topical GC sprays or drops in mild to moderate NP, to a short 
course of systemic GCs in severely affected patients. Systemic application affects all 
NP tissues within the nose and sinuses, but has the disadvantage of systemic 
side-effects when used for long-term treatment. Topical application significantly 
reduces adverse effects but does not impact nasal polyps within the sinus.  
 
The biological effect of GCs is mediated through activation of intracellular 
glucocorticoid receptors (GRs). Activated GRs bind to the DNA sequence called 
glucocorticoid response element (GRE) and perform transactivation of target gene 
transcription (often anti-inflammatory molecules) [Beato, 1989]; while activated GRs 
also interact with transcription factors such as AP-1 and NF-kappaB to perform 
transrepression of some inflammatory genes [Cato et al., 1996].  
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With regard to the transcriptional activation, GRs can increase gene transcription 
through an action on chromatin remodeling and recruitment of RNA polymerase II to 
the site of local DNA unwinding [Hayashi et al., 2004]. GRs can also interact with other 
coactivator proteins such as SRC-1, TIF-2, p300/CBP that enhance local histone 
acetylation activity. It has been found that GRs could up-regulate the transcription of 
some anti-inflammatory genes such as annexin-1, inhibitors of NF kappa B, and MAP 
kinase phosphatase [Hayashi et al., 2004]. 
 
Except for the ability of GCs to induce gene expression, the major anti-inflammatory 
effects of GCs are thought to suppress the transcription of those inflammatory genes. 
This inhibitory effect of GCs could be attributed to the interaction between GRs and 
the proinflammatory transcription factors, such as NF kappa B and AP-1 [Hayashi et al., 
2004]. For example, NF kappa B recruits transcriptional coactivators, such as CBP or 
p300/CBP associated factor which have intrinsic histone acetyltransferase (HAT) 
activity, leading to increased transcription of inflammatory genes. Activated GRs can 
then translocate to the nucleus and interfere the binding between NF kappa B and its 
coactivators, resulting in the inhibition of HAT activity and reduction of histone 
acetylation. Those pro-inflammatory genes such as chemokines, cytokines, and 
leucotrienes, have been found to be suppressed by GCs [Hayashi et al., 2004].  
 
GCs also affect migration, activation and survival of inflammatory cells such as 
eosinophils [Burgel et al., 2004], by regulating a variety of mediators such as cytokines 
(e.g. IL3, IL-5 and IL-13), chemokines (e.g. eotaxin and RANTES), adhesion 
molecules (e.g. ICAM-1, VCAM-1 and integrins), growth factors (e.g. GM-CSF) and 
leukotrienes [Bachert et al., 1999]. 
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There is a good amount of evidence that topical as well as systemic GCs are effective 
in reducing the size and symptoms (e.g. nasal blockage, rhinorrhoea and hyposmia) of 
NP [Ruhno et al., 1990; Small et al., 2005]. After surgery, high dosage of topical GC may 
reduce the incidence of NP recurrences or prolong the symptom-free time interval. 
Nevertheless, a substantial number of patients appear to be refractory to both topical 
and systematic GC treatments, or seem to develop a decreasing GC sensitivity during 
the medication period. The underlying mechanism for this glucocorticoid resistance 
has not been fully clarified; some reports suggested GR-beta isoform was increased in 
glucocorticoid insensitive patients and may interfere with GR-alpha function [Pujols et 
al., 2004]. Although the clinical efficacy of GCs in alleviating NP inflammation is 
prominent, the molecular mechanism has been poorly understood due to the 
pleiotropic effects of GCs on multiple signaling pathways. Therefore, to identify the 
candidate molecules which may contribute to beneficial or side effects of GCs will be 
helpful in developing GC therapy. 
 
1.5.3.2 Antimicrobials 
Several microorganisms have been investigated to indicate their role in NP. 
Antibacterials can control the bacterial infection effectively and their potential benefit 
in bilateral NP has been discussed by Bachert and Van Cauwenberge [Bachert & Van 
Cauwenberge, 2003]. It has been suggested that macrolide antibiotics not only decrease 
the colonizing bacteria, but also perform anti-inflammatory activities: (i) in a clinical 
study, an improvement in 52% of 20 NP patients was observed after treating with 
roxithromycin, one macrolide antibiotic, 150 mg/day for at least 8 weeks [Ichimura et al., 
1996]; (ii) Nonaka demonstrated that roxithromycin, could directly suppress NP 
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fibroblast proliferation [Nonaka et al., 1999]; (iii) Yamada reported the three-month 
administration of macrolides in patients with NP resulted in reduced polyp size 
paralleled by a decrease of local IL-8 level [Yamada et al., 2000]; (iv) Iino showed that 
macrolides enhance CD80 positive macrophages which was negatively correlated 
with eosinophil infiltration in NP [Iino et al., 2001].  
 
As discussed in Chapter 1.4.4, the possible role of S.aureus enterotoxins in the 
pathogenesis of NP calls for placebo-controlled clinical trials to confirm if antibiotics 
could be effective for this pathogen in NP. However, it should be noted that low-dose 
and long-term treatment with antibiotics may also induce bacterial resistance, which 
may limit this approach. 
 
1.5.3.3 Antihistamines 
Histamine, which be released from mast cells in NP, significantly increases the 
expression of intracellular adhesion molecule (ICAM)-1 and HLA-DR in epithelial 
cells. However, their use in patients with only polyps has not been extensively studied. 
Several studies have shown that in vitro, antihistamines significantly inhibit the 
leukotriene (LT) C4/D4, LTB4, prostaglandin (PG) D2, TNFα and GM-CSF in NP 
cell cultures in a dose-dependent manner [Carayol et al., 2002; Crampette et al., 1996]. One 
clinical study reported that after polypectomy, NP patients were treated with 
antihistamines (20mg, twice daily) for 3 months [Haye et al., 1998]. The results showed 
that the number and size of polyps remained unchanged, while nasal sneezing and 




1.5.3.4 Possible future medical treatment approaches 
Consistent with current knowledge on the pathophysiology of NP, new therapeutic 
approaches may focus on eosinophilic inflammation, eosinophil recruitment, the T 
cell as the orchestrating cell and IgE antibodies, as well as on tissue destruction and 
remodeling processes. Some interesting markers may act as possible drug targets, 
such as IL-5 antagonists, chemokine receptor 3 and eotaxin antagonists, IL-4 and 
IL-13 antagonists, local IgE antagonists, matrix metalloproteinase inhibitors.  
 
1.5.3.5 Surgical operation 
Surgical polypectomy is the preferred treatment for NP with many patients 
undergoing repeated operations. Functional endoscopic sinus surgery (FESS) is the 
standard surgical treatment of NP nowadays, and it has been proven to improve the 
quality life of the patients satisfactorily [Uri et al., 2002]. Whereas, some studies have 
shown that the effect of surgery had no significant difference from medical treatment 
[Lildholdt et al., 1988]. One recent clinical study showed the sense of smell improved 
after treatment with systemic and topical GCs, and surgery had additional beneficial 
effects on nasal obstruction and secretion [Blomqvist et al., 2001]. The study suggests that 
surgical treatment is applicable if nasal obstruction is the main problem which cannot 
be relieved by GCs, and surgery should be based on the patient’s symptoms rather 
than the examiner’s polyp score. However, to date there is too little data available to 
determine if there is any difference between surgery and GC therapy in the long-term 





Chapter 2. Objectives and Significance 
 
2.1 Research questions 
The pathogenesis of NP is highly complicated due to its heterogeneity. Fundamental 
research on the pathogenesis of NP is hampered by two main problems: (i) various 
clinical phenotypes influence the nature of NP; (ii) whether NP should be considered 
a local disease or a local manifestation of a systemic disease. Although numerous 
papers have dealt with the pathogenesis of this nasal disease, the molecular/cellular 
alterations required for its development and progression are poorly understood. 
Several research questions concerning the pathogenesis and treatment of NP have 
been raised in this thesis. 
 
(1) Are Staphylococcus aureus and its superantigens involved in inflammation of 
Asian NP? 
Staphylococcus aureus (S. aureus) and its superantigen have been thought to result in 
Th2 shift, eosinophil activation, and overproduction of IgE observed in NP (Chapter 
1.4.4, Page 9). Most superantigen studies have focused on Caucasian NP patients, 
who show eosinophil dominant polyps with less abundant neutrophils [Bachert et al., 
2008]. However, NP in Asian patients has been found to show a neutrophilic pattern 
with a relative lack of eosinophil-dominated inflammation [Jareoncharsri et al., 2002]. In 
addition, our previous results demonstrated a combined cell infiltration with 
eosinophils, neutrophils and CD4+/CD8+ T lymphocytes in Asian patients with NP 
[Hao et al., 2006]. Importantly, activation of neutrophils is likely associated with innate 
immune defense which counteract the microbial infection. Hence, the evidence raises 
an issue whether S. aureus and its superantigens have some role in this differential 
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infiltration of inflammatory cells in Asian NP.  
 
(2) Is methylation of tumor suppressor genes associated with NP inflammation? 
NP has not been considered a cancer-prone lesion, but the hyperplasia feature 
(especially increase of squamous cells) and high recurrence rate of NP raises the 
question as to whether NP would share some pathological mechanisms with those 
malignant (e.g. nasopharyngeal carcinoma, NPC) and benign (e.g. inverted papilloma, 
IP) neoplasms in upper respiratory tissues. Promoter methylation of tumor suppressor 
genes (TSGs) is a major molecular defect in cancers and is associated with loss of 
protein expression in cancer cells [Jones et al., 2001]. Patients with cancer-prone chronic 
inflammatory diseases, such as ulcerative colitis, gastritis, and some hyperplastic 
polyps showed hypermethylation in several TSGs [Abraham et al., 2004; Chan et al., 2002;]. 
In addition, it was shown that inflammation mediated cytokine damage can alter the 
methylation pattern and critical gene regulation [Valinluck et al., 2007]. This evidence 
suggests that DNA methylation is a mechanism that could link inflammation with 
tumorigenesis.  
 
In nasopharyngeal carcinoma, a high frequency of epigenetic inactivation of TSGs 
was confirmed [Kwong et al., 2002]. The methylation profile of TSGs in inverted 
papilloma has not been intensively studied, and only one report demonstrated that the 
cell cycle marker, CDKN2B was frequently methylated in inverted papilloma [Stephen 
et al., 2007]. In regard to the hyperplastic property of NP, it is worth studying whether 
methylation of some TSGs could occur in NP, although NP is generally considered a 
benign proliferative lesion. As far as we know, the methylation status of TSGs has not 
been reported in NP. 
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(3) What are the molecular evidences underlying the histopathologic patterns of NP 
as well as the GC effects on NP? 
NP represents severe inflammatory cell infiltration and structure remodeling. A 
number of molecular/chemical mediators have been shown to be associated with NP 
histopathologic features (reviewed in Chapter 1.4.6, Page 15). However, most of 
these NP studies investigated inflammatory mediators objectively and could not elicit 
an overall picture of the molecular profile of NP. Hence, to explore the genes as well 
as their interaction network underlying the NP pathogenesis, it has been necessary to 
identify a large number of differentially expressed genes simultaneously and novel 
disease related candidates in NP.  
 
GCs are considered the most effective pharmacological therapy for chronic upper 
airway inflammation including NP and asthma [Fokkens et al., 2007; Bateman et al., 2008]. 
The predominant effects of GCs are to suppress eosinophil infiltration and relieve 
tissue damage and remodeling in NP by altering the expression of inflammation 
related genes. However, the underlying molecular mechanism of GCs in treating NP 
has not been fully elucidated.  
 
DNA microarray technology consists of a matrix with attached sequences that allow 
simultaneous analysis of expression of panels of human genes. This provides unique 
opportunities to identify the change of disease-associated gene and analyze the effects 
of drug treatment on a genome-wide scale. In addition, the comparison of profiles of 
significant genes can highlight the involvement of both expected and unsuspected 




Therefore, it is of interest to investigate the presence of genes differentially 
transcribed in human NP tissues and nasal mucosal control, and to analyze the 
alteration of gene expression in NP in response to oral GC treatment by using DNA 
microarray. Furthermore, the biological function and pathways associated with the 
micorarray-identified genes could also be explored by using bioinformatics software. 
So far, no report has shown the gene expression profiles in Asian NP and its response 
to oral GC treatment. Moreover, no integrated functional pathway analysis has been 
performed in previous NP studies. 
 
2.2 Aims of the study 
The principal aims of this thesis are to investigate the molecular/cellular mechanisms 
underlying the pathogenesis of NP as well as the response of NP to GC treatment. 
 
Specific aims of the thesis are as follows: 
(1) To test the superantigen hypothesis in Asian NP. (Chapter 4) 
(2) To study if methylation of tumor suppressor genes has some role in the 
hyperplasia of NP. (Chapter 5) 
(3) To identify the candidate genes/gene families underlying the development of NP 
as well as the response of NP to GC treatment. (Chapter 6) 
(4) To explore the biological functions and interactive pathway among the 





Most NP studies have been performed in Caucasian patients, but Asian (especially 
Chinese) NP may present different histopathological features, indicating the 
underlying molecular mechanisms of Chinese NP may be different from those of 
Caucasian NP. Our studies systemically study the pathogenic mechanisms of NP from 
Asian/Chinese patients at molecular and cellular levels: (i) superantigen study can 
elicit the involvement of Staphylococcus aureus and its superantigens in Asian NP; (ii) 
methylation study can provide novel information for possible epigenetic alterations of 
the commonly reported TSGs in a benign outgrowth situation in upper airway tissues; 
(iii) microarray study is applicable to identify disease/therapeutic candidates as well 
as their functional networks, and then to enhance the knowledge of the 













Chapter 3. Materials and Methods 
 
3.1 Study Subject 1 (for superantigen and methylation studies) 
Fresh NP tissues were obtained from 24 patients (19 males and 5 female, aged from 
21 to 58 years old, median age of 44) with unilateral/bilateral NP. They were 
scheduled for functional endoscopic sinus surgery at the Department of 
Otolaryngology, Head & Neck Surgery in the National University Hospital of 
Singapore. A control biopsy of inferior turbinate (IT) mucosa was obtained from 10 
non-NP patients (7 males and 3 females, aged from 18 to 56 years old, mean age of 
24), who were scheduled for septal plastic surgery due to septal deviation in the same 
hospital. All NP and control subjects did not have aspirin intolerance and asthma 
diagnosed by means of clinical history, and did not take either any form of antibiotics 
or GCs within 3 months before the study. In addition, three nasal inverted papilloma 
(IP) samples were obtained after being reviewed by a pathologist to confirm diagnosis, 
and none of the patients with IP had evidence of carcinoma. Papilloma biopsies from 
these IP patients were only used in methylation study. Three to five milliliters of 
peripheral blood were taken during surgery in all NP and IP patients as well as 
controls. Cases were coded to provide confidentiality. Fresh specimens were dissected 
into two sections: one section was quickly frozen by liquid nitrogen for DNA analysis; 
and the other section was wrapped with tissue freezing medium and then frozen by 
liquid nitrogen for histo-immunohistological examination. All samples were preserved 
at -80℃ until use. 
 
A signed informed consent was obtained from the study patients before surgery. 
Approval to conduct this study was granted by the National Medical Research 
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Council of Singapore and the Institutional Review Board of the Medical Faculty of 
National University of Singapore.  
 
3.2 Study Subject 2 (for gene expression study) 
In this prospective study, NP patients and non-NP controls were recruited from the 
Otorhinolaryngology Hospital, the First Affiliated Hospital, Sun Yat-Sen University. 
All subjects are Chinese. Twelve patients (9 males and 3 females; median age of 36; 
age range, 18-55 years) with bilateral NP that have refractory nasal obstruction 
requiring functional endoscopic sinus surgery (FESS) were included in this study. The 
diagnosis of NP was based on medical history and clinical examinations. Two sets of 
polyp biopsies were taken from the same patient, i.e., before the initiation (GC-naïve) 
and after (GC-treated) the oral prednisone treatment (10 mg thrice per day for 3-5 
days). Biopsy of inferior turbinate was obtained from control subjects (7 males and 3 
females; median age of 28 years; age range, 23-36 years) who underwent surgery for 
nasal septal deviation. This tissue served as nasal mucosal control. None of the 
patients and controls had upper respiratory infection nor undertook any forms of GCs 
and antibiotics for more than three months before the study. All subjects did not have 
history of aspirin exposure, asthma, and cystic fibrosis. Cases were coded to provide 
confidentiality. Fresh specimens were dissected into two sections: one section was 
preserved with RNAlater (Ambion, Austin, TX) for gene expression profiling and the 
other section was fixed in formalin for histological evaluation. All patients were 
recruited through physician referrals. Approval to conduct this study was obtained 
from the Institutional Review Board of the First Affiliated Hospital, Sun Yet-Sen 




3.3 Allergy test 
Serum samples from all study subjects were analyzed for total IgE levels, Phadiatop 
assay, and specific IgE (sIgE) to a common panel of inhalant allergens, including 
Dermatophagoides pteronyssinus, Dermatophagoides farianae, Aspergillus fumigatus, 
cockroach, common pollen, and ragweed mixtures. IgE test was carried out by using 
the ImmunoCAP system (Phadia AB, Uppsala, Sweden). The results were evaluated 
following manufacture’s instruction: a Phadiatop PAU/l (Pharmacia Arbitrary Units/l) 
value ≥ 0.35 was considered as atopy. 
 
3.4 DNA extraction 
Genomic DNA was extracted from frozen solid tissues and peripheral blood by using 
the Gentra Puregen Kit (Gentra Systems, Suite, MN). Both solid tissues and 
peripheral blood were collected from study subject 1 as indicated in Chapter 3.1.  
 
3.4.1 Extraction from solid tissues 
Solid tissues (including NP, IT, and IP) were frozen by using liquid nitrogen and then 
stored at -80℃ until used. DNA extraction followed the manufacturer’s protocols: (i) 
solid tissue was merged in Cell Lysis Solution followed by homogenizing; (ii) 
homogenate was treated with Proteinase K Solution and then incubated overnight; (iii) 
RNasae treatment (by using RNase A Solution) followed by protein precipitation (by 
using Protein Precipitation Solution) was done in cell lysate; (iv) DNA was 
precipitated was by using by using 100% Isopropanol (Sigma Aldrich, St.Louis, MO); 
(v) DNA hydration was used by DNA Hydration Solution. DNA concentration and 
purity were determined by using NanoDrop™ 1000 Spectrophotometer (Thermo 
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Fisher Scientific, Waltham, MA). DNA was then stored at -20℃. 
 
3.4.2 Extraction from peripheral blood mononuclear cell (PBMC) 
Clotted whole blood from both patients and controls was separated into serum and 
cellular components, both of which were stored at -20℃ until use. DNA extraction 
from PBMC was performed according to the manufacturer’s protocol: (i) blood clot 
was dispersed using a Clotspin™ basket; (ii) red blood cells were removed using 
RBC Lysis solution; (iii) cell pellet was lysed using Cell Lysis Solution with 
Priteinase K and then incubated overnight; (iv) protein precipitation was collected 
using Protein Precipitation Solution in cell lysate; (v) DNA was precipitated using 
100% Isopropanol (Sigma Aldrich); (vi) DNA hydration was performed using DNA 
Hydration Solution. DNA concentration and purity were determined by using 
NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific). DNA was then 
stored at -20℃. 
 
3.5 Experiments for superantigen study 
3.5.1 Standard polymerase chain reaction (PCR) 
The DNA (both solid tissues and PBMC) from Study Subject 1 (except the patients 
with IP) were selected. DNA from bacterial strain Oxford Heatley NCTC 657 was 
used as a positive control (kindly provided by Dr. Taylor, Department of Microbiology, 
NUS). Primers for the S.aureus related superantigens and nuc gene were described in 
Table 3.1. The PCR mixture contained 1x PCR Buffer II (Applied Biosystems, Foster 
City, CA), 3 mM MgCl2, 0.2 mM dNTP, 0.5 µM each primer (sense and antisense), 1 
U Taq-Gold polymerase (Applied Biosystems), and 1µl DNA template in a final 
volume of 25 µl. Reactions were initially denatured at 94℃ for 5 minutes followed by 
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35 cycles (30 sec at 94℃, 30 sec at 55℃, and 60 sec at 72℃) and finally followed by 
a 5-min extension at 72℃. Negative control without DNA template was performed for 
each set of PCR. PCR products were separated by electrophoresis on agrose gel with 
proper concentration (from 1% to 1.8%), stained with ethidium bromide, and 
visualized under UV illumination. 
 
Table 3.1 Primers for the detection of S.aureus related superantigens and nuc gene 
*Ref: 
1. Johnson et al., 1991 
2. Mclauchlin et al., 2000 
3. Brakstad et al., 1992 
 
3.5.2 Direct sequencing 
The PCR product amplified by primers of nuc gene was subjected to direct 
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sequencing analysis. The PCR mixture contains 1X PCR Buffer II (Applied 
Biosystems), 3mM MgCl2 , 0.2mM dNTP, 0.5µM each primer (sense and antisense), 
1U AmpliTaq polymerase (Amplied Biosystems), and 100 ng DNA template in a final 
volume of 25µl. Reactions were initially denatured at 94℃ for 5 minutes followed by 
40 cycles (30 sec at 94℃, 30 sec at 55 , and 30 sec at℃  72℃), and finally followed by 
a 5-min extension at 72℃. PCR products were separated by electrophoresis on 1.8% 
agrose gel, stained with ethidium bromide, and visualized under UV illumination. The 
correct size band was excised from agrose gel, purified by using the GFX PCR DNA 
and Gel Band Purification Kit (Amersham Biosciences) following the manufacture’s 
instruction. Purified PCR product was subjected to cycle sequencing PCR by using 
ABI Prism BigDye® Terminator v3.1 (Applied Biosystems) and reverse primer of nuc 
gene. The cycle sequencing PCR product was then sent to service lab for sequencing.  
 
3.6 Experiments for methylation study 
3.6.1 Bisulfite modification of DNA 
Purified DNA (both solid tissues and PBMC) and CpGenome Universal Methylated 
DNA (Chemicon International, Temecula, CA) were subjected to bisulfite 
modification by using EZ DNA Methylation-Gold Kit™ (Zymo Research Corporation, 
Orange, CA). Briefly, 1 µg of DNA was denatured by a thermal cycle (98°C /10 min, 
64°C /2.5 h) with CT Conversion Reagent (Zymo Research Corporation). Denatured 
DNA was applied in column for desulphonation and clean-up. Finally the DNA was 
eluted in M-Elution Buffer (Zymo Research Corporation) and stored at -20°C. 
 
3.6.2 Methylation-specific PCR (MSP) 
Primer were designed at the promoter regions and described in Table 3.2. The PCR 
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mixture contained 1x PCR Buffer II (Applied Biosystems), 2 mM MgCl2, 0.2 mM 
dNTP, 0.6 µM each primer (sense and antisense), 1.875 U Taq-Gold polymerase 
(Applied Biosystems), and 25ng bisulfite treated DNA template in a final volume of 
12.5 µl. Reactions were initially denatured at 95℃ for 8 minutes followed by 35 to 40 
cycles (30 sec at 94℃, 30 sec at the annealing temperature listed in Table 3.2, and 30 
sec at 72℃) and finally followed by a 3-min extension at 72℃ [Tao et al., 1999]. 
CpGenome Universal Methylated DNA was used as a methylation-positive control, 
while negative control without DNA template was performed for each set of PCR. 
PCR products were separated by electrophoresis on 1.8% agrose gel, stained with 

















Table 3.2 MSP and BGS primers 
 
* M, methylated sequence; U, unmethylated sequence. 
† AT, annealing temperature. 
a p16 MSP primer sequences described by Herman et al. [Herman et al., 1996]; Genbank accession 
numbers: X94154. 
b RASSF1A, PTPN6 and TSLC1 MSP or BGS primers designed by us; Genbank accession numbers: 
RASSF1A, AF102770; PTPN6, AB079851; TSLC1, AP003174. 
c CDH1 MSP primers described by Graff et al. [Graff et al., 1997]. Genebank accession number: 
L34545. 
d DAPK1 MSP primers described by Katzenellenbogen et al. [Katzenellenbogen et al., 1999]; Genbank 
accession numbers: AL161787. 




3.6.3 Bisulfite genomic sequencing (BGS) 
BGS primers for the indicated genes were shown in Table 3.2. The PCR mixture 
contained 1x PCR Buffer II (Applied Biosystems), 2 mM MgCl2, 0.2 mM dNTP, 0.6 
µM each primer (sense and antisense), 1.875 U Taq-Gold polymerase (Applied 
Biosystems), and 100 ng bisulfite treated DNA template in a final volume of 25 µl. 
PCR condition is the same as that described in MSP. The PCR products amplified 
with BGS primers were separated by electrophoresis on agrose gel. The band of the 
interest was carefully excised from the gel, and the gel slice was placed into the 
Spin-X® Centrifuge Tube Filters (Corning Incorporated Life Sciences, Lowell, MA) 
and mixed with distilled water. The DNA was eluted by centrifuging the tube at 
13,000 × g for 10 minutes at room temperature. 
 
Eluted DNA was cloned into pCR2.1-TOPO® vector by using TOPO® TA Cloning kit 
(Invitrogen, Carlsbad, CA). In brief, the steps include: (i) TOPO® cloning reaction – 
mix DNA with TOPO® vector; (ii) One Shot® Chemical transformation – mix the 
TOPO® cloning reaction with One Shot® Chemically Competent E.coli; (iii) 
incubation – incubate the transformants on Luria Broth (LB) plates containing 
ampicillin; (iv) selection of clones – randomly pick the white colonies; (v) isolation of 
plasmid DNA – use Wizard® Plus SV Minipreps kit (Promega, Madison, WI). Isolated 
plasmid DNA was subjected to cycle sequencing PCR by using ABI Prism BigDye® 
Terminator v3.1 (Applied Biosystems) and M13 reverse primers supplied by TOPO® 
TA Cloning kit. The PCR product was then sent to service lab for sequencing.  
 
3.7 Experiments for gene expression study 
3.7.1 RNA extraction from nasal tissues  
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Total RNA was extracted from solid tissues (NP and IT) by using RiboPure kit 
(Ambion), according to the manufacture protocol. Briefly, the procedures were 
described as follows: (i) tissues were removed from RNAlater and submerged in TRI 
Reagent® (Molecular Research Center Inc, Cincinnati, OH), followed by 
homogenizing; (ii) chloroform was added in homogenate and centrifuge at 12,000 × g 
to separate the mixture into a lower, red, organic phase, an interphase, and a colorless, 
upper aqueous phase; (iii) RNA remains in the aqueous phase while DNA and 
proteins are in the interphase and organic phase; (iv) aqueous phase was transferred 
into a filter cartridge-collection tube and RNA was binding to the filter; (v) after 
washing steps, the RNA was eluted through the filter.  
 
3.7.2 Quantification and gel electrophoresis of RNA 
Total RNA was quantified by NanoDrop™ 1000 Spectrophotometer (Thermo Fisher 
Scientific). The overall quality of total RNA can be assessed by electrophoresis on a 
denaturing agarose gel. To prepare the gel, 0.5 g agarose was dissolved in 1×MOPS 
running buffer (Ambion) mixed with 37% formaldehyde (12.3 M). 1 µg of total RNA 
was mixed with 1×volume Formaldehyde Load Dye (Ambion) and ethidium bromide 
(10 µg/ml), and then RNA samples were heated to denature at 65℃. Load the gel and 
electrophoresis at 5-6 V/cm. Visualize the gel on a UV transilluminator (UVP, Upland, 
CA). The RNA samples with good integrity which showed the ratio of 28S rRNA: 
18S rRNA at least 1.2:1 in gel picture were selected for downstream work (microarray 
and real-time RT PCR). This quality assessment led to exclude 2 pairs of NP samples 
and 4 controls. 
 
3.7.3 Microarray experiment 
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Ten pairs of NP samples (before and after GC treatment) and six controls were 
recruited in microarray experiment. Each subject was analyzed with a single gene 
chip. Preparation of cDNA, labeled cRNA, hybridization, staining, and scanning of 
Human Genome U133 Plus 2.0 (HG_U133 plus 2.0) arrays (Affymetrix, Santa, Clara, 
CA) was performed according to the technical manual outlined by Affymetrix 
(http://www.affymetrix.com/ Auth/ support/ downloads /manuals/ 
expression_ever_manual.zip)”. Figure 3.1 shows the flowchart of the microarray 
experiment procedures. Briefly, 1 µg of total RNA and diluted poly-A RNA controls 
were reverse transcribed to double-stranded cDNA using an T7-oligo (dT) primer 
(Affymetrix). In vitro transcription from the double-stranded cDNA was carried out 
using IVT Labeling Kit (Affymetrix). The biotinylated cRNA (20 µg) was fragmented 
by using 5× Fragmentation Buffer (Affymetrix). The fragmented cRNA was 
hybridized for 16 h at 45°C in a Hybridization Oven 640 (Affymetrix) to a HG-U133 
plus 2.0 chip (Affymetrix). Washing and staining of the arrays with 
phycoerythrin-conjugated streptavidin (Molecular Probes, Eugene, OR) was 
completed in a Fluidics Station 450 (Affymetrix). The arrays were then scanned using 




Figure 3.1 Flowchart of affymetrix gene chip experiment. Labeled cDNA or cRNA targets derived 
from the mRNA of a tissue are hybridized to nucleic acid probes attached to the gene chips. This 
picture is cited from Paszek, E. Introduction, Connexions Web site. http: // cnx.org/ content/ m12370/ 
1.3/, Sep 13, 2004.  
 
3.7.4 Quality control (QC) assessment for microarray experiment and data 
3.7.4.1 QC for fragmentation 
The unfragmented cRNA and fragmented cRNA were loaded into agarose gel with 
tris-acetate EDTA (TAE) buffer. cRNA with no more than 300 bp size was considered 
to be successfully fragmented and can be used in hybridization step. 
 
3.7.4.2 QC for assay performance 
To achieve the quality assessment for assay/hybridization performance, several 
control parameters were evaluated in data report (.rpt file) following the criteria 
outlined in “data analysis fundamentals” (https://support/downloads/manuals/ data_ 
analysis_ fundamentals_ manual.pdf). The control parameters include: (i) average 
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background and noise values; (ii) Poly-A controls; (iii). hybridization controls; (iv) 
internal control genes; (v) percent present; (vi) scaling factor.  
 
The average background and noise values represent the electrical noise of the scanner 
and sample quality. Affymetrix guideline recommends that typical average 
background values range from 20 to 100 for arrays scanned with the GeneChip 
Scanner 3000. Although each scanner has a unique inherent electrical noise associated 
with its operation, array data acquired from the same scanner should ideally have 
comparable noise values.  
 
Poly-A RNA controls can be used to monitor the entire target labeling process, and all 
of the Poly-A controls should be called “Present” with increasing signal values in the 
order of lys, phe, thr, and dap. Hybridization controls can be used to evaluate sample 
hybridization efficiency, and all of the controls should be called “Present” with 
increasing signal values in the order of bioB, bioC, bioD, and cre, reflecting their 
relative concentration.  
 
The 3’ to 5’ ratio of the internal control genes (β-actin and GAPDH) in each sample 
should not be more than 3, which indicate intact RNA and efficient transcription of 
double-strand cDNA. Compared array samples should have similar percent present 
values, and extremely low percent present values are a possible indication of poor 
sample quality. 
 
Differences in overall intensity are most likely due to assay variables including 
pipetting error, hybridization, washing, and staining efficiencies, which are all 
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independent of relative transcript concentration. Scaling/normalization method can 
correct these variables. Therefore, larger discrepancies among scaling/normalization 
factors of the studied arrays (e.g. 3-fold or greater) may indicate significant 
assay/biological variability or sample degradation, which leads to noisier data. 
 
3.7.4.3 QC for raw array data 
In Affymetrix GeneChip (HG-U133 Plus 2.0™), oligonucleotides of 25 base pairs in 
length are used to probe genes. There are two types of probes: reference probes that 
match a target sequence exactly, called the perfect match (PM), and partner probes 
which differ from the reference probes only by a single base in the center of sequence, 
so called mismatch (MM) probes. Typically 11 of these probe pairs, each interrogating 
a different part of the 3’-end sequence for a gene, make up what is known as a 
probeset. The intensity information from the values of each of the probes in probeset 
are combined together to get an expression measure. 
 
RMAexpress software version 1.0 Release (Free version available in 
http://rmaexpress.bmbolstad.com/) can analyze the unadjusted PM intensities of 
Affymetrix array data. The undjusted PM intensity of raw array data could be 
visualized by the “RMAExpress Raw Data Visualizer” window. Two output plots 
available: boxplots and density plots. Potential low quality data often present 
higher/lower PM intensity than the other arrays in the dataset in boxplots; while in 





3.7.4.4 Data normalization by Robust Multichip Average method 
The need for normalization arises naturally when dealing with experiments involving 
multiple arrays. To reduce the variation that is introduced during the process of 
carrying out the experiment, a total of 54,000 probesets, representing approximately 
38,500 genes on the HG-U133 Plus 2.0™ arrays from three Affymetrix probe-level 
datasets were underwent normalization. The three datasets are as follows: (i). 
GC-naïve NP (8 chips) versus controls (5 chips); (ii). GC-treated NP (8 chips) versus 
controls (5 chips); (iii). GC-treated NP and GC-naïve NP from the same patient (8 
pairs of chips). Each set was normalized by the Robust Multichip Average (RMA) 
method [Irizarry et al. 2003], available in RMAexpress software version 1.0 Release 
(Free version available in http://rmaexpress.bmbolstad.com/). RMA method does not 
depend on the choice of a baseline array, but rather treat PM and MM all as intensities 
that need to be normalized. The processing steps of RMA consist of a background 
adjustment, quantile normalization, and the median-polish summarization method, 
producing a single normalized expression set for each comparison. Therefore, 
RMAExpress computed expression value for each probeset and exported the results in 
log scale. Detail instruction of RMAexpress software can be referred to its Users 
Guide (http://rmaexpress.bmbolstad.com/RMAExpress_UsersGuide.pdf ). 
 
3.7.4.5 QC for normalized array data 
In addition to normalizing array data, RMAExpress software can also be used to carry 
quality assessment for normalized array data. Two main QC options were available in 
RMAExpress software: chip pseudo-images of residues and probe-level model (PLM) 
based quality statistics. The detailed instruction and algorithm of these two options 





When selecting the “Store Residuals” option from the software dialog box, chip 
pseudo-images are generated. Poor quality data typically has large intense patches of a 
single color in distinct regions. The typical images, both of good and poor quality, are 
listed in the online resource http://PLMImageGallery.bmbolstad.com.  
 
When using “PLM” as summarization method instead of “median-polishing” in the 
software dialog box, the QC statistics can be examined. Two PLM methods are used 
in RMAExpress: Relative Log Expression (RLE) and Normalized Unscaled Standard 
Errors (NUSE). Specifically, RLE values are computed for each probeset by 
comparing the expression value on each array against the median expression value for 
that probeset across all arrays. On the other hand, NUSE estimates the standard error 
for each gene on each array across arrays so that the median standard error for that 
gene is 1 across all arrays. Both RLE and NUSE processes account for differences in 
the variability between genes. Typically arrays with poor quality show up with boxes 
that are not centered about 0 (for RLE) / 1(for NUSE) and are more spread out; hence, 
RLE and NUSE are useful in determining outliers among the normalized data. 
 
3.7.5 Statistical analysis by Significant Analysis of Microrarray (SAM) 
Three RMA normalized data sets were then imported to Microsoft Excel spreadsheets, 
respectively, and formatted for analysis by the Significant Analysis of Microrarray 
(SAM) software, version 3.00 (Free version available in http://www-stat.stanford. 
edu/~tibs/SAM/) [Tusher et al., 2001]. Differentially expressed genes in each comparison 
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were identified by using SAM. SAM computes a statistic measuring the strength of 
the relationship between gene expression and a response variable, while taking into 
account the multiple testing nature of a microarray experiment. SAM method accepts 
normalized expression data sets and identifies statistically significant changes in gene 
expression by assigning each gene a score (called “d score”) based on its change in 
expression relative to the standard deviation of repeated measurements. Genes with 
score greater than a threshold, as determined by a tuning variable ∆, are deemed 
potentially significant. The percentage of such genes identified by chance is the false 
discovery rate (FDR). SAM uses permutations of empirical measurements to estimate 
the FDR for the called list in the form of a 90% confidence interval. FDR controls the 
expected proportion of incorrectly rejected null hypotheses (type I errors). In addition, 
fold change has also been indicated in each probeset ID in SAM generated gene list. 
The options selected for the SAM analysis: (i) response type: two-class, unpaired data 
(comparison of GC-naïve/GC-treated NP versus control); two-class, paired data 
(comparison of NP without versus with GC treatment); (ii) data logged: logged (base 
2); (iii) number of permutations: 5000. Hence, genes identified with FDR of 
0.8%/0.7% in the datasets of GC-naïve/GC-treated NP vs. control and with a FDR of 
6% in the dataset of GC-treated vs. GC-naïve NP were deemed significant if they 
passed a 1.5-fold change filter [Liu et al., 2004].  
 
How to define and control the FDR has been hotly debated, since each dataset is 
particular and must be treated as a special case. Based on the literature, we could not 
find the any widely accepted FDR bench mark. Therefore, to estimate a proper FDR 
for the given dataset, we have compared different gene lists based on different FDR 
value issued to the dataset.  
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With regard to the gene lists generated from the datasets of GC-naïve NP vs. control 
and GC-treated NP vs. control, the cut-off of FDR was defined strigenently low, 
otherwise there would be huge amount of significant genes. In contrast, the threshold 
of FDR for the dataset of GC-treated vs. GC-naïve NP was defined a little bit higher 
since the number of GC-responsive genes was not large. Then we have tried to use 
FDR 0.005, 0.006, 0.007, 0.008, 0.009, and 0.01 to the datasets of GC-naïve NP vs. 
control and GC-treated NP vs. control; while used FDR 0.05, 0.06, 0.07, 0.08, 0.09, 
and 0.10 to the dataset of GC-treated vs. GC-naïve NP.  
 
To compare the gene lists generated based on different FDR values, we always looked 
for those genes assigned with the cut-off FDR value (here we called them “marginal 
genes”), i.e., examining the genes with FDR 0.005 in the gene list generated from 
FDR 0.005. Some parameters of these “marginal genes” were examined in order to 
evaluate the suitability of the prescribed FDR: (i). the SAM score; (ii). the expression 
level (i.e., extent of detection signal); (iii). the biological sense. For example, if the 
“marginal genes” with FDR 0.005 matched the criteria of high SAM score (> 2.0 or < 
-2.0), expression with detection signal, and biological sense, FDR 0.005 is proper for 
the dataset. Then we went to check the “marginal genes” from gene list with FDR 
0.006, if it also passed the criteria, we looked for the FDR 0.007; in such sequence, 
we chose the next to last FDR which cannot pass the criteria. Finaly, FDR 0.008, FDR 
0.007, and FDR 0.06 were considered to be suitable for the datasets of GC-naïve NP 
vs. control, GC-treated NP vs. control, and GC-treated vs. GC-naïve NP, respectively. 
 
After generating the gene list based on proper FDR, we filtered these genes by fold 
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change. From the literature, 1.5- or 2-fold appears to be commonly used as bench 
mark. Hence, we also compared the gene lists filtered by 1.5-fold and 2-fold. In this 
case, we considered that 1.5-fold should be a suitable cut-off since it can guarantee 
most genes with biological sense.  
 
3.7.6 Annotation analysis 
Gene annotations of the analyzed transcripts were verified by means of web-based 
program Netaffx™ Analysis Center (http://www.affymetric.com/analysis/index.affx). 
This resource contains probe sequences and up-to-date gene annotations and allows 
researchers to quickly search for information of gene annotation, compare and refine 
results, and export data into Excel-friendly formats. Two filtration steps were 
performed: firstly, those transcripts which did not contain identified gene symbols 
were filtered; secondly, those genes with redundant probe identities and those 
transcripts with unknown gene ontology (such as those annotated with “chromosome 
open reading frame”, “hypothetical protein”, “KIAAs” and “family with sequence 
similarity”) were filtered. 
 
3.7.7 Class predictor analysis 
The SAM-generated significant genes from two datasets (GC-naïve NP vs. control 
and GC-treated vs. GC-naïve NP) with their identifiers were imported in GeneSpring 
software version 7.3 (Agilent Technologies, Santa Clara, CA) and subjected to class 
predictor analysis, including hierarchical clustering analysis and principal component 
analysis (PCA). 
 
3.7.7.1 Cluster analysis 
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Tree view cluster, which is composed of gene tree and condition tree, is useful to 
explore the similarity among the genes and conditions (or say “samples”, such as NP 
and control samples) [Eisen et al., 1998]. Gene trees are dendrograms used as a method 
of showing relationships among the expression levels of genes over a series of 
conditions. Condition trees like gene trees, instead of showing the relationships 
between genes, they show the relationships among the expression levels of conditions. 
Gene trees and condition trees were built up by selecting “Clustering>Gene 
Tree/Condition Tree” option from the Tools menu of the software. In both of these 
two “trees”, spearman correlation was used in similarity measure, while average 
linkage was used in clustering algorithm. In addition, similar branches were merged 
by default and confidence levels of each branch were calculated by bootstrapping. 
Cluster analysis was also conducted in those 31 eosinophil associated genes by using 
the same algorithm.  
 
3.7.7.2 Principal component analysis 
PCA is a decomposition technique that produces a set of expression patterns known as 
principal component [Raychaudhuri et al., 2000]. It is helpful to find out how samples can 
be separated after the analysis. Liner combinations of these patterns can be assembled 
to represent the behavior of all of the conditions in a given dataset. PCA scores (or 
called eigenvalues, between -1 and 1) are calculated by computing the standard 
correlation between each condition’s expression profile vector and each principal 
component vector (eigenvector). Eigenvalues can be representative of the level of 
explained variance as a percentage of total variance (reported under “Percent 
Variance” in the results window). The percent of variance explained is dependent on 
how well all the components summarize the data. To run PCA, just select “Principal 
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Components Analysis” from the Tools menu of the software and then choose “PCA on 
Conditions” tab. The output results can be chosen as two-dimensional (2D) plot. 
 
3.7.8 Ingenuity Pathways Analysis (IPA) 
The gene lists identified by SAM, containing affymetrix proset ID as transcript 
identifiers and corresponding expression values (d scores), were uploaded into the 
Ingenuity Pathway Analysis (IPA) tool (version 6.0, Ingenuity® Systems, 
www.ingenuity.com), a web-delivered application that enables the discovery, 
visualization, and exploration of molecular interaction networks in gene expression 
data. Each gene identifier was mapped to its corresponding gene object in the 
Ingenuity Pathway Knowledge Base (IPKB), which provided up-to-date high quality 
knowledge of pathway interactions in broad-genome-wide coverage. Functional 
analysis, network analysis, and Canonical Pathway analysis were executed by IPA. 
 
3.7.8.1 Functional analysis 
The database of IPA functional analysis currently has three primary categories: (i) 
Diseases & Disorders; (ii) Physiological System Development & Function; (iii) 
Molecular & Cellular Functions. There are 85 high level functional categories that are 
classified under these primary categories. Lower level functions are classified within 
the high level categories. Specific functions are the lowest level functions found in 
IPA. Each lowest level function has a population of associated molecules. The 
example for this hierarchical classification is: Molecular & Cellular Functions 
(primary category) > Cellular Movement (high level function) > Migration (lower 
level function) > Migration of Eukaryotic Cells (specific function). Three types of 
functional analysis can be performed in IPA: functional analysis for a dataset, 
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comparison of functional analysis, and functional analysis for a network. For more 
details, see the Ingenuity Functional Analysis p-value whitepaper (https:// 
analysis.ingenuity.com/ pa/ info/ help/ help.htm#ipa_help.htm). 
 
(1) Functional analysis for a dataset 
Genes from the dataset that were associated with biophysiological functions and/or 
diseases in the IPKB were considered for the functional analysis. Fischer’s exact test 
was used to calculate a p-value determining the probability that each biophysiological 
function and/or disease assigned to that dataset is due to chance alone. In this method, 
the p-value for a given function is calculated by considering (i) the number of 
functional analysis molecules that participate in that function; (ii) the total number of 
molecules that are known to be associated with that function in IPKB. In general, 
p-value less than 0.05 indicates a statistically significant, non random association. 
 
IPA then generated a series of significant high level functions in each primary 
category for each dataset. In the category of Molecular & Cellular Functions, top-10 
high level functions were selected based on the rank of the significant level (p-value) 
assigned to function (Appendix I, Page 265). However, in the other two primary 
categories, some respiratory irrelevant diseases/disorders (e.g., reproductive system 
disease, ophthalmic disease and metabolic disease) and some respiratory irrelevant 
physiological development/functions (e.g. embryonic development, behavior and 
reproductive system development and function), no matter how significant or not, 
were filtered out first; consequently, the top significant functions of these two 
categories were selected according to the significant level assigned to the high level 
function (Appendix I, Page 265).  
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(2) Comparisons of functional analysis 
To determine whether and to what extent a given high level function is affected from 
one observation to another within a comparison we can start by comparing the extent 
to which the significances change from one observation to another, i.e. if the 
significance of a function changes from one treatment (e.g., GC treatment) to the next, 
then it is likely that the treatment had an impact on the function under investigation. 
 
The strategy to compare the GC treatment effects on the high level functions among 
these three datasets are described here: (i) Step 1, the functions in dataset of GC-naïve 
NP vs. control were set as baselines and these selected functions in other two datasets 
were automatically arranged side-by-side with the baselines by IPA software; (ii) Step 
2, if the significant levels of the relevant functions in the dataset of GC-treated NP vs. 
control were much lower than the baselines, it means that GCs may have effects on 
the genes associated with these functions; (iii) Step 3, the functions found to be 
associated with GC effects in step 2 were referred to dataset of GC-treated vs. 
GC-naïve NP, if these functions showed similar or higher significant levels in dataset 
of GC-treated vs. GC-naïve NP as compared to dataset of GC-treated NP vs. control, 
it double confirms the GC effects on these functions in NP.  
 
(3) Functional analysis for a network 
The functional analysis of a network identifies the biophysiological functions and/or 
diseases that are most significant to the genes in the network. The network genes 
associated with biophysiological functions and/or diseases in the IPKB were 
considered for the analysis. Fisher’s exact test was used to calculate a p-value 
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determining the probability that each biophysiological function and/or disease 
assigned to that network is due to chance alone. In general, p-values less than 0.05 
indicate a statistically significant, non random association. 
 
3.7.8.2 Network analysis 
The uploaded significant gene lists were also subjected to network analysis by IPA. 
The molecules of interest which interact with other molecules in IPKB are identified 
as Network Eligible molecules. These so-called focus genes were then used as a 
starting point for generating biological networks. To start building networks, the 
application queries the IPKB for interactions between focus genes and all other gene 
objects stored in the knowledge base, and generates a set of networks. Every resulting 
gene interaction has supporting literature findings available online. Networks are 
limited to 35 molecules each to keep them to a usable size. IPA then computes a score 
for each network according to the fit of the user’s set of significant genes. The score is 
derived from p-value and indicates the likelihood of the focus genes in a network 
being found together as a result of random chance. A score of 2 indicates that there is 
a 1-in-100 chance that the focus genes are together in a network as a result of random 
chance. Therefore, scores of 2 or higher have at least a 99% confidence of not being 
generated by random chance alone. The score is not an indication of the quality or 
biological relevance of the network; it simply calculates the approximate “fit” 
between each network and the Network Eligible molecules. For more details, see the 
Ingenuity Pathways Analysis Network Generation Algorithm whitepaper (https:// 
analysis.ingenuity.com/ pa/ info/ help/help.htm#ipa_help.htm). 
 
3.7.8.3 Canonical Pathway Analysis 
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IPA provides the Canonical Pathways, which are well-characterized cell signaling 
pathways that have been curated and hand-drawn by Ph.D. level scientists. The 
information contained in Canonical Pathways comes from specific journal articles, 
review articles, text books, and KEGG Ligand. The diagram displayed in the 
Canonical Pathway view is representative of the canonical pathway at the cellular 
level. The significance of the association between the dataset and the Canonical 
Pathway was measured in 2 ways: (i) a ratio of the number of genes from the dataset 
that map to the pathway divided by the total number of genes that map to the 
Canonical Pathway is displayed; (ii) Fischer’s exact test was used to calculate a 
p-value determining the probability that the association between the genes in the 
dataset and the Canonical Pathway is explained by chance alone. In general, p-value 
less than 0.05 indicate a statistically significant, non random association. 
 
Since most canonical pathways are specifically made up of limited well-known genes, 
the involvement of just one key gene within a Canonical Pathway may be still 
biologically interesting, even if this pathway is not statistically significant. So that we 
prefer to look for the ratio of the number of genes rather than the p-value, and focus 
on those pathways related to the results of functional analysis (e.g., inflammation, 
cellular growth, proliferation, movement and death) and the NP pathological patterns. 
In addition, in order to narrow down the selection of the Canonical Pathways, some 
“redundant” pathways (e.g., apoptosis signaling vs. death receptor signaling, 
EGF/EGFR signaling vs. neuregulin signaling, and ERK/MAPK signaling vs. 
p38/MAPK signaling), and the pathways without alteration of key genes (e.g., no 
alteration of IL-10 in IL-10 signaling pathway) were filtered. Finally, top-7 relevant 
Canonical Pathways were selected, including apoptosis signaling, complement system, 
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EGF/EGFR signaling, eicosanoid signaling, ERK/MAPK signaling, IL-6 signaling, 
and NF-kappaB signaling. 
 
3.7.9 Real-time reverse transcription (RT) PCR 
One microgram of the total RNA was reversely transcribed using TaqMan Reverse 
Transcription Reagents kit (Applied Biosystems) based on the manufacturer’s 
protocol. Briefly, the reverse transcription PCR (RT-PCR) mixture contained 1X 
TaqMan RT buffer, 5.5 mM MgCl2 , 500 µM dNTP, 2.5 µM Random Hexamer, 
0.4U/µl RNase inhibitor and 1.25U/µl MultiScribe Reverse Transcripase in a final 
volume of 50 µl. RT-PCR reactions were performed in thermal cycler with the 
following conditions: 25℃/10 min, 48℃/30 min, 95℃/5 min. cDNA samples were 
stored in aliquots at -20℃ until use. 
 
Real-time RT PCR analysis was performed to validate the expression of selected 
target genes which showed significant differences in microarray analysis. In addition, 
the expression of two GR gene products (GRα and GRβ) whose probe IDs were not 
available in affymetrix arrays was also determined. The TaqMan assays (Applied 
Biosystems) of target genes were described in Table 3.3. Both target and reference 
(GAPDH) genes were amplified in separate wells in triplicate. The PCR amplification 
was performed in a final volume of 25 µl, containing 10 ng of cDNA, 1× TaqMan 
Gene Expression Assay (Applied Biosystems), and 1× TaqMan Universal PCR Master 
Mix (Applied Biosystems). The cycling conditions for ABI Prism 7300 Sequence 
Detection System (Applied Biosystems) were 50°C for 2 min and 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Briefly, each gene was 
amplified in separate tubes, and the increase in fluorescence was measured in 
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real-time. The threshold cycle (Ct), which is defined as the fractional cycle number at 
which the fluorescence reaches 10× the standard deviation of the baseline that was 
calculated. Relative gene expression was calculated using the comparative 2-∆∆Ct 
method as previously described [Livak et al. 2001]. 
 
Table 3.3 Identity for human Taqman Gene Expression Assays-On-Demand™ 
Gene Symbol Description Assay ID 
AP-1 genes   
c-Fos v-fos FBJ murine osteosarcoma viral oncogene homolog Hs00170630_m1 
c-Jun Jun oncogene Hs00277190_s1 
FosB FBJ murine osteosarcoma viral oncogene homolog B Hs00171851_m1 
JunB Jun B proto-oncogene Hs00357891_s1 
AP-1 related genes  
COX-2 Cyclooxygenase-2 Hs00153133_m1 
IL-6 Interleukin 6 Hs00174131_m1 
HBEGF Heparin-binding EGF-like growth factor Hs00181813_m1 
AREG Amphiregulin Hs00155832_m1 
EGR1 Early growth response 1 Hs00152928_m1 
Pro-inflammatory genes in NP in response to GCs  
CXCL9 Chemokine (C-X-C motif) ligend 9 Hs00171065_m1 
CXCL11 Chemokine (C-X-C motif) ligend 11 Hs00171138_m1 
MMP7 Matrix metallopeptidase 7 Hs00159163_m1 
MMP9 Matrix metallopeptidase 9 Hs00234579_m1 
Anti-inflammatory genes in NP in response to GCs  
DUSP1 Dual specificity phosphatase 1 Hs00610256_g1 
DUSP2 Dual specificity phosphatase 2 Hs00358879_m1 
DUSP6 Dual specificity phosphatase 6 Hs00169257_m1 
SPRY1 Sprouty homolog 1 Hs00398096_m1 
SPRY2 Sprouty homolog 2 Hs00183386_m1 
SPRY4 Sprouty homolog 4 Hs00540086_m1 
NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, zeta 
Hs00230071_m1 
SOCS3 Suppressor of cytokine signaling 3 Hs00269575_s1 
ANXA1 ANNEXIN A1 Hs00167549_m1 
SCGB1A1 Secretoglobin, family 1A, member 1 (uteroglobin) Hs00171092_m1 
ZFP36 Zinc finger protein 36 Hs00185658_m1 
THBD Thrombomodulin Hs00264920_s1 
Eosinophil related genes  
CD69 CD69 molecule Hs00156399_m1 
NR4A1 Nuclear receptor subfamily 4, group A, member 1 Hs00374230_m1 
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Gene Symbol Description Assay ID 
NR4A2 Nuclear receptor subfamily 4, group A, member 2 Hs00428691_m1 
CXCL2 Chemokine (C-X-C motif) ligand 2 Hs00236966_m1 
CCL11 Chemokine (C-C motif) ligand 11 (eotaxin) Hs00237013_m1 
IL5Ra Interleukin 5 receptor, alpha Hs00602482_m1 
C3 Complement component 3 Hs00163811_m1 
IL13RA2 Interleukin 13 receptor, alpha 2 Hs00152924_m1 
IL18 Interleukin 18 Hs00155517_m1 
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, alpha 
Hs00230071_m1 
Glucocorticoid receptor genes  
GRα   Glucocorticoid receptor alpha isoform Hs01005211_m1 
GRβ  Glucocorticoid receptor beta isoform Hs00354508_m1 
House keeping gene  
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 4333764T 
 
3.8 Histo-immunohistochemical examination 
Evaluation of the Study Subject 1 was used by frozen tissues, while evaluation of the 
Study Subject 2 was used by paraffin embedded tissues. The frozen tissue specimens 
were sectioned into a thickness of 4 µm by using Leica CM 1850 Cryostat (Leica, 
Wetzlar, Germany); while the paraffin embedded tissues were sectioned at 4 µm with 
Leica RM2125 Microtome (Leica). To obtain a general impression of the 
histopathological features of the examined specimens, slides were stained with 
hematoxylin and eosin (H&E). In addition, several interesting cellular markers and 
target genes were evaluated by immunohistochemical staining.  
 
3.8.1 Staining procedures for frozen tissues 
Frozen sections were fixed in cold methanol:acetone (1:1) and then blocked by 3% 
hydrogen peroxide, and 2% normal goat serum (Dako A/S, Glostrup, Denmark). 
Slides were stained with anti-CDH1 monoclonal antibody [mouse IgG2a; clone, 36] 
(BD Biosciences, San Jose, CA), anti-CD8 monoclonal antibody [mouse IgG1 kappa; 
clone, C8/144B] (Dako A/S), and anti-neutrophil elastase monoclonal antibody 
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[mouse IgG1 kappa; clone, NP57] (Dako A/S) at dilutions of 1:100, and then were 
incubated at room temperature for 1 h. Species- and subtype-matched antibodies were 
used as negative controls [N-Universal Negative Control for mouse IgG and 
N-Universal Negative Control for rabbit IgG] (Dako A/S) and were performed in 
parallel with the specific staining. The sections were blocked with 2% normal goat 
serum (Dako A/S) again. The slides were then incubated with DAKO EnVision 
System Peroxidase kit (Dako A/S) for 30 minutes at room temperature. 
Diaminobenzidine (DAB) was used as substrate for color development. In the end, 
sections were counterstained with hematoxylin, dehydrated with serial concentration 
of ethanol, hydrated with xylene and mounted with mounting medium (Dako A/S). 
 
3.8.2 Staining procedures for paraffin embedded tissues 
Deparaffinization and rehydration were performed in prior to the staining of paraffin 
embedded sections. Slides were processed with Target Retrieval Buffer (Dako A/S). 
Endogenous peroxidase activity was blocked with 3% H2O2. Slides were stained with 
anti-c-Jun monoclonal antibody [mouse IgG2a; clone, 3/Jun] (BD Biosciences) and 
anti-c-Fos polyclonal antibody [Rabbit IgG; clone, K-25] (Santa Cruz Biotechnology, 
Santa Cruz, CA) at dilutions of 1:100 and 1:300, respectively, and then were 
incubated at room temperature for 1 hour. Species- and subtype-matched antibodies 
were used as negative controls [N-Universal Negative Control for mouse IgG and 
N-Universal Negative Control for rabbit IgG] (Dako A/S) and were performed in 
parallel with the specific staining. The slides were then incubated with DAKO 
EnVision+System-HRP (Dako A/S) at room temperature for 30 min. 
Diaminobenzidine was used as substrate for color development. All slides were 
counterstained with hematoxylin (Sigma Aldrich), dehydrated with serial 
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concentration of ethanol, hydrated with xylene and mounted with mounting medium 
(Dako A/S).  
 
3.8.3 Evaluation of histo-immunohistochemical patterns 
Several histo-immunohistochemical patterns were examined with a light microscope 
including infiltration of inflammatory cells, epithelial integrity, edema status, and 
target gene expression. To have a standardized histological evaluation of the staining 
(including both H&E staining and immunostaining), the pathologist independently 
assessed all cases in a blind fashion. 
 
3.8.3.1 Evaluation of infiltrated inflammatory cells 
Infiltration of eosinophils was evaluated based on H&E staining, while infiltration of 
neutrophils and CD8+ cells was examined based on immuno-staining. The results of 
cell counting were showed in percentage, which were calculated by positive staining 
cells per 200 cells at 400× magnification in every five fields with high-intensity 
positive cells. The percentage of these inflammatory cells was categorized into four 
grades: Grade 0, none; Grade 1, less than 10%; Grade 2, 10% to 40%; Grade 3, more 
than 40%.  
 
3.8.3.2 Evaluation of epithelial integrity and edema status in the nasal tissues 
Since the tissue morphology was preserved well in formalin fixed specimens, only the 
paraffin embedded sections were examined for assessing epithelial integrity as 
described [Wladislavosky-Waserman et al., 1984]. Grade 0 indicated intact epithelium 
which all layers of epithelial cells were present; grade 1 indicated moderately 
damaged epithelium which 2 or more layers of cells were present; grade 2 indicated 
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severely damaged epithelium which only 1 layer of cells or no epithelial cells (naked 
basement membrane) remained. In this study, grade 0 was defined as “intact” 
epithelium, while grade 1 and 2 were defined as “damaged” epithelium. The status of 
edema is also evaluated and classified as: grade 0, no edematous stoma; grade 1, mild 
or moderate edematous stoma and grade 2, severe edematous stoma. 
 
3.8.3.3 Evaluation of target gene expression 
In methylation study, protein level of CDH1 was evaluated from frozen sections; 
while in gene expression study, protein level of c-Jun and c-Fos was examined from 
paraffin embedded sections. 
 
Differential CDH1 expression was defined in three categories as described [Zheng et al., 
1999]: high level of expression (>75% cells were positive), intermediate level of 
expression (35% to 75% cells were positive), and low level of expression (<35% cells 
were positive). The counting was performed blindly without the investigator knowing 
the identity of the sample. 
 
For slides stained with antibodies to c-Jun and c-Fos, a semi-quantitative scoring 
system considering the extent of immunoreactivity and staining intensity was 
performed [Putti et al., 2002]. The immunoreactivity of c-Jun or c-Fos within the 
epithelium region was graded as “0 point” for negative staining, “1 point” for < 15% 
positive cells, “2 points” for 15-60% positive cells, and “3 points” for > 60%. The 
intensity of c-Jun or c-Fos staining was graded as “1 point” for weak staining, “2 
points” for moderate staining, and “3 points” for strong staining. The overall score 
was calculated by multiplying the score of immunoreactivity and intensity of staining 
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in each case. Hence, the maximum score for individual case is 9. In this study, the 
overall score of ≥ 6 was defined as “strong” expression while the overall score < 6 
was defined as “weak” expression. 
 
3.9 Statistical analysis 
All data in methylation study and gene expression study were analyzed using the 
SPSS statistical software V14.0 (SPSS Inc., Chicago, IL).  
 
3.9.1 Statistics in methylation study 
Fisher’s exact test and continuity correction were used to compare the methylation 
frequency in different study groups (NP versus control) and in different sample types 
(solid tissues versus PBMC samples) in NP and control group, respectively. Fisher’s 
exact test was used to analyze the methylation status of CDH1 in relation to the 
expression of this gene. The Mann-Whiney two-tailed test was used to compare the 
gene methylation status in clinical parameters (such as atopic, 
eosinophil/neutrophil/CD8+ cell infiltration). Values were considered significant if p 
< 0.05. 
 
3.9.2 Statistics in gene expression study 
Power and sample size estimation suggested that a minimum of four biopsies in each 
study group are required to detect a 1.5-fold difference in gene expression with a 1% 
significance level and a 90% power. Hence, we would expect to detect a 2.0-fold 
difference in gene expression with p < 0.01 and with a 90% chance of avoiding a type 
II error.  
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Wilcoxon matched pairs sign rank test was used to compare eosinophils and 
neutrophils count, epithelial integrity, edema status and gene expression levels, in 
GC-treated versus GC-naïve NP samples. Mann-Whitney two-tailed test was 
performed to compare gene expression levels between NP tissues, either GC-treated 
or GC-naïve, versus nasal mucosal controls. Spearman rank analysis was used to 
analyze the correlation between the gene expression levels assessed by microarray 
and those measured by quantitative PCR; and between fold change of c-Jun and other 
AP-1 related genes. Fisher’s exact test was used to assess the relationship between 
protein expression of c-Jun and epithelium integrity in NP tissues. Values were 

















Chapter 4. Role of Staphylococcus Aureus and Superantigens in Nasal 
Polyposis 
 
To test the superantigen hypothesis in Asian NP, we carried out a pilot study 
performed in 24 cases of NP samples and 10 inferior turbinate (IT) samples as 
controls. Standard PCR was used to detect S. aureus specific gene (nuc) and 9 S. 
aureus derived enterotoxins (superantigens) (listed in Table 3.1, Page 40) by using 
DNA samples isolated from NP and IT tissues. 
 
Part I Results 
4.1.1 Patient characteristics and histological evaluation 
The NP and control subjects selected here are the same as the subjects selected in the 
methylation study, so that their clinical characteristics were summarized in Table 5.1 
(page 76). The majority of the NP patients are Chinese ethnics (about 70%). All NP 
patients had sinusitis, which was confirmed by CT scan of the sinuses. Atopy, a 
positive serum specific IgE antibody to common local allergens, was founded in 33% 
(8 out of 24) of NP patients and 50% (5 out of 10) of controls, respectively; but the 
IgE results were not significantly different between NP and controls (data not shown 
here). An increase of eosinophils, neutrophils, and CD8+ cells was evident in NP 
samples, but not in control turbinate samples. 
 
4.1.2 Detection of S. aureus and superantigens 
Nuc gene which encodes the thermostable nuclease of S. aureus has been considered a 
diagnostic marker for S. aureus infection [Brakstad et al., 1992]. Positive PCR results of 
nuc gene with bands of the expected size were obtained for only 2 out of 24 NP 
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tissues and 1 out of 10 IT tissues (Figure 4.1). No detection signal of nuc gene was 
found in all PBMC samples. Interestingly, there was one confounding PCR band close 
to the expected size of nuc gene in some NP tissues (e.g., NP1, NP3, and NP4 in 
Figure 4.1). To evaluate the positive PCR results, direct sequencing was performed 
and then the sequencing results were uploaded to Blast (online source: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). The blast results confirmed that the sequence 
from the nuc positive PCR band was amplified from the whole mRNA sequence of 
the nuc gene; while the sequence from the PCR band close to the correct size of nuc 
gene was confirmed to not be related to the nuc gene sequence (Figure 4.2). As far as 
the superantigens, there was no evidence to support that the 9 S. aureus enterotoxins 
DNA existed in any of the nasal mucosa samples and PBMC samples by PCR 
detection (Data not shown here).  
 
 
Figure 4.1 PCR product of S.aureus specific nuc gene. Gel picture shows the nuc gene in 
representative NP samples and NCTC 657 S.aureus bacteria chain (positive control). Only the band 








  Figure 4.2 









Figure 4.2 Direct sequencing results of nuc gene. (A) Blast results of direct sequencing for positive 
control. (B) Blast results of direct sequencing for NP18, which has PCR product with correct size. (C) 
Blast results of direct sequencing for NP1, which has PCR product with confounding size. 
 
Part II Discussion 
S. aureus and its superantigens have been proposed as elemental causes for the Th2 
shift and increase of eosinophils in NP (reviewed in Chapter 1.4.4, Page 9). We 
assumed the potential roles of S. aureus and its superantigens in NP in this 
prospective study. However, we found that S. aureus was only detected in 8% (2 out 
of 24) of the NP tissues and in 10% (1 out of 10) of the control IT tissues, indicating 
that the prevalence rate of S. aureus in NP is low and existence of S. aureus is not 
specific to NP. S. aureus was not found in any of the PBMC samples, indicating no 
systemic infection of S. aureus. Moreover, we could not find the presence of 
superantigens in NP. The results of no detection signal in superantigens were 
consistent with the low prevalence rate of S. aureus in NP. 
 
Although the prevalence rate of S. aureus in NP has not been summarized in the 
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literature, based on the current results and some published reports, it may range from 
8% to 64% [Fan et al., 2006; Niederfuhr et al., 2008; Van Zele et al., 2004]. Possible reasons for 
this wide range include the heterogeneities of NP (eosinophilic vs. neutrophilic), 
different studied populations (Asian vs. Caucasian), method and location of tissue 
sampling (nasal swab vs. mucosa biopsy; middle meatus vs. sinus mucosa), and 
different microbiological detection techniques (IgE test vs. PCR assays). Our study 
used PCR to directly detect S. aureus specific nuclease genes (nuc) in NP biopsy in 
Asian patients. The advantages of PCR are that it is a fast method that detects DNA of 
living as well as dead bacteria; and the PCR detection of nuc gene has shown a greater 
specificity (> 90%) in S. aureus measurement than the other methods [Brakstad et al., 
1992; Niederfuhr et al., 2008]. However, nuc-PCR assays may have low sensitivities 
(about 58%) if small amounts of DNA are used [Niederfuhr et al., 2008]. Therefore, 
whether the lack of detection signal for nuc gene is attributed to the little inputed 
DNA copy numbers need to be carefully examined in the future study. 
 
With regard to the superantigens, their prevalence rates appear to be different from the 
incidence of S. aureus in NP without asthma. For example, Van Zele et al. showed that 
only about 43% of S. aureus positive NP demonstrated an IgE response to 
superantigens [Van Zele et al., 2004]. In addition, there was no major difference in the 
presence of enterotoxin genes in S. aureus strains derived from NP or control patients 
[Van Zele et al., 2008]. Similarly, another study also showed no difference in the 
incidence of S. aureus among chronic sinusitis patients with or without NP and 
controls. S. aureus did not intensify the Th2 shift in NP patients [Niederfuhr et al., 2008]. 
Our results were in line with the recent reports which showed no detection of specific 
IgE of anti- S. aureus enterotoxins in Chinese NP [Fan et al., 2006]. In contrast, one 
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study showed that about one-third of the Chinese patients with NP presented an IgE 
response to superantigens, but the relationship between eosinophil inflammation and 
superantigens was low [Zhang et al., 2006]. The discrepancy in these results may be due 
to the different detection methods used in these studies and different histopathological 
features in the studied NP.  
 
Part III Conclusion 
In summary, the roles of S. aureus superantigens may not be evident in Asian NP, at 
least in our study population. Although there is increasing evidence that S. aureus 
superantigens may participate in the chronic inflammation of NP, our results and some 
published reports suggest that of S. aureus and its superantigens may not have a 
substantial role in Asian NP. The evidence for the role of S. aureus and its 
superantigens in NP is thought to be circumstantial and not present in all types of NP. 
Nevertheless, the potential role of S. aureus superantigens in NP cannot be ruled out. 
Some confounding factors (e.g., NP characteristics, studied population, and detection 
methods) in future superantigen studies in NP need to be carefully categorized and 
standardized. In addition, further studies are necessary to answer the question whether 
the presence of S. aureus and its superantigens in both NP and nasal mucosal controls 








Chapter 5 Methylation of Tumor Suppressor Genes in Nasal 
Polyposis 
To evaluate the promoter methylation status of some common tumor suppressor genes 
(TSGs) in NP, six commonly reported TSGs (p16, RASSF1A, CDH1, TSLC1, DAPK1, 
and PTPN6) whose expressions were frequently silenced by promoter methylation in 
multiple cancers were studied. In this study, we recruited three groups of subjects: 
three inverted papilloma (IP) served as controls representing benign tumors; 24 NP 
were the sample group; and 10 inferior turbinates (IT) from patients with septal 
deviation served as healthy controls. Methylation of the TSGs was evaluated in solid 
tissues and PBMC from all studied subjects by using methylation specific PCR 
(MSP). 
 
Part I Results 
5.1.1 Patient characteristics and histological evaluation 
The clinical and histological characteristics of the subjects (IP, NP, and controls) are 
summarized in Table 5.1. H&E staining was used in IP, NP, and healthy controls; 
while, immunostaining (for neutrophils and CD8+ T cells) was only applied in NP and 
controls. Atopy was evident in 33% of the NP patients and 50% of the healthy 








Table 5.1 Patient clinical and histological characters 
Sample 
ID 




NP1 M 47 - 1 1 1 - 
NP2 M 58 - 1 3 3 - 
NP3 F 50 - 3 1 2 - 
NP4 M 50 + 2 1 2 - 
NP5 M 53 - 3 2 2 - 
NP6 M 38 - N.A N.A N.A N.A 
NP7 F 23 - 2 3 3 + 
NP8 M 47 - N.A N.A N.A N.A 
NP9 M 54 - 2 2 2 - 
NP10 M 49 + 3 1 1 - 
NP11 M 34 - N.A N.A N.A N.A 
NP12 M 29 + 3 1 1 - 
NP13 F 40 - N.A N.A N.A N.A 
NP14 M 21 + 1 1 1 + 
NP15 M 42 - 2 2 2 - 
NP16 M 58 - 1 2 3 - 
NP17 F 46 - 1 3 1 - 
NP18 M 33 - 3 2 3 - 
NP19 M 29 + 1 1 1 - 
NP20 M 48 + 3 3 2 + 
NP21 M 49 - 1 2 3 - 
NP22 F 28 + 3 2 3 - 
NP23 M 42 + 2 3 2 + 
NP24 M 32 - 3 3 3 + 
IT1 M 23 - 0 1 1 - 








IT3 M 25 + 1 1 1 - 
IT4 F 40 - 0 1 2 - 
IT5 M 29 - 1 1 1 - 
IT6 M 29 + 1 2 2 - 
IT7 F 56 + 1 1 2 - 
IT8 M 18 - 1 1 1 - 
IT9 M 21 + 1 2 2 - 
IT10 M 23 - 1 1 1 - 
IP1 M 45 N.A 1 N.A N.A + 
IP2 F 36 N.A 1 N.A N.A + 
IP3 M 52 N.A 1 N.A N.A + 
 
* A Phadiatop PAU/L (Pharmacia Arbitrary Units/L) value ≥ 0.35 was considered as atopy. “+”, atopy; 
“-”, non-atopy. 
† The percentage of eosinophil/neutrophil/CD8+ cell was categorized into four grades: Grade 0, none; 
Grade 1, less than 10%; Grade 2, 10% to 40%; Grade 3, more than 40%. Grade 2 and Grade 3 were 
considered increased infiltration of the indicated cell type. 
# Squamous metaplasia of epithelium was evaluated qualitatively in H&E staining sections, i.e., “+” 
presence of sqamous metaplasia; “-”, absence of squamous metaplasia. 
Abbreviations: NP, Nasal polyposis; IT, inferior turbinate; IP, Inverted papilloma; N.A., not applicable. 
 
H&E staining revealed the patterns of eosinophil infiltration and epithelium structure 
in IP, NP, and controls. An increase cell count of eosinophils, neutrophils, and CD8+ 
cells was significant in NP, but not in IP or controls. With regard to the epithelium 
(Figure 5.1), IP showed an inversion of the neoplastic squamous epithelium with 
minimal mitosis and atypia, and rarely presented a respiratory epithelial structure. The 
surface epithelium of NP was typically respiratory mucosa with areas of transitional 





Figure 5.1 Histological patterns of epithelium with squamous metaplasia. (A) Squamous metaplasia 
from representative NP sample; (B) Squamous metaplasia from representative IP sample. All sections 
were stained with H&E staining and evaluated at ×100 magnification. 
 
5.1.2 Detection of methylation status by methylation-specific PCR (MSP) 
The DNA of solid tissues (IP, NP, and control IT) and the PBMC from the subjects 
were examined for promoter methylation in p16, RASSF1A, CDH1, TSLC1, DAPK1 
and PTPN6 genes by MSP. Representative MSP results of these genes are presented in 
Figure 5.2. The presence of a methylated signal always occurs with the presence of 
unmethylated signal, but not vice versa, indicating that these tissues consist of mixed 
cell populations in terms of methylation of these genes. In all samples, MSP results 
were confirmed by repeated tests in order to avoid any technical bias. The summary 
of the promoter methylation status of all six genes are shown in Table 5.2. The 
frequency of methylation of these TSGs in NPC was cited from the published results. 
For p16 and RASSF1A, only unmethylated alleles were detected in all of the studied 
samples. Methylation of CDH1, TSLC1, and DAPK1 was found in some samples from 
IP, NP and control groups; furthermore, methylation of PTPN6 was detected in all 
solid tissues. The methylation rate was significantly higher in solid tissues than in 
corresponding PBMC. However, no significant difference was detected in the 
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methylation frequencies of CDH1, TSLC1, DAPK1, and PTPN6 between NP tissues 
and control IT tissues (data not shown). Note that since the sample size of IP was too 
small, statistical comparison was not performed in this sample group.  
 
 
Figure 5.2 Representative samples of MSP analyses of DNA samples from NP, IT, and PBMC. 
Methylation (M) and unmethylation (U) primers sets were used to amplify the methylated and 
unmethylated sequences, respectively. L, size marker (100-bp DNA ladder); P, positive control. 
CpGenome Universal Methylated DNA was used as a methylation-positive control. 
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Table 5.2 Summary of TSGs methylation status (by MSP analysis) of different groups 












p16 0 0 0 0 0 46% d 
RASSF1A 0 0 0 0 0 84% d 
CDH1  46% 70% 30% 20% 2 52% e 
TSLC1 29% 30% 0 0 1 68% f 
DAPK1 38% 50% 5% 0 1 76% d 
PTPN6 100% 100% 0 0 3 N.A. 
 
NP, Nasal Polyp; IT, Inferior Turbinate; IP, inverted papilloma; NPC, Nasopharyngeal carcinoma 
N.A., not applicable.  
  a Methylation frequency of each gene in different sample type from NP patients and IT controls.  
   b Only counted the number of IP samples with methylated status, due to the small sample size. 
  c Methylation frequency of NPC is referred to published reports. 
d Kwong et al., 2002 
e Tsao et al., 2003 
f Zhou et al., 2005 
 
5.1.3 Confirmation of MSP results by bisulfite genomic sequencing (BGS) 
For CDH1, TSLC1, DAPK1, and PTPN6, BGS analysis was further performed to 
check their detailed methylation status (Figure 5.3). BGS showed that all the 
cytosines at non-CpG sites were converted to thymines, validating the adequacy of the 
bisulfite modification. BGS results for CDH1, TSLC1, and DAPK1 showed that only 
low levels of methylation (1 out of 10-15 alleles sequenced was fully methylated) 
were detected in samples with methylation detected by MSP; while BGS of PTPN6 
showed extensive methylation of CpG sites in most alleles (3 out of 5). Hence, the 
methylation signals of the genes (CDH1, TSLC1, and DAPK1) detected by MSP were 
mainly derived from a small percentage of cells (< 10%) in NP and control mucosa. 
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Figure 5.3 Detailed methylation analysis in promoter of selected genes (SHP-1, DAPK1, TSLC1, and 
CDH1) by using BGS. CpG sites are shown on the top row as numbers. Each row of circles represents 
a single allele of the respective gene promoter analysed. Open circles: unmethylated CpG sites; filled 
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circles: methylated CpG sites. For BGS, at least 10 bacterial colonies were analysed for each DNA 
sample (except SHP-1). In all of the four genes, methylated alleles are present in respective NP solid 
tissue with MSP methylated signal, while unmethylated alleles are shown in the NP samples (except 
BGS of SHP-1 was analysed in PBMC) with no MSP methylated signal. (A) BGS primers amplify a 
589-bp region with 22 CpG sites in the SHP-1 promoter. (B) BGS primers amplify a 351-bp region 
with 36 CpG sites in the DAPK1 promoter. (C) BGS primers amplify a 211-bp region with 22 CpG 
sites in the TSLC1 promoter. (D) BGS primers amplify a 372-bp region with 30 CpG sites in the CDH1 
promoter.  
 
5.1.4 Correlation between methylation status versus histopathological patterns of 
NP and protein expression 
Methylation of CDH1, TSLC1, and DAPK1 was not significantly associated with the 
appearance of squamous metaplasia in IP and NP samples (data not shown). In 
addition, there is no significant correlation between promoter methylation status of 
these three genes (CDH1, TSLC1, and DAPK1) and cell counts for 
eosinophils/neutrophils/CD8+ T cells in NP tissues (data not shown). In the above 
analysis, all known confounding variables, such as age, sex and atopic status were not 
found to be associated with methylation status of individual genes (data not shown). 
 
Due to the importance of CDH1 in epithelial development, we attempted to 
investigate the relationship between methylation status of CDH1, and its protein 
expression in the NP and control mucosa. Our results showed that CDH1 expression 
was found in all NP and IT specimens, which was mainly in the area of epithelium 
and endothelium (Figure 5.4). However, we did not find the anticipated correlation 
between CDH1 promoter hypermethylation and down-regulation of CDH1 expression 
in these nasal tissues (Table 5.3). 
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Figure 5.4 Immunohistochemical staining of CDH1 in NP samples. CDH staining is shown in right 
column, while the corresponding negative control is shown in left column. (A) High level of expression 
(>75%) of CDH1 in sample NP12 which does not have methylation of CDH1. (B) Intermediate level of 
expression (35% to 75%) of CDH1 in sample NP15 which has methylation of CDH1. (C) High level of 
expression of CDH1 in sample IT8 which has methylation of CDH1. A, B, and C ×100 magnification. 
 
Table 5.3 Correlation between CDH1 expression and methylation status of CDH1 in 
nasal tissues (both NP and IT) 
Methylation Status of CDH1b Expression of CDH1a 
No/weak methylation Methylation 
p- valuec 
Low/intermediate level  







a  High level of expression (>75% cells are positive), intermediate level of expression (35% to 75% cells 
are positive), and low level of expression (<35% cells are positive)  
b  Methylation status was determined by methylation-specific PCR analysis. 
c  p-value was determined by two-sided Fischer’s exact test, and p < 0.05 was regarded as statistically 
significant.  
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Part II Discussion 
In the head and neck region, the most common lesion encountered by the 
otolaryngologist relates to alterations of the surface squamous epithelium. The 
epithelium of NPC represents dysplastic epithelial changes (e.g., poorly differentiated 
squamous cells). IP is generally regarded as a benign neoplasm of the sinonasal cavity, 
although the metaplastic epithelium may exhibit dyplasia, and up to 10% of the IP 
transform into squamous cell carcinoma [Dictor et al., 2000]. There is increasing 
evidence suggesting that IP may arise from a background of sinonasal mucosal 
inflammation, and clinically IP is frequently associated with NP [Robinson et al., 2006]. 
Promoter methylation-mediated gene silencing is a hallmark of many squamous cell 
carcinomas, including NPC [Hasegawa et al., 2002], and methylation of TSGs in IP was 
also implied in the association between IP and squamous cell cancers [Stephen et al., 
2007].  
 
NP represents a damaged respiratory epithelium with areas of squamous metaplasia 
after abnormal remodeling. The gross view of NP is similar to IP (Figure 5.5), while 
in histological observation, the severity of squamous cell remodeling in NP is much 
lesser than that in IP (Figure 5.1, Page 78). Although NP has not been regarded as a 
cancer-prone lesion, the high recurrence rate of NP after surgical polypectomy and the 
abnormal remodeling of epithelium raise the question as to whether NP could share 
some pathological mechanisms with those malignant (e.g., NPC) and benign (e.g., IP) 
neoplasms in upper respiratory tissues. Indeed, some hyperplastic polyps from gastric 
and colorectal tissues have been considered to present malignant potential even 




Figure 5.5 Gross view of nasal polyps and nasal inverted papilloma. (A) Nasal polyps; (B) inverted 
papilloma. Both are under endoscope examination. Picture was taken from patients with NP or 
papilloma under endoscope examination. 
 
The six selected genes are regarded as common TSGs which control and prevent 
cancer development. P16 and RASSF1A are cell cycle inhibitors which can prevent 
the cancer cell from going through the G1/S phase transaction. CDH1 and TSLC1 are 
adhesion molecules which can control the tumor cell invasions. DAPK1 is a 
pro-apoptotic factor which can mediate death of cancer cells. PTPN6 is a negative 
regulator of cellular signaling in immune cells which antagonize the 
growth-promoting tyrosine kinases in leukemia/lymphoma. Inactivation of these 
TSGs contributes to the aberrant proliferation and differentiation of squamous cancer 
cells. In addition, methylation of these genes was also observed in the chronic 
inflammation of gastric and intestinal epithelial lesions which have been considered to 
predispose to cancers.  
 
Methylation of CDH1, TSLC1, and DAPK1 was observed in IP and NP, confirming 
that the methylation of some TSGs could also be detected in benign growths and 
inflammatory conditions. In addition, the methylation rate of these three genes was 
significantly higher in solid tissues than the corresponding PBMC, indicating it is 
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more likely a local event. However, methylation of CDH1, TSLC1, and DAPK1 was 
also found in control nasal mucosa and the methylation rate of these three genes was 
not significantly different between NP and controls. Indeed, sequencing results of 
CDH1, TSLC1, and DAPK1 in NP and IP tissues demonstrated that the CpG sites 
between the MSP primer sequences were not completely methylated and the 
percentage of methylated alleles was low. Furthermore, significant negative 
correlation between CDH1 promoter methylation and CDH1 expression was not 
found in the nasal tissues and some clinical characteristics of the patients (including 
age, appearance of squamous metaplasia, and infiltration of eosinophils) were not 
associated with methylation status of CDH1, TSLC1, and DAPK1. Hence, all this 
evidence would suggest that a low level of methylation of CDH1, TSLC1, and DAPK1 
may have a minimal contribution to the pathogenesis of the nasal benign lesions (IP 
and NP), and indicate that IP and NP should still be considered non-malignant. 
 
Methylation of TSGs is commonly negative in PBMC from non-cancer subjects 
[Gutierrez et al., 2003] and has been used as molecular detection strategies in tumors. 
However, methylation of CDH1 and DAPK1 was detected in PBMC from some of the 
IP, NP, and control subjects, and was in line with the previous studies which showed 
methylation of DAPK1 in PBMC from healthy subjects [Reddy et al., 2003]. Therefore, 
the methylation status of CDH1 and DAPK1 in PBMC may act as a confounding 
factor in tumor detection. 
 
Interestingly, it is obvious that methylation of PTPN6 was found in all solid tissues (IP, 
NP, and healthy control), but not at all in PBMC from all study patients. BGS results 
confirmed that methylation of PTPN6 in nasal solid tissues occurred in all CpG sites 
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of the amplified regions in most alleles. PTPN6 is primarily expressed in 
hematopoietic cells, and considered a putative tumor suppressor gene in lymphoma 
and leukemia. Most of the methylation studies of PTPN6 focused on the malignancy 
of the hematologic system [Oka et al., 2002]. Only one report showed a high frequency 
of methylation of PTPN6 in gallbladder carcinoma (GBC) and chronic cholecystitis. It 
was postulated that methylation of PTPN6 was an early event in GBC pathogenesis 
[Takahashi et al., 2004], however this study did not obtain normal gallbladder epithelium 
as control. Based on our data, we suggest that methylation of PTPN6 is only a 
tissue-specific phenomenon at least in upper airway mucosa and it may not contribute 
to any pathogenic mechanism in epithelial alteration on cellular infiltration. In 
addition, the lack of PTPN6 methylation in normal PBMC confirms that it should be a 
specific serum tumor marker for the detection of lymphoid/hematopoietic cancers, but 
PTPN6 is not a suitable molecular marker in detection of carcinoma (at least in airway 
tissues) based on PTPN6 methylation. 
 
It should be noted that there are limitations in this study. Because NP and IT are 
infiltrated by various cell populations, it is hard to identify which cell types contribute 
to the gene methylation. One report showed that infiltrating leukoctyes might account 
for the methylated CpGs in breast cancer tissues and confound the methylation 
detection [Lombaerts et al., 2004]. So the impurity of cell types may be a reason that 
normal control tissues also showed methylation signals, and that nasal samples with 
normal CDH1 expression showed a strong MSP product. Therefore, in future studies, 
it is recommended that different components of NP (especially epithelial area) could 
be isolated by laser capture microdissection and the gene methylation could be 
determined in a cell-specific manner. 
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Part III Conclusion 
In conclusion, this study compared the methylation status of six commonly reported 
TSGs in IP, NP and healthy nasal mucosa. Methylation of p16 and RASSF1A, were 
considered tumor-specific. Methylation of CDH1, TSLC1, and DAPK1 was found at 
low level in IP, NP, and control nasal mucosa with no difference in the detection rates. 
Methylation of PTPN6 is tissue-specific and should only be studied in hematopoietic 
disorders. The role of methylation of these genes in nasal mucosal inflammation 
appears to be minimal, and IP and NP are still regarded as benign lesions. Nonetheless, 
our study indicates that when using CDH1, TSLC1, and DAPK1 in studies of tumors, 
one need to bear in mind that weak methylation of these genes could still be detected 
in inflammatory or benign conditions, or even normal PBMCs, hence they may not be 















Chapter 6. Gene Expression Profiles in Nasal Polyposis and its 
Response to GC Treatment 
 
In this gene expression study, of 12 patients with untreated (GC-naïve) bilateral NP, 
two sets of NP biopsies were taken from each patient, i.e., before the initiation and 
after GC treatment. Biopsies of the inferior turbinate from 10 patients who underwent 
surgery for nasal septal deviation served as nasal mucosal controls. DNA microarrays 
containing 38,500 genes were used to characterize the global gene expression profile. 
Integrated microarray analyses, including functional analysis, network analysis, and 
canonical pathway analysis as well as the comparison of literature reviews were 
applied to identify key molecular pathways and genes underlying the pathogenesis of 
NP and the response of NP to GC treatment. Selected genes were validated by means 
of quantitative RT-PCR and immunohistochemistry in the polyps and control samples.  
 
Part I Results 
[Note that in the following content, the prefix of GC-naïve NP sample ID is indicated as “NP”, while 
the prefix of GC-treated NP sample ID is indicated as “NPR”; i.e., NP1 means the sample is from NP 
patient 1 before GC treatment, and NP1R means the sample is from NP patient 1 after GC treatment.] 
 
6.1.1 Patient characteristics and histological evaluation 
The demographic characteristics of the studied subjects are listed in Table 6.1. Atopy 
status was present in 8 patients and 2 controls, respectively. GC-naïve NP tissues 
revealed distinct histopathological patterns compared to control turbinates and the 
comparison is summarized in Table 6.2. The representative pictures for these 
histopathological profiles of NP (including infiltration of eosinophils, neutrophils, and 
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lymphocytes, epithelial damage and squamous remodeling, status of edema and 
fibrosis, density of glands) and the histological pictures of controls were shown in 
Figure 6.1. 
Table 6.1 Clinical and histological characteristics of NP patients and control 
 
Abbreviations: NP, Nasal polyposis; IT, inferior turbinate; GC, glucocorticoidsteroid; N.A., not 
applicable.  
a “+”, atopy, and “-”, non-atopy. 
b Eosinophil and neutrophil counting were showed in percentage, which were calculated by 
positive staining cells per 200 cells at 400× magnification in every five fields with high-intensity 
positive cells.  
Grading of cell count: Grade 0 = none; Grade 1 = less than 10%; Grade 2 = 10% to 40%; Grade 3 
= more than 40%.  
c Edema status: Grade 0 = absent; Grade 1 = mild or moderate; Grade 2 = severe. 
   d Epithelium integrity: 0, intact epithelium; 1, moderately damaged epithelium; 2, severely 
damaged epithelium. 




Figure 6.1 Representative staining pictures of nasal tissues. In GC-naïve NP tissues, some 
histopathological features are prominent: (A) epithelial damage and edema (grade 2); (B) eosinophil 
infiltration (grade 3); (C) neutrophil infiltration (grade 3); (D) high infiltration of lymphocytes; (E) 
dilation of glands. In GC-treated NP tissues, (G) absence of eosinophils and significant reduction of 
edema in GC-treated NP tissue. In control turbinate, (H) absence of eosinophils and edema, and 
presence of typical intact epithelium; (F) non-distensible glands in control turbinate. Pictures (A), (E), 
(C), (F), (G), and (H) were taken at magnification ×100, while pictures (B) and (D), were taken at 
magnification ×200. 
 92




GC-naïve NP Nasal mucosal control 
Epithelium Damaged epithelium; 
Parts of squamous metaplasia; 
Thickening of basement membrane.
Typical intact respiratory 
epithelium containing 
columnar ciliated cells. 
Stroma Severe edema in most NP tissues. No edema but with 
significant connective 
tissues 
Glands Low density, uneven distribution, 
and dilation with varying 
shape/size. 
High density, even 
distribution, and small 
tubulo-alveolar shape 
Infiltration cells High infiltration of eosinophils, 
neutrophils, and lymphocytes. 
Low infiltration of 
leukocytes. 
 
Significant correlation between the infiltration of eosinophils and neutrophils among 
subjects of GC-naïve NP and control was evident (r = 0.846, p < 0.001) (Figure 6.2). 
However, among these GC-naïve and control subjects, infiltration of both eosinophils 
and neutrophils was not correlated with atopic status; and infiltration of these two cell 
types was also not correlated with epithelial damage and edema status (data not 
shown here). 
 
Figure 6.2 Correlation between infiltration of eosinophils and neutrophils in nasal tissues (GC-naïve 
NP and control). Eosinophil and neutrophil counting were calculated in percentage, which were 
calculated by positive staining cells per 200 cells at 400× magnification in every five fields with 






















the square shapes outside the rectangle indicate GC-naïve NP samples. 
 
Most of the pathological findings in GC-naïve NP were reduced in response to GC 
treatment. Before GC treatment, epithelial damage (9 out of 12), high infiltration 
(grade ≥ 2) of eosinophils (10 out of 12) and neutrophils (8 out of 12), and severe 
edema (7 out of 12) were found in NP patients (Table 6.1). A short course of oral 
prednisone was effective in epithelial restitution, decrease of nasal eosinophil 
recruitment and tissue edema (Table 6.1). Among those 8 NP patients with increase of 
neutrophil infiltration, a reduction of neutrophil count following GC treatment was 
observed in 4 NP patients, but it did not reach statistical significance (p = 0.05). 
Interestingly, with regard to those 2 GC-naïve NP samples (NP3 and NP10) without 
significant epithelial damage, squamous metaplasia was observed in some parts of the 
epithelium; while improvement (i.e., no squamous metaplasia) in epithelium structure 
was evident after GC therapy, suggesting the effect of GCs on NP epithelial 
remodeling. 
 
6.1.2 Strategy for identifying candidate genes by microarray analyses 
After evaluating the histopathological patterns of NP as well as its response to GCs, 
we would like to study the molecular profiles underlying these histological changes in 
NP. The integrated microarray data analyses were therefore carried out. These 
analyses include the quality control evaluation of the samples/array data, statistical 
analysis of the genome-wide transcriptional alterations, class predictor analysis of 
gene expression patterns, functional and network analyses of the significant genes, 
and identification of candidate genes. 
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There are three comparison groups in the current microarray study: (i) the genes in the 
dataset of GC-naïve NP vs. control are considered to be involved in NP pathogenesis, 
i.e., NP disease associated genes; (ii) the genes in the dataset of GC-treated vs. 
GC-naïve NP are considered to underlie the molecular mechanism of the GC effect on 
NP, i.e., GC-responsive genes; while (iii) the genes in the dataset of GC-treated NP vs. 
control would more likely serve as references for the expression levels of NP 
associated genes which are regulated by GCs, i.e., whether the indicated NP relative 
gene is normalized by GCs or not. Therefore, the results from datasets of GC-naïve 
NP vs. control and GC-treated vs. GC-naïve NP are of great interest. Figure 6.3 



















6.1.3 Quality of samples and array data 
Quality assessments, which can potentially flag outlier samples, should be carried out 
in the initial analysis of Affymetrix GeneChip dataset. Serials of quality control (QC) 
procedures have been done before analyzing the significant genes. These steps include 
the evaluation of RNA quality, QC for microarray experiment, QC for assay 
performance, QC for raw array data, data normalization, and QC for normalized data. 
 
6.1.3.1 RNA quality 
Quality evaluation was performed in extracted RNA by determining RNA 
concentration, purity, and integrity. Since the least amount of RNA loaded in a gene 
chip is 1 µg and the volume of RNA cannot be more than 8 µl, the concentration of 
the selected RNA samples must be more than 150 µg/ml. The A260/A280 ratio was 
confirmed between 1.9 and 2.1 for pure RNA. 
 
The integrity of RNA was assessed by electrophoresis on a denaturing agarose gel. 
Figure 6.4A shows that the studied RNA have sharp 28S and 18S rRNA bands, and 
the 28S rRNA band is approximately 1.8 times as intense as the 18S rRNA band, 
indicating that these RNA are intact and acceptable for downstream work (micorarray 
and real-time PCR). Only the samples NP11, NP12, NP12R, IT7, IT8, IT9 and IT10 
showed faint 28S:18S bands (Figure 6.4B) and were considered partially degraded. 
Since the NP samples are compared pair-wise (before versus after GC treatment), this 
assessment led to the exclusion of 2 pairs of NP samples and 4 control samples for 
downstream RNA work. 
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Figure 6.4 Gel electrophoresis of RNA samples. One µg of total RNA from nasal tissues (both NP and 
IT) were run on a 1% denaturing agarose gel. The 18S and 28S ribosomal RNA bands are clearly 
visible in the all RNA samples from plate (A), but are smear and faint in samples NP11, NP12, NP12R, 
IT7, IT8, IT9 and IT10 from plate (B). Human Lung Total RNA (Ambion) was served as quality 
control.  
 
6.1.3.2 Quality of fragmented cRNA 
During the microarray experiment, fragmentation of cRNA target before hybridization 
onto GeneChip probe arrays has been shown to be critical in obtaining optimal assay 
sensitivity. The size of fragmented cRNA run on the gel picture should not be more 
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than 300 bp. All of the cRNA ready to load in a gene chip were confirmed 
successfully fragmented and representative samples were shown in Figure 6.5. 
 
Figure 6.5 Gel electrophoresis of fragmented/unfragmented cRNA. Lane 1 and 2 represent 
unfragmented cRNA from NP6 and NP6R; L3 and L4 represent corresponding fragmented cRNA from 
sample NP6 and NP6R. L,size marker (100-bp DNA ladder)  
 
6.1.3.3 Quality of assay performance 
Once the microarray experiment is completed, the operating software generates an 
Expression Analysis report file (.rpt) for each array and allows the researcher to 
review the assay/hybridization performance. Following the Affymetrix guideline (see 
Chapter 3.7.4, Page 47), several QC parameters were assessed (Table 6.3): (i) 
comparable average background values and noise were within the arrays; (ii) poly-A 
controls were called ‘Present’ with increasing signal values in the order of lys, phe, thr 
and dap; (iii) hybridization controls were called ‘Present’ with increasing signal 
values in the order of bioB, bioC, bioD and cre; (iv) 3’ to 5’ ratio for GAPDH or 
β-actin was no more than 3; (v) present value is more than 40%; (vi) consistency of 
array data was validated by confirming that the range of Present Calls is 40% to 50% 
and the difference in scaling factor is less than 3-fold within the compared arrays. 
Most of the arrays match these criteria, only arrays of NP9, NP10, and IT6 show high 
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value (> 3) of 3’ to 5’ ratio for β-actin and GAPDH. Since the NP samples are 
compared pair-wise (before versus after GC treatment), this assessment lead to 
exclude two pairs of NP arrays (NP9/9R and NP10/10R) and one control array (IT6) 
for downstream microarray analysis.  
   Table 6.3 Parameters for assessing assay performance (part 1) 
Internal control genes
(Signal 3’/5’)  
 






β-actin   GAPDH Present  Absent 
Scale 
factor 
NP1 32.18 0.79 2.73 1.03 45.80 52.70 4.639 
NP1R 32.03 0.74 2.52 0.99 43.90 54.60 5.004 
NP2 26.91 0.72 2.38 1.10 47.10 51.10 4.594 
NP2R 30.75 0.73 2.47 1.13 44.50 54.00 5.723 
NP3 31.81 0.80 2.65 1.11 45.50 52.90 4.363 
NP3R 30.81 0.75 2.30 1.02 45.10 53.40 4.759 
NP4 33.28 0.82 2.80 1.17 45.80 52.70 4.330 
NP4R 32.03 0.73 2.60 1.20 42.70 55.60 5.701 
NP5 32.01 0.80 2.85 1.56 43.90 54.60 5.626 
NP5R 32.06 0.76 2.75 1.45 44.80 53.70 5.305 
NP6 30.05 0.70 2.52 1.04 41.40 57.00 6.709 
NP6R 31.66 0.70 2.85 1.69 40.70 58.50 7.021 
NP7 33.59 0.73 2.60 1.20 44.00 54.40 5.694 
NP7R 31.26 0.71 2.69 1.69 41.40 57.10 5.809 
NP8 29.47 0.68 2.68 1.12 45.20 53.10 6.160 
NP8R 31.23 0.71 2.68 1.27 44.40 54.10 6.381 
IT1 28.17 0.69 2.35 1.14 42.10 56.10 7.313 
IT2 33.21 0.77 2.37 1.33 42.90 55.50 5.476 
IT3 30.57 0.78 2.50 1.24 44.40 54.10 6.205 
IT4 32.13 0.69 2.61 1.45 41.20 57.30 7.519 









Table 6.3 Parameters for assessing assay performance (part 2) 
Sample ____Poly-A controls (Signal)____ ___Hybridization controls (Signal)__ 
ID Lys Phe Thr Dap bioB bioC bioD cre 
NP1 96.35 113.42 145.26 751.87 223.75 576.33 1809.19 7810.37 
NP1R 96.71 99.82 123.47 671.58 246.48 573.04 1747.9 7679.04 
NP2 72.73 80.13 100.12 541.26 229.04 633.64 1987.55 7877.54 
NP2R 81.45 85.22 106.98 560.37 274.42 694.89 2027.72 8108.03 
NP3 67.58 80.97 102.41 565.63 207.29 501.68 1594.34 6632.25 
NP3R 78.35 85.65 128.46 616.36 197.07 591.29 1692.26 7439.61 
NP4 80.78 98.76 144.56 675.00 248.97 606.55 1932.21 7564.7 
NP4R 107.85 117.54 165.16 760.38 237.4 644.57 2000.11 8171.95 
NP5 79.65 99.36 112.60 553.63 290.54 730.56 2064.21 8796.98 
NP5R 82.04 98.97 114.85 612.37 235.95 618.88 1817.48 7838.46 
NP6 97.94 105.13 179.4 772.2 277.1 735.69 2017.83 9237.74 
NP6R 131.2 177.73 180.24 853.78 371.4 995.56 2660.38 12707.16 
NP7 113.83 126.09 181.24 821.08 231.99 582.43 1549.17 7789.59 
NP7R 102.97 143.96 198.7 759.92 222.37 559.17 1875.27 7825 
NP8 104.85 116.26 152.29 705.3 239.05 643.26 1977.44 8901.95 
NP8R 141.75 150.27 212.34 940.76 239.1 662.81 1906.72 9271.03 
IT1 122.01 131.97 185.09 798.05 262.46 686.88 1949.58 9822.6 
IT2 140.13 155.36 197.78 903.21 268.99 706.06 2154.29 9134.91 
IT3 114.84 124.97 163.84 777.20 259.28 717.81 1983.03 9057.46 
IT4 126.48 164.26 200.02 841.56 335.15 822.44 2159.50 11559.7 
IT5 148.34 186.3 239.63 1108.41 275.69 787.52 2282.75 10793.5 
 
6.1.3.4 Quality of raw array data 
Unlike the Affymetrix’s array data report which only gives the quality information of 
individual array, RMAExpress can assess the quality of array data within a whole set 
of compared arrays before data normalization. The arrays from eight pairs of NP 
samples (before and after GC treatment) and 5 controls, which passed the QC for 
assay performance, were recruited for analyzing perfect match (PM) intensity. Two 
optional plots (boxplots and density plots) generated by RMAExpress show the PM 
intensities for each array (Figure 6.6). Both of the two plots show that all the selected 
arrays have similar shape and trend, and comparable PM intensities, i.e., no outliers 





       (B) 
 
Figure 6.6 Visualization of array raw data. (A) Boxplots and (B) Density plots for visualization of the 
array data. For better visualization, perfect match intensities are log2 transformed. 
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6.1.3.5 Normalization of array data 
Normalization is a process for reducing variation among the multiple high density 
arrays of non-biological origin. RMAExpress software performs a Robust Multichip 
Average (RMA) method to compute normalized expression values of arrays by doing 
background correction, quantile normalization, and median-polish summarization. 
RMA normalization is carried out at probe level for all the probes on an array. The 
arrays from three datasets (GC-naïve NP vs. control, GC-treated NP vs. control, and 
GC-treated vs. GC-naïve NP) were normalized. An expression value for each probeset 
was generated. 
 
6.1.3.6 Quality of normalized data 
The quality of normalized arrays could also be assessed by several tools in the 
RMAExpress software. 
 
(1) Chip pseudo-images 
Chip pseudo-images of residuals are very useful for detecting artifacts on arrays that 
could pose potential quality problems. RMAExpress software can produce residual 
images on a chip-by-chip basis when computing normalization expression values. 
Figure 6.7 shows that the residual image of each array presented homogenized color 










(2) Probe level model (PLM) based quality assessment 
Two main PLM based quality statistics are available in RMAExpress: Relative Log 
Expression (RLE) and Normalized Unscaled Standard Error (NUSE). To identify the 
lower quality arrays, RMAExpress also provides quality control cutoffs applied to the 
RLE/NUSE Multiplot. The arrays which fall well outside the control limits for both 
RLE and NUSE metrics are considered outliers. Within our dataset, the boxplots of all 
the arrays demonstrated similar shape and locate near the center position (data not 
shown here); moreover, no outlier array was found from the summarized RLE/NUSE 
Multiplot (Figure 6.8).  
 
Figure 6.8 RLE and NUSE single summary plots of normalized array data. Normalized Unscaled 
Standard Error (NUSE) and Relative Log Expression (RLE) were used to access the quality of 
normalized data from NP and control samples. Dash lines are used to indicate the control limits. 
 
In summary, the QC assessments of samples and array data are critical in successful 
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microarray analysis, since it facilitates filtering the outlier arrays and significantly 
reduces the obscuring variation which may arise during the experimental procedures. 
Our results indicate that (i) after step-by-step QC assessment, the final 
RMA-processed arrays are in good quality and comparable with each other; and (ii) 
these normalized array data are suitable for downstream statistical analysis. 
 
6.1.4 Genome-wide transcriptional alterations 
Following the normalization by RMA method and statistical analysis by SAM (See 
Chapter 3.7.5, Page 51), each transcript (with identified probeset ID) was assigned a 
score with a fold change and a proper false discovery rate (FDR) to represent its 
relative expression level. Therefore, we identified 3,833 differentially regulated 
transcripts in GC-naïve NP versus control. They differed in their relative intensities by 
at least 1.5-fold with FDR of 0.008. These transcripts represented 3,833/54,677 ≈ 0.07 
(7%) of the total genes expressed in the nasal mucosal controls. Apart from the 
transcripts of GC-naïve NP versus control, comparisons between transcripts of 
GC-treated NP versus control and transcripts of GC-treated versus GC-naïve NP were 
also performed. In summary, 2,312 transcripts differed in relative expression (by at 
least 1.5-fold with FDR of 0.007) in GC-treated NP versus control, while 121 
transcripts were different (by at least 1.5-fold with FDR of 0.06) in GC-treated versus 
GC-naïve NP.  
 
After filtering the unmapped genes, genes with unknown gene ontology and genes 
with redundant probe identities, further search uncovered 1,989 and 1,330 genes 
which were differentially expressed in GC-naïve and GC-treated versus nasal mucosal 
controls, respectively (Figure 6.9). Expressions of 71 genes were different in 
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GC-treated versus GC-naïve NP tissues (Figure 6.9, Table 6.4). The Venn Diagram 
summarizes the relationship among the three comparisons (Figure 6.9): (i) among the 
71 GC-responsive genes, most of them (n=51, 72%) were also found to be 
differentially expressed in GC-naïve NP versus control; (ii) these 51 genes 
represented 2.5% (51/1,989) of the NP disease associated genes, and underlie the 
molecular effects of GCs in NP; (iii) 88% (45/51) of these GC-responsive plus NP 
related genes were normalized in GC-treated NP; (iv) six out of the 51 genes were 
either under-expressed or over-expressed in GC-treated NP as compared to the 




Figure 6.9 Overlapping genes in three datasets. Venn diagram shows the overlapping of differentially 
expressed genes in GC-naïve NP tissues versus nasal mucosal controls, GC-treated NP tissues versus 



























  Up-regulated genes in NP after GC treatment (n=55)   
222162_s_at ADAMTS1 
ADAM metallopeptidase with thrombospondin 
type 1 motif 1. 
3.319  2.464  0.000 
233011_at ANXA1 ANNEXIN A1. 5.260  5.905  0.000 
201525_at APOD Apolipoprotein D. 3.218  2.412  0.000 
221031_s_at APOLD1 Apolipoprotein L domain containing 1. 3.139  4.004  0.000 
205239_at AREG amphiregulin (schwannoma-derived growth factor) 3.024  6.474  0.000 
203946_s_at ARG2 Arginase type II. 2.624  3.299  3.560 
202672_s_at ATF3 Activating transcription factor 3. 2.472  7.548  3.904 
238987_at B4GALT1 
BetaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1. 
2.459  2.254  3.904 
205430_at BMP5 Bone morphogenetic protein 5. 2.248  3.287  6.101 
201236_s_at BTG2 BTG family,member 2. 3.286  2.225  6.101 
210735_s_at CA12 Carbonic anhydrase XII. 3.044  2.145  1.309 
1555827_at CCNL1 Cyclin L1. 3.426  5.841  0.000 
209795_at CD69 CD69 molecule 3.357  2.999  0.000 
206932_at CH25H Cholesterol 25-hydroxylase.Less info. 2.979  2.046  1.309 
213992_at COL4A6 Collagen,type IV,alpha 6. Less info. 3.071  2.262  1.309 
209774_x_at CXCL2 Chemokine (C-X-C motif) ligand 2, CXCL2 3.646  5.423  0.000 
210764_s_at CYR61 Cysteine-rich,angiogenic inducer,61. 2.503  4.127  3.904 
201041_s_at DUSP1 Dual specificity phosphatase 1. 5.316  4.977  0.000 
204794_at DUSP2 dual specificity phosphatase 2 2.391  3.197  4.413 
208893_s_at DUSP6 Dual specificity phosphatase 6. 3.549  2.077  0.000 
227404_s_at EGR1 Early growth response 1. 5.245  7.810  0.000 
205249_at EGR2 Early growth response 2. 5.097  4.242  0.000 
206115_at EGR3 Early growth response 3. 2.415  7.293  4.413 
1564796_at EMP1 Epithelial membrane protein 1. 3.049  4.734  1.309 
209189_at FOS 
v-fos FBJ murine osteosarcoma viral oncogene 
homolog, (known as c-Fos). 
6.144  14.859 0.000 
202768_at FOSB 
FBJ murine osteosarcoma viral oncogene homolog 
B. 
4.002  16.671 0.000 
209304_x_at GADD45B Growth arrest and DNA-damage-inducible,beta. 2.413  2.209  4.413 
203821_at HBEGF Heparin-binding EGF-like growth factor. 3.382  5.454  0.000 
208937_s_at ID1 Inhibitor of DNA binding 1. 3.638  2.012  0.000 
205207_at IL-6 interleukin 6 (interferon, beta 2). 3.185  7.867  1.309 
231183_s_at JAG1 jagged 1 (Alagille syndrome). 3.711  2.007  0.000 
201464_x_at JUN  jun oncogene, (known as c-Jun). 4.119  3.390  0.000 
201473_at JUNB Jun B proto-oncogene.  3.677  3.377  0.000 
219371_s_at KLF2 Kruppel like factor 2 2.933  2.084  2.046 
221841_s_at KLF4 Kruppel like factor 4  3.796  2.965  0.000 













v-myc myelocytomatosis viral oncogene homolog 
(avian) 
2.561  2.610  4.413 
223218_s_at NFKBIZ NF-kappaB inhibitor,zeta. 2.411  2.223  4.413 
202340_x_at NR4A1 Nuclear receptor subfamily4,group A,member1.  3.256  4.357  0.000 
216248_s_at NR4A2 Nuclear receptor subfamily4,group A,member2. 3.396  7.019  0.000 
243296_at PBEF1 Pre-B-cell colony enhancing factor 1. 4.973  3.707  0.000 
204748_at PTGS2 
Prostaglandin-endoperoxide synthase 2, (known as 
COX-2) 
3.565  3.469  0.000 
216834_at RGS1 Regulator of G-protein signalling 1. 3.350  3.195  0.000 
212099_at RHOB ras homolog gene family, member B. 3.937  1.886  0.000 
205725_at SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) 3.522  5.511  0.000 
206211_at SELE Selectin E (endothelial adhesion molecule 1). 4.241  7.597  0.000 
225660_at SEMA6A 
Sema,transmembrane domain, and cytoplasmic 
domain 6A. 
2.331  1.710  6.101 
204466_s_at SNCA Synuclein,alpha  3.680  2.008  0.000 
227697_at SOCS3 suppressor of cytokine signaling 3 3.537  4.202  0.000 
212558_at SPRY1 Sprouty homolog 1,antagonist of FGF signaling. 2.859  2.485  2.046 
204011_at SPRY2 Sprouty homolog 2. 2.734  2.114  2.840 
221489_s_at SPRY4 Sprouty homolog 4. 3.857  2.137  0.000 
203888_at THBD  Thrombomodulin.  3.676  2.631  0.000 
1555938_x_at VIM Vimentin. 3.048  3.105  1.309 
201531_at ZFP36 Zinc finger protein 36. 3.467  3.777  0.000 
  Down-regulated genes in NP after GC treatment (n=16)   
205692_s_at CD38 CD38 molecule -2.801  0.674  6.101 
230609_at CLINT1 Clathrin interactor 1. -3.473  0.493  0.618 
210163_at CXCL11 Chemokine (C-X-C motif) ligend 11. -3.752  0.404  0.000 
203915_at CXCL9 Chemokine (C-X-C motif) ligend 9. -4.127  0.404  0.000 
222858_s_at DAPP1 
Dual adaptor of phosphotyrosine and 
3-phosphoinositides. 
-3.444  0.651  2.282 
227609_at EPSTI1 Epithelial stromal interaction 1. -4.264  0.467  0.000 
205890_s_at GABBR1 gamma-aminobutyric acid (GABA) B receptor, 1 -3.659  0.482  0.000 
202270_at GBP1 Guanylate binding protein 1 (interferon-inducible). -4.711  0.475  0.000 
211597_s_at HOP Homeodomain-only protein. -5.424  0.420  0.000 
204415_at IFI6 Interferon,alpha-inducible protein 6. -3.420  0.479  0.618 
226757_at IFIT2 
Interferon-induced protein with tetratricopeptide 
repeats 2. 
-2.703  0.624  6.101 
204747_at IFIT3 
Interferon-induced protein with tetratricopeptide 
repeats 3. 
-3.241  0.495  1.127 
201744_s_at LUM Lumican. -4.714  0.456  0.000 
204259_at MMP7 matrix metallopeptidase 7 (matrilysin, uterine) -4.258  0.474  0.000 
203936_s_at MMP9 Matrix metallopeptidase 9. -3.822  0.439  0.000 
215342_s_at RABGAP1L RAB GTPase activating protein 1-like. -3.118  0.632  6.101 
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6.1.5 Classification of samples based on gene expression patterns 
Cluster analysis and principal component analysis (PCA) were first used to visualize 
the overall gene expression patterns throughout the three groups compared (GC-naïve 
NP, GC-treated NP and control). Cluster and PCA analyses were carried out by 
Genespring software (See Chapter 3.7.7, Page 54). 
 
6.1.5.1 Tree view cluster 
Cluster analysis for genome-wide expression data from the DNA microarray is 
described using standard statistical algorithms to arrange “conditions” (or say 
“samples”) according to the similarity in pattern of gene expression, or genes 
according to similarity of expression profiles throughout the samples. Therefore, the 
relationships among objects (samples and genes) are represented by a tree whose 
branch lengths reflect the degree of similarity between the objects, i.e., genes/samples 
with similar expression patterns are placed closer to each other. The output is 
displayed graphically, conveying the cluster patterns and the underlying expression 
data simultaneously in a form intuitive for biologists. 
 
In our study, two sets (GC-naïve NP vs. control and GC-treated vs. GC-naïve NP) of 
the significant genes were used to perform two-dimensional hierarchical clustering. 
The genes with similar expression profiles (i.e., up-regulation or down-regulation in 
NP or control group) were clearly separated (Figure 6.10) in each dataset. The more 
interesting dendrogram is to specify the arrangement of samples based on their gene 
expression patterns. Figure 6.10 shows two distinct subclasses in each dataset: (i) for 
dataset of GC-naïve NP vs. control, one subclass consists entirely of NP tissues while 
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the other subclass consists primarily of control samples (except NP6); (ii) for the 
dataset of GC-treated vs. GC-naïve NP, one subclass consists primarily of GC-treated 
NP (except NP7) while the other consists primarily of GC-naïve NP (except NP4R). 




  (B) 
 
Figure 6.10 Cluster pictures generated from the results of significance analysis of microarrays (SAM) 
identified genes. Hierarchical cluster analysis was performed using the genes differentially expressed in 
(A) GC-naïve NP vs. control, and (B) GC-treated vs. GC-naïve NP. Each row represents an individual 
gene, and each column represents a tissue sample. Relative distance of each gene (vertical axis) and 
individual sample (horizontal axis) are also demonstrated. The color spectrum for the range of 
expression values is shown at the right: the red color indicates high expression and green color low 
expression. The tissue type color bar is shown at the bottom: in (A), purple color represents GC-naïve 
NP samples, while blue color represents control samples; in (B), purple color represents GC-naïve NP 
samples, while blue color represents GC-treated NP samples. 
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6.1.5.2 PCA classification 
The expression of thousands of genes is measured across many conditions in a typical 
microarray experiment. Therefore, it becomes impossible to make a visual inspection 
of the relationship between genes or conditions in such a multi-dimensional matrix. 
PCA is a statistical method that can be used to reduce complex data sets with multiple 
variables into significantly smaller number of variables (known as components), 
which retain the relevant variance information used to distinguished the sample 
groups from one to another.  
 
We applied PCA to the significant genes in each of the three comparisons to establish 
the inter-relationships among the tissue samples. Figure 6.11 shows the 
two-dimensional (2D) plots for gene expression data of each comparison. The first 
two components, which accounted for more than 70% variance in our gene expression 
data, could be used to distinguish the overall gene expression profiles of GC-naïve NP, 
GC-treated NP and control. In order to interpret the variance of different samples 
intuitively, the 2D PCA plot can be separated like the four quadrants of a Cartesian 
coordinate system. Since the PCA component 1 represents the most variance of 
expression patterns (> 55%) among the objects, the samples in Quadrant II and III can 
be classified in one group, while the samples in Quadrant I and IV can be classified in 
another group (Figure 6.11). 
 
The analysis demonstrates that most of the nasal tissues from the three sample groups 
can be separated easily in their pairwise comparisons, while the same cannot be said 
of one to two NP samples in these comparisons which were also described in cluster 
analyses. PCA figures showed that NP6 was located in the “control” Quadrant (I, IV) 
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in comparisons of GC-naïve NP versus control (Figure 6.11). Regarding the PCA for 
comparison of GC-treated versus GC-naïve NP (Figure 6.11), NP4R was located in 
the “GC-naïve NP” Quadrant (I, IV) and the distance between NP4 and NP4R was 
very close. The NP7 was located in the “GC-treated NP” Quadrant (II, III), but the 
distance between NP7 and NP7R was not close. 
   (A) 
 
   (B) 
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Figure 6.11 Principal component analysis (PCA) plots generated from the results of significance 
analysis of microarrays (SAM) identified genes. The gene expression profiles of (A) comparison of 
GC-naïve NP versus control and (B) comparison of GC-treated versus GC-naïve NP were analyzed by 
PCA. The two-dimensional plot view of gene expression data is shown, with respect to their correlation 
to the first two principal components, which account for more than 70% variance in the expression data. 
The PCA plot are separated into four quadrants (I~IV) like a Cartesian coordinate system for easy 
interpretation.  
 
In summary, the results of cluster analysis and PCA were comparable to each other 
and both of them showed that different types of nasal tissues were almost classified 
into corresponding group. 
 
6.1.6 Functions of the significant genes  
Cluster and PCA analyses describe overall changes in apparent gene expression, but 
provide few insights into the biological process and signaling networks involved in 
the formation and development of NP, as well as its response to GC treatment. 
Therefore, it requires systematic analyses in the context of known biophysiological 
function and/or diseases, derived from the three datasets.  
 
The three sets (GC-naïve NP vs. control, GC-treated NP vs. control and GC-treated vs. 
GC-naïve NP) of SAM identified significant genes accompanied by their effective 
significance as indicated by the d score, were uploaded to Ingenuity Pathway Analysis 
(IPA) for functional analysis. Biophysiological functions and/or diseases were 
assigned to each dataset by using the Ingenuity Pathway Knowledge Base (IPKB) as a 
reference set and a proprietary ontology representing over 500,000 classes of 
biological objects and consisting of millions of individually modeled relationships 
between proteins, genes, complexes, cells, tissues, small molecules and diseases. 
These encoded relationships are based on a continual formal extraction from the 
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public domain literature and cover more than 10,300 human genes. The 
biophysiological functions and/or diseases assigned to each dataset were ranked 
according to the significance (p-value) of that function to the dataset. Thus, the top 
significant and relevant functional annotations in each main category (Diseases & 
Disorders; Physiological System Development & Function; Molecular & Cellular 
Functions) of each dataset were listed in the respective tables (Appendix I, Page 
259). 
 
Briefly, the NP associated genes (from dataset of GC-naïve NP vs. control) and the 
GC-responsive genes (from dataset of GC-treated vs. GC-naïve NP) were most likely 
involved in: (i) the molecular functions such as cellular movement, growth, 
proliferation, development, and death; (ii) the physiological functions such as tissue 
morphology/development, organ development/function, and immune response; (iii) 
the diseases such as cancer, inflammatory and immunological diseases. 
 
Once we get the top relevant functions in each primary category from each 
comparison, we can compare these relevant functions among the three datasets (i.e., 
GC-naïve NP vs. control, GC-treated NP vs. control, and GC-treated vs. GC-naïve NP) 
by IPA. This comparison analysis can be used to quickly gain an overview over the 
effect of GC treatment on a variety of high level functions (See Chapter 3.7.8.1, Page 
56). Figure 6.12 summarizes the comparison of the top relevant functional 
annotations in each primary category among these three datasets: (i) in the primary 
category of Diseases & Disorders, GC treatment mainly affects the genes involved in 
cancer, inflammatory disease, connective tissue disorders, and immunological disease; 
(ii) in the primary category of Physiological System Development & Function, GC 
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treatment mainly affects the genes involved in tissue development, organismal 
development, and cardiovascular system development & function; (iii) in the primary 
category of Molecular & Cellular Functions, GCs have potent effects on most of the 
selected functions, including cellular movement, cellular growth & proliferation, cell 








Figure 6.12 Functional comparison among the datasets. Top relevant functional annotations for gene 
sets differentially expressed in three comparisons: GC-naïve NP versus control, GC-treated NP versus 
control and GC-treated versus GC-naive NP. Three main categories of the functions are listed in (A) 
Diseases & Disorders, (B) Physiological System Development & Function, (C) Molecular & Cellular 
Functions. Statistic p value for a given function is calculated by considering 1) the number of 
functional analysis genes that participate in that function and 2) the total number of genes that are 
known to be associated with that function in the Ingenuity Pathway Knowledge Base (IPKB). On the 
y-axis of the diagram, the significance is expressed as the exponent of the p value calculated for each 
function. Dashed line represents the threshold (p = 0.05) of the significant level of the functions. 
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6.1.7 Identification of GC-responsive genes by network analysis 
To further elucidate the global changes in NP tissue and its response to GC treatment, 
we sought to computationally decipher the principal networks involved in the given 
significant genes. Based on the computed scores, 68 and 5 significant networks were 
generated from the dataset of GC-naïve NP vs. control (data not shown here), and 
GC-treated vs. GC-naïve NP (Table 6.5), respectively. Since the numbers of 
significant networks and significant genes in the dataset of GC-naïve NP vs. control 
are huge, it is too complicated to select the representative networks and interpret the 
functional relationships among the interacting genes in the analysis of GC-naïve NP 
vs. control. In contrast, the dataset of GC-treated vs. GC-naïve NP contains fewer 
amounts of significant networks and genes, so that it is intuitive to explain the 
functional interaction among the genes of interest in the generated networks. For this 
reason, we intend to use network analysis to identify GC-responsive genes and their 
related network; but apply Canonical Pathway Analysis to identify the networks 












Table 6.5 Functional network analysis for GC-responsive genes (Part I) 
Network 
ID Molecules in Network
* Score Focus Molecules
1 
ANXA1, AREG, BTG2, Calpain, Cbp/p300, Creb, 
CXCL2, Cyclin A, DUSP6, EGR1, ERK1/2, ETS, 
ETS2, Fgf, FOS, GADD45B, GC-GCR dimer, 
HBEGF, ID1, IFIT2, IL6, JUN, Mek1/2, MHC Class 
II, PBEF1, PTGS2, SPRY1, SPRY2, SPRY4, 
STAT5a/b, SWI-SNF, Tgf beta, ZFP36 
43 20 
2 
Alkaline Phosphatase, ATF3, B4GALT1, CCNL1, 
CD38, CXCL9, CXCL11, Cyclin D, CYR61, 
DAPP1, DUSP1, DUSP2, FOSB, Gsk3, Hsp27, Ikb, 
IL1, JAK, JUNB, LDL, LIF, NFkB, NFKBIZ, Pdgf, 
PDGF BB, PDGF-AA, PI3K, Rb, RHOB, SCGB1A1, 
SOCS, SOCS3, STAT, THBD 
35 18 
3 
14-3-3, Akt, Ap1, CD69, Cyclin E, EGR2, EGR3, 
EMP1, GABBR1, Hsp70, Hsp90, Ige, Insulin, Jnk, 
KLF2, KLF4, Mapk, Mek, MMP7, MMP9,MYC, 
Nfat, NR4A1, NR4A2, P38 MAPK, Pkc(s), Pld, Ras, 




15-(S)-hydroperoxyeicosatetraenoic acid, APOD, 
ARF4, CA12, CH25H, CIDEC, Ck2, COL4A6, 
ELK3, FZD5, HAS1, HNRNPC, HOPX, HOXA11, 
IFI6, IFIT3, JAG1, JAG2, LRP6, LTBP2, MFAP2, 
MPZ, NOP5/NOP58, PBEF1, PDGFC, progesterone, 
RASA3, RNA polymerase II, SLC7A1, TERT, 
TGFB1, TGFBI, THBD, TNF 
20 11 
5 
ADAMTS1, AP2A2, APOLD1, ARL6IP1, BCAS3, 
beta-estradiol, BMP5, CCNL2, CDKN1A, CLINT1, 
COMT, CTSH, DDR1, EGF, ELK3, ELL, FAT2, 
GBP1, GPX3, GSTA4, Hexokinase, Histone h3, 
HSPH1, KIAA0101, leukotriene D4, LUM, MCM5, 
MKI67, PELP1, TP53, UBE2S, VIM, ZFP36 
18 9 
 
*The underlied words in bold: Up-regulated genes in NP after GC treatment. 






Table 6.5 Functional network analysis for GC-responsive genes (Part II) 
 Top three functions/diseases of each network p-value# 
Network1 Cellular Development 1.61E-10 
 Cellular Growth and Proliferation 2.50E-09 
 Cell Death 6.09E-09 
Network2 Immunological disease 2.89E-06 
 Inflammatory disease 5.18E-06 
 Cellular movement 3.56E-05 
Network3 Tissue morphology 7.97E-06 
 Cell cycle 1.13E-05 
 Gene expression 2.72E-05 
Network4 Cellular development 4.38E-07 
 Cancer 4.34E-06 
 Cell death 4.34E-06 
Network5 Gene expression 5.07E-09 
  Cancer 8.17E-08 
 Cell death 8.17E-08 
 
# Fisher’s exact test was used to calculate a p-value determining the probability that each biological 
function and/or disease assigned to that network is due to chance alone. 
 
6.1.7.1 Identification of GC-responsive gene networks 
In the dataset of GC-responsive genes, all five significant networks and their 
respective related functions are listed in Table 6.5. Among these networks, the 
top-scoring one (score = 43) contains two central molecules including JUN (also 
known as c-Jun) and FOS (also known as c-Fos), which are the most abundant 
components of activation protein 1 (AP-1) heterodimer (Figure 6.13A). Since these 
two important AP-1 genes are the prominent interaction partners at the level of 
interconnecting functional modules, this network is the so called AP-1 network. 
Notably, 20 of the 71 GC-responsive genes that were differentially expressed have at 
least one gene in the AP-1 pathway, underscoring its pivotal role in its corresponsive 
to GC therapy. In addition, evaluation of the AP-1 sub-network regions revealed that a 
group of AP-1 related genes (PTGS2, IL-6, AREG, HBEGF and EGR1) were 
modulated by GC administration in NP tissues (Figure 6.13A). Functional analysis 
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for this network indicates that GCs may have significant effects on NP by regulating 
cellular development, growth, proliferation and death (Table 6.5). Note that since 
AP-1/AP-1 related genes are altered in GC-naïve NP as compared to the control, they 
will also be identified in Canonical Pathways (See Chapter 6.1.8, Page 126).  
 
The 2nd ranking network from the GC-responsive gene set is also of great interest, 
since the molecules in the network are likely associated with inflammatory and 
immunological diseases (Figure 6.13B). Although the core molecule (NF-kappa B) 
was not altered by GC treatment, most of its interacted genes were considered to have 
pro-/anti-inflammatory function, including CXCL9, CXCL11, DUSP1, DUSP2, 
NFKBIZ, SOCS3, SCGB1A1, and THBD. Some of the other anti-inflammatory genes 
(such as ANXA1, ZFP36, DUSP6, and SPRYs (1, 2, 4)) were also found in the 
top-scoring network, while two pro-inflammatory genes (MMP7 and MMP9) were 
found in the 3rd ranking network (Table 6.5). Moreover, two other AP-1 genes (FosB 
and JunB) were presented in this 2nd ranking network. Note that since some 
anti-inflammatory genes (such as DUSPs, SPRYs, SOCS3, and NFKBIZ) are also 
altered in GC-naïve NP as compared to the control, they will also be identified in the 















Figure 6.13 Network pathways of GC-responsive genes. Networks composed of GC-responsive genes 
were complemented by an unsupervised relevance network learning algorithm without any priori 
assumptions and post adjustment. (A) Top-scoring network with highlight (in dark blue color) of AP-1 
and AP-1 related genes. (B) 2nd ranking network. Nodes represent genes, with their shape representing 
the functional class of the gene product, and edges indicate the biological relationship between the 
nodes (see network legend). Nodes are color coded according to their d score generated by SAM (red, 
overexpression in GC-treated vs. GC-naïve NP; green, underexpression in GC-treated vs. GC-naïve NP) 
and the color intensity increases with the magnitude of altered regulation.  
 
6.1.7.2 Identification of core GC-responsive candidate genes 
Another application of network analysis is to identify core genes among the total 
genes. This identification can be facilitated by merging the individual networks and 
then the graphic visualizations of all potential connections are generated. The genes 
with most prominent interaction partners within the merged networks are considered 
the central molecules. Since the total selected molecules for merging networks is 
limited to 500 nodes (i.e., focused genes), the total significant networks (containing 
more than 500 nodes) in dataset of GC-naïve NP vs. control cannot be merged. 
Therefore, only the networks from GC-responsive gene set were able to be merged. A 
high-resolution picture of the entire merged network and an enlarged portion with 
core genes of the merged network are shown in Figure 6.14.The combined networks 
revealed that c-Jun and c-Fos map the central nodes among all the GC-responsive 
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genes, which are the same as the core genes in the top-ranking GC-responsive 
network (AP-1 network). In addition, the merged networks showed that 3 of the AP-1 
related genes (PTGS2, IL-6 and EGR1) in the AP-1 network also contain prominent 
interactions with other GC-responsive molecules (Figure 6.14). 
 
Figure 6.14 Merged network of GC-responsive genes. Networks composed by an unsupervised 
relevance network learning algorithm without any priori assumptions and post adjustment were 
generated by IPA. All five networks composed of GC-regulated genes were merged. The highlighted 
box shows that c-Jun and c-Fos are the core molecules. Nodes represent genes, with their shape 
representing the functional class of the gene product, and edges indicate the biological relationship 
between the nodes (see network legend in Figure 6.13). Nodes are color coded according to their d 
score generated by SAM (red, overexpression; green, underexpression) and the color intensity 
increases with the magnitude of altered regulation.  
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In summary, the network analysis provides comprehensive molecular networks 
involved in GC mechanisms in NP, and also facilitates the identification of key genes 
underlying the GC effects on NP. The AP-1 network appears to be particularly 
important, because it is not only the top-ranking network but also includes the core 
genes (AP-1 genes) which interact with the most GC-responsive genes. In addition, 
those pro-/anti-inflammatory genes identified in the networks are also worth studying 
since GCs have been traditionally considered a potent anti-inflammatory agent.   
 
6.1.7.2 Transcriptional levels of the GC-responsive genes 
The network analysis identified that GCs mainly regulated AP-1/AP-1 related genes 
and inflammation related genes in NP. Appendix II (Page 268) lists the alteration 
(fold change) of these genes in GC-naïve NP, GC-treated NP, and control tissues. In 
addition, Appendix III (Page 271) describes the relative expression level of the genes 
validated by real-time RT PCR. c-Jun and c-Fos mRNA in GC-naïve NP tissues were 
only 29% and 8% of the nasal mucosal control, respectively. c-Jun and c-Fos mRNA 
were increased 3.39-fold and 14.85-fold in GC-treated versus GC-naïve NP, 
respectively. Both c-Jun and c-Fos mRNAs were normalized by GCs in NP. A similar 
trend was also observed in two other AP-1 members (FosB and JunB) and those 5 
important AP-1 related genes. Transcripts of FosB, JunB, COX-2, IL-6, AREG, 
HBEGF, and EGR1 were markedly repressed in GC-naïve NP as compared to the 
control. Transcripts of these genes were increased in GC-treated NP tissues. However, 
expression of JunB, IL-6 and EGR1 were still lower in GC-treated NP tissues as 
compared to controls.  
 
With regard to the inflammation related genes, expression of pro-inflammatory genes 
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(CXCL9, CXCL11, MMP7, and MMP9) was higher in GC-naïve NP than control; 
while anti-inflammatory genes (ANXA1, DUSP1, DUSP2, DUSP6, SPRY1, SPRY2, 
SPRY4, NFKBIZ, SOCS3, SCGB1A1, THBD, and ZFP36) were expressed at lower 
levels in GC-naïve NP than controls (Appendix II, Page 268). In response to GC 
treatment, down-regulation of these pro-inflammatory genes but up-regulation of the 
anti-inflammatory genes was evident in GC-treated NP tissues (Appendix II, Page 
268). Since the expression levels of these pro-/anti-inflammatory genes were not 
significantly different between GC-treated NP and control, they were considered to be 
normalized by GCs. These results confirm the potent anti-inflammatory effect of GCs. 
 
6.1.8 Identification of NP associated genes by Canonical Pathway analysis 
The networks described above are generated de novo, based on the input data without 
any prior assumptions, while IPA also provides Canonical Pathways which are 
generated prior to data input and based on a pre-described well-known knowledge 
base. Since the amount of significant NP associated genes is large, and in order to 
narrow down the genes of interest which could represent NP pathogenesis, it is 
applicable to perform Canonical Pathway analysis. More importantly, it also provides 
a systemic view to reveal those well known signaling pathways underlying the NP 
pathogenesis. 
 
As described in Chapter 3.7.8.3 (Page 59), the top-7 relevant Canonical Pathways 
potentially associated with NP pathogenesis were selected: apoptosis signaling, 
complement system, EGF/EGFR signaling, eicosanoid signaling, ERK/MAPK 
signaling, IL-6 signaling, and NF-kappaB signaling. All these signaling pathways are 
regarded to be related to cellular proliferation, growth, and development and the 
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inflammatory process, which are consistent with the functions of NP associated genes 
(See Chapter 6.1.6, Page 114). The involved genes as well as their transcriptional 
levels in NP in these pathways are described in the following paragraphs. These 
Canonical Pathways are composed of genes differentially expressed in GC-naïve NP 
as compared to control. Figure 6.15 demonstrates all of these 7 Canonical Pathways: 
the legend of Figure 6.15A describes the general components in these Canonical 
Pathways; and the legends of Figure 6.15 B-H describe the specific content of the 
signaling pathways. The fold changes of the genes which are indicated in the 
following paragraphs are listed in Appendix II (Page 268). 
 
Figure 6.15 (A) General network legends of the Canonical Pathways 
 
Figure 6.15 Canonical pathways in NP. (A) General network legends for Figure 6.15 B-H: nodes 
represent genes, with their shape representing the functional class of the gene product, and edges 
indicate the biological relationship between the nodes (see network legend). In Figure 6.15 B-H, nodes 
are color coded according to their d score generated by SAM (red, up-regulation in GC-naïve NP 
versus controls; green, down-regulation in GC-naïve NP versus controls) and the color intensity 
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increases with the magnitude of altered regulation. Up arrow in blue indicates up-regulation of the 
genes in NP after GC treatment. 
 
6.1.8.1 Genes in apoptosis signaling 
Apoptosis involves a series of biochemical events leading to a variety of 
morphological changes, including blebbing, changes to the cell membrane, cell 
shrinkage, nuclear fragmentation, chromatin condensation, and DNA fragmentation 
[Nagata, 1997]. Figure 6.15B highlights the key molecular events in triggering 
apoptosis. The central executioner of apoptosis, caspase 3 (CASP3) was up-regulated 
at 1.73-fold in GC-naïve NP as well as 1.85-fold up-regulation of caspase 7 (CASP7). 
BID, which act as a direct molecular link between the activated caspase 8 and 
mitochondrial death machinery, was increased at 1.65-fold in NP compared to the 
control; while AIF, which mediates caspase-independent DNA fragmentation, was 
up-regulated at 1.60-fold. However, none of these apoptosis related genes were 
changed in NP after GC treatment. These results indicate the increase of apoptosis 












Figure 6.15 (B) Apoptosis signaling 
 
Figure 6.15 (B) Apoptosis signaling is a coordinated, energy-dependent process that involves the 
activation of a group of cysteine proteases called caspases and a cascade of events that link the 
initiating stimuli to programmed cell death. The two main pathways of apoptosis are the intrinsic and 
extrinsic pathways. The intrinsic signaling pathways are non-receptor-mediated and 
mitochondria-dependent. The end result is a change in mitochondrial transmembrane potential and 
release of two main groups of pro-apoptotic proteins from the intermembrane space into the cytosol. 
The first group consists of cytochrome c, DIABLO, and HTRA2, which activate the caspase-dependent 
mitochondrial pathway. The second group includes AIF and Endo G, which directly translocate to the 
nucleus and cause DNA fragmentation. The extrinsic signaling pathways that initiate apoptosis involve 
transmembrane receptor-mediated interactions (e.g., TNF receptors). The activation of these receptors 
triggers caspase 8 or 10 which can then activate the execution pathway. Alternatively, triggered caspase 
8 or 10 could result in the activation of the pro apoptotic protein BID and then lead to a cross talk with 
the mitochondria-dependent intrinsic pathway of apoptosis. Each pathway requires specific triggers to 
initiate a cascade of molecular events that converge at the stage of caspase 3 activation. Up-regulation 
of caspase 3 &7, AIF, and BID in GC-naïve NP indicates the enhancement of apoptosis signaling in 
GC-naïve NP; while GCs have no effect on these apoptosis markers. 
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6.1.8.2 Genes in complement system  
The complement system is not only important in innate immunity which contributes 
to host defense, but also mediates various inflammatory responses in airway disorders 
[Markiewski et al., 2007]. The Canonical Pathway of the complement cascade reveals the 
alteration of the complement components in NP (Figure 6.15C). Our results show that 
expression of the key complement components C3 and C4a was up-regulated at 
2.64-fold and 5.54-fold in GC-naïve NP as compared to control, respectively. With 
regard to the other molecules related to complement pathways, C1QB was increased 
at 4.73-fold, while CFH (also known as HF1), which is the inhibitor of complement 
system, was decreased at 2.01-fold in GC-naïve NP as opposed to controls. However, 
expression of all the molecules in this complement pathway was not changed in NP 
after GC treatment. These results indicate the enhancement of the complement 














Figure 6.15 (C) Complement system 
 
Figure 6.15 (C) The complement system has three pathways based on initiation of the complement 
cascade: classical pathway, alternate pathway and lectin pathway. The classical pathway is triggered by 
the binding of C1 to the antigen-antibody (Ag-Ab) complex. The lectin pathway is initiated by MBL 
(mannose binding lectin), a serum protein, binding to mannose groups on bacterial cell walls. The 
alternate pathway is activated by C3, a complement protein, binding to components of microbial cell 
surfaces. The three activation pathways converge into a final common pathway when C3 convertase 
cleaves C3 into C3a and C3b where C3b is directly linked to opsonization and also goes on to form part 
of the complex that cleaves C5 into C5a and C5b. C5b with C6, C7, C8, and C9 form (C5b6789) 
membrane attack complex, which is inserted into the cell membrane and initiates cells lysis. Moreover, 
fragments of C3, C4, and C5 can interact with the cell membrane receptor directly to trigger activation 
of inflammatory cells. The key promoters in complement system (C3, C4, and C1QB) are up-regulated 
while one complement inhibitor (HF1) is down-regulated in GC-naïve NP; however, none of them 
responds to GC treatment. These results indicate the increase of complement activity in NP. 




6.1.8.3 Genes in EGF/EGFR signaling 
The interaction between EGF receptors and their corresponding ligands have been 
considered an important mechanism in regulating cellular growth and proliferation 
[Citri et al., 2006]. In the Canonical Pathway of EGF/EGFR signaling, a uniform 
down-regulation of EGF receptor (ERBB4, 2.12-fold) and EGF ligands (AREG, 
4.01-fold; HBEGF, 4.56-fold; EGF, 3.93-fold; NRG3, 4.44-fold) were found in 
GC-naïve NP as compared to controls (Figure 6.15D); while expression levels of 
AREG and HBEGF were significantly normalized after GC treatment with 6.48-fold 
and 5.45-fold up-regulation in GC-treated versus GC-naïve NP tissues, respectively. 
These results indicate the defect of EGF mediated proliferation signaling in NP, and 
GCs may correct the insufficient activity of EGF signaling.  
 
Figure 6.15 (D) EGF/EGFR signaling 
 
Figure 6.15 (D) The epiermal growth factor (EGF) receptors and their corresponding ligands play an 
important role in cell differentiation, proliferation, and survival. EGFR is the prototype of the EGF 
receptor family, and it can either homo-/or hetro-dimerize with other members including ERBB2, 
ERBB3, and ERBB4. The known EGFR ligands include EGF, AREG, HBEGF, NGR3, and TGF-alpha. 
Ligands bind to the EGF receptors results in series activation/phosphorylation events, which mainly 
trigger MAPK cascade and PI3K-AKT signaling. Down-regulation of the EGFR (e.g., ERBB4) and 
EGFR ligands (EGF, AREG, HBEGF, and NRG3) is significant in GC-naïve NP, and AREG and 
HBEGF are normalized by GCs. The results suggest the low activity of EGF signaling in NP, and GCs 
may promote EGF mediated proliferation signaling. Up arrow in blue indicates up-regulation of the 
genes in NP after GC treatment. 
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6.1.8.4 Genes in eicosanoid signaling 
Eicosanoids transduce signals via their membrane receptors and mediate complex 
biological processes like inflammation, vascular permeability, allergic reactions, 
induction of labor and carcinogenesis. The Canonical Pathway picture of eicosanoid 
signaling (Figure 6.15E) highlights the alteration of some key receptors and enzymes 
in GC-naïve NP. In the leukotriene (LT) pathway, the LT receptors LTB4R and 
CYSLTR1 were up-regulated at 1.66-fold and 2.92-fold in GC-naïve NP, respectively; 
while the LT syntheis related enzymes ALOX5AP and LTA4H were increased at 
2.61-fold and 1.53-fold, respectively. In the prostaglandin (PG) pathway, we found 
down-regulation of PTGS2 (or COX-2) (2.58-fold), PTGIS (3.88-fold) and PTGER3 
(6.53-fold), but up-regulation of PTGER2 (1.99-fold) in GC-naïve NP compared to 
controls. Regarding the PLA2 enzymes, expression levels of PLA2G4A (also known 
cPLA2 alpha) and PLA2G10 were increased 2.61-fold and 2.51-fold in GC-naïve NP 
versus control, respectively. Among these molecules in the eicosanoid signal pathway, 
only COX-2 was normalized (3.47-fold up-regulation in GC-treated vs. GC-naïve NP) 
in response to GC treatment. The results suggest the increase of LT mediated 
inflammation and alteration of PGE2 signaling activity in NP, and GCs mainly have an 









Figure 6.15 (E) Eicosanoid signaling  
 
Figure 6.15 (E) Eicosanoid-mediated signaling plays a diverse role in many biological processes, such 
as inflammation, angiogenesis, and osmoregulation. There are four types of eicosanoids: prostaglandins 
(PGs), lipoxins, leukotrienes (LTs) and thromboxanes. Arachidonic acid (AA), the precursor for most 
eicosanoids, is produced by hydrolysis of membrane phospholipids by phospholipaseA2 (PLA2). AA is 
then converted to eicosanoids by one of two types of enzymes: (1) prostaglandin endoperoxide 
synthases (PTGS), commonly referred to as cyclooxygenases (COX-1 and COX-2), catalyze the key 
step in the synthesis of biologically active prostaglandins, the conversion of AA into prostaglandin H2 
(PGH2). PGH2 serves as the precursor for thromboxanes and prostaglandins; (2) The lipoxygenases 
include ALOX5, ALOX12 and ALOX15; ALOX5 catalyzes the key step in the conversion of AA to 
leukotriene A4, B4 and C4; ALOX15 in concert with ALOX5 is involved in the formation of lipoxins 
A4 and B4; ALOX12 synthesizes 12(S)-HETE [12(S)-hydroxyeicosatetraenoic acid]. Eicosanoid 
receptors include LTB4Rs and CYSLTRs for leukotrienes, PTGERs for prostaglandin E2, PTGFR for 
prostaglandin F2, PTGDR for prostaglandin D2 and TBXA2R for thromboxane A2. The leukotriene 
and PGE2 pathways are highlighted in orange. Up-regulation of LT pathway related markers (such as 
LTB4R, CYSLTR1, ALOX5AP, and LTA4H) is evident in GC-naïve NP, and GCs have no effect on LT 
mediated signaling. In PG pathway, the key catalyzer COX-2 is down-regulated as well as 
down-regulation of PGER3; but PTGER2 is up-regulated. The response of COX-2 to GC treatment 
indicates that GCs may have effect on PG pathway. Up arrow in blue indicates up-regulation of the 
genes in NP after GC treatment. 
 135
6.1.8.5 Genes in ERK/MAPK signaling 
Mitogen-activated protein kinase (MAPK) families mediate transcriptional and 
posttranscriptional changes in gene expression in response to proinflammatory stimuli 
and are considered to play an important role in inflammation [Chang et al., 2001]. Dual 
specificity protein phosphatases (DUSPs) (also known as MKPs) are the key negative 
regulators of the MAPK signaling cascade by dephosphorylating the theronine and 
tyrosine motifs on MAPK proteins [Farooq et al., 2004; Shepherd et al., 2007]. The canonical 
pathway of MAPK signaling reveals the down-regulation of these DUSPs in 
GC-naïve NP as compared to control (Figure 6.15F): DUSP1 (also known as MKP1) 
(9.61-fold), DUSP2 (also known as PAC1) (5.68-fold), DUSP4 (also known as MKP2) 
(4.78-fold), DUSP5 (4.50-fold), and DUSP6 (also known as MKP3) (2.91-fold). 
Furthermore, DUSP 1, DUSP2, and DUSP6 were normalized in NP in response to GC 
treatment with increase of 4.98-fold, 3.19-fold, and 1.73-fold, respectively. 
 
Another gene family which also inhibits MAPK cascade is so called Sprouty (SPRY) 
homolog. SPRYs are essential in negative regulation of receptor tyrosine kinases 
(RTKs) signaling pathways. As shown in the canonical pathway figure, DUSPs 
specifically inhibit MAPKs at p38, ERK, and JNK levels, but SPRYs control the 
MEK or Raf level which is the up-stream kinase of MAPKs (Figure 6.15F). Similar 
to DUSPs, three SPRY homologies were observed to be down-regulated in GC naïve 
NPs compared to control nasal mucosa: SPRY1 (3.02-fold), SPRY2 (1.61-fold), and 
SPRY4 (1.62-fold); while all of them were normalized in NP in response to GC 
treatment: SPRY1 (2.49-fold), SPRY2 (2.11-fold), and SPRY4 (2.13-fold). 
 
These results suggest that the negative regulation system of the inflammatory process 
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is inadequate in GC-naïve NP, leading to chronic inflammation; while GCs may 
perform the anti-inflammatory effect in NP via up-regulation of these negative 
regulators in the inflammatory pathway. 
 
Figure 6.15 (F) ERK/MAPK signaling 
 
Figure 6.15 (F) The ERK (extracellular-regulated kinase)/MAPK (mitogen activated protein kinase) 
pathway is a key pathway that transduces cellular information on meiosis/mitosis, growth and 
differentiation during inflammatory process. Binding of ligand to RTK activates the intrinsic tyrosine 
kinase activity of RTK. Adaptor molecules like GRB2, SOS and Shc form a signaling complex on 
tyrosine phosphorylated RTK and activate Ras. Activated Ras initiates a kinase cascade, beginning with 
Raf (a MAPK kinase kinase) which activates and phosphorylates MEK (a MAPK kinase); MEK 
activates and phosphorylates ERK (a MAPK). ERK in the cytoplasm can phosphorylate a variety of 
targets which include cytoskeleton proteins, ion channels/receptors and translation regulators. The 
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ERK/MAPK signaling is controlled by its negative regulators at different cascade level. PP1/PP2A and 
Sprouty homolog (SPRYs) inhibit MEKs activity, while Dual specificity protein phosphatases (DUSPs) 
(known as MKPs) inhibit ERKs activity. DUSP1 known as MKP1, DUSP2 known as PAC1, DUSP4 
known as MKP2 and DUSP6 known as MKP3. Down-regulation of the negative regulators of MAPK 
cascade was significant in GC-naïve NP, including DUSP1, DUSP2, DUSP4, DUSP6, SPRY1, SPRY2, 
and SPRY4; moreover, most of them (except DUSP4) are up-regulated in response to GC treatment. 
The results indicate that the negative regulation system of pro-inflammatory signaling is inadequate in 
NP, and the increase of these controllers represents the anti-inflammatory function of GCs. Up arrow in 
blue indicates up-regulation of the genes in NP after GC treatment. 
 
6.1.8.6 Genes in IL-6 signaling 
IL-6 mediated signaling pathway is important in the growth and differentiation of 
numerous cell types (including epithelial cells) [Gallucci et al., 2000]. As shown in the 
Canonical Pathway of IL-6 signaling, the key factors (including activation factors and 
inhibition factors) involved in the IL-6 signaling pathway were all down-regulated in 
GC-naïve NP as compared to controls (Figure 6.15G): IL-6 (6.10-fold), IL6ST 
(known as GP130) (1.69-fold), STAT3 (1.73-fold), and SOCS3 (3.21-fold). In 
response to GC treatment, IL-6 and SOCS3 were increased at 7.87-fold and 4.81-fold, 
respectively; but the expression level of IL-6 was still lower in GC-treated NP as 
compared to control. These results suggest that the IL-6 signaling is insufficient in 
GC-naïve NP, and the increase of both IL-6 and its inhibitor SOCS3 represents the 









Figure 6.15 (G) IL-6 signaling 
 
Figure 6.15 (G) IL-6 mediates both pro- and anti-inflammatory signaling. IL-6 responses are 
transmitted through Glycoprotein 130 (GP130), which serves as the universal signal-transducing 
receptor subunit for all IL-6-related cytokines. IL-6-type cytokines utilize tyrosine kinases of the Janus 
Kinase (JAK) family and signal transducers and activators of transcription (STAT) family as major 
mediators of signal transduction. Dimer of STATs translocate to the nucleus, where they regulate 
transcription of target genes. In addition, IL-6 also activates the extracellular signal-regulated kinases 
(ERK1/2) of the mitogen activated protein kinase (MAPK) pathway. The SHC protein is activated by 
JAK2 and thus serves as a link between the IL-6 activated JAK/STAT and RAS-MAPK pathways. 
Suppressor of cytokine signaling (SOCS) can negatively regulate IL-6-mediated JAK/STAT pathway. 
Down-regulation of the key genes in IL-6 signaling is obvious in GC-naïve NP, including IL-6, GP130, 
STAT3, and SOCS3; while up-regulation of IL-6 and SOCS3 after GC treatment. The results indicate 
the IL-6 pathway activity is low in GC-naïve NP, and GCs have an regulatory effect on IL-6 mediated 
proliferation signaling. Up arrow in blue indicates up-regulation of the genes in NP after GC treatment. 
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6.1.8.7 Genes in NF-kappaB signaling 
NF-kappaB is a multi-subunit transcription factor that is involved in the regulation of 
a large number of genes that control various aspects of the immune and inflammatory 
response [Baldwin et al., 1996]. The activity of NF-kappaB is largely controlled by 
inhibitors of NF-kappaB (IkappaB), which bind to NF-kappaB, preventing its 
association with DNA and causing its localization to the cytoplasm [Baldwin et al., 1996]. 
The Canonical pathway of NF-kappaB signaling showed a decrease of IkappaB in 
GC-naïve NP (Figure 6.15H): IkappaB-α (also known as NFKBIA) and IkappaB-ζ 
(also known as NFKBIZ) were down-regulated at 1.53-fold and 2.19-fold respectively, 
while only NFKBIZ was increased at 2.22-fold in NP in response to GC treatment. 
These results suggest that the negative regulation of NF-kappaB signaling in 
GC-naïve NP is insufficient, and GCs may have an inhibitory effect on NF-kappaB 














Figure 6.15 (H) NF-kappaB signaling 
 
Figure 6.15 (H) The Nuclear factor kappa B (NF-kappaB) transcription factors are key regulators of 
gene expression culminating in response to stress and the development of innate and acquired 
immunity, leading to activation of inflammatory process. RELA/p65 and p50 are the two major 
subunits of NF-kappaB hetero-/homodimers. In quiescent situation, cytoplasmic NF-kappaB are bound 
to inhibitor of NF-kappaB (IkappaB), thereby sequestering them in the cytoplasm. Activators of 
NF-kappaB mediate the site-specific phosphorylation of seriene on IkappaB, making IkappaB for 
ubiquitination and destruction. NF-kappaB is then free to translocate to the nucleus and bind DNA 
leading to the activation of a host of inflammatory response target genes. IkappaB not only inhibits 
NF-kappaB mediated transcription, but also transports NF-kappaB back to the cytoplasm. Two 
members of NF-kappaB inhibitor, NFKBIA and NFKBIZ are down-regulated in GC-naïve NP, leading 
to increase of NF-kappaB signaling. However, only NFKBIZ is responded to GC treatment, indicating 
the inhibitory effect of GCs on NF-kappaB mediated inflammatory process. Up arrow in blue indicates 
up-regulation of the genes in NP after GC treatment. 
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6.1.9 Identification of NP associated genes by literature reviews 
To broaden the identification of NP related genes in the microarray results, we intend 
to review more genes associated with NP histopatholgical patterns by literature 
reports, such as infiltration of eosinophils and neutrophils, edema, tissue damage, and 
mucus hypersecretion. The following paragraphs describe these disease related genes 
as well as their expression profiles in response to GC treatment. The fold changes of 
the genes which are indicated in the following paragraphs are listed in Appendix II 
(Page 268). 
 
6.1.9.1 Eosinophil related genes 
NP has been considered an eosinophil predominant inflammatory disease and GC can 
potently suppress eosinophil infiltration in NP (Table 6.1, Page 90). To identify the 
eosinophil associated genes, we mainly relied on the authoritative reviews which 
discussed eosinophil biological features [Rothenberg, 1998; Rothenberg & Hogan, 2006] and 
then 60 important genes were selected from the published sources. Table 6.6 
summarizes and categorizes these eosinophil related genes based on the biological 
process of eosinophils. Among the 60 eosinophil-associated genes, microarray data 
suggested that 31 genes (21 up-regulated and 10 down-regulated genes) differed 
significantly in GC-naïve NP compared to controls. Hierarchical cluster results 
indicate that the differential expression of these 31 genes may reflect the phenotypic 
differences in eosinophil infiltration between NP and control samples (Figure 6.16). 
Results showed a clear separation of NP and control subjects, i.e., the tissue sample 
dendrogram (condition tree) divided NP samples as one group and control samples as 
another group; while the gene dendrogram (gene tree) also divided up-regulated and 
down-regulated genes in two distinct groups. Furthermore, two GC-naïve NP subjects 
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(NP6 and NP7) with a low grade (grade=1) of eosinophil count have shown a 
difference in expression pattern with other NP subjects with higher grades (grade=2 or 
3) of eosinophil infiltration. 
 
Effects of oral GCs on 5 important eosinophil-associated genes (MMP9, CD69, 
DUSP1, NR4A1, and NR4A2) were evident. Expression of MMP9 in GC-treated NP 
tissues was significantly reduced as compared to GC-naïve tissues. Moreover, 
expression of CD69, DUSP1, NR4A1 and NR4A2 in GC-treated NP tissues was 
completely normalized as compared to controls. 
Table 6.6 Microarray expression profiles of eosinophil-associated genes in NP (before 
GC treatment) as compared to control 
Genes with significant change* Biological 
process of 
Eosinophil 
Genes without significant 










ITGA4 (VLA-4); ITGB7; 
SELEP; ICAM1; VCAM1; 
ITGB1(CD29). 
ITGB2 (CD18); 




C5; CCL5 (RANTES);  
CCL7 (MCP-3); CCL13 
(MCP-4); CCL24; CCL2; 
CCR3; CYSLTR2; 
HRH4; GPR44 (CRTH2); 













CD95L; BCL2L1 (Bcl-xl); 
TGFβ; CD95; CYSLTR2; 
CCR3; Siglec-8; Bax; 












Genes in bold and underlines style were found significant changes after GC treatment. 
*: Significant change in microarray analysis. 
#: Genes have dual functions and been listed twice. 
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Figure 6.16 Cluster views of eosinophil associated genes in nasal tissues. Supervised hierarchical 
cluster analysis based on analysis of significance of microarrays (SAM) selected genes which are 
associated to eosinophil bio-physiological function. Each row represents an individual gene, and each 
column represents a tissue sample (GC-naïve NP or control) with grades (0 to 3) of eosinophil 
infiltration. Relative distance of each gene (vertical axis) and individuals (horizontal axis) are also 
demonstrated. The color spectrum for the range of expression values is shown at the left: the red color 
indicates high expression and green color low expression. The tissue type color bar is shown in the 









n-regulated genes in N
P 
GC-naïve NP vs. control
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6.1.9.2 Neutrophil associated genes 
Besides well-recognized eosinophil-dominated inflammation in Caucasian studies, 
predominant infiltration of other types of cells, especially neutrophils, could be a key 
component underlying the pathogenesis of NP in Asian populations [Jareoncharsri et al., 
2002; Zhang et al., 2006]. The results from our research group also reported a high 
infiltration of neutrophils in Chinese NP [Hao et al., 2006]. Therefore, it is worthwhile to 
review and identify the genes associated with the neutrophil biological process in NP, 
particularly in the Asian polyps. 
 
Following a strategy similar to the selection of eosinophil associated genes, 77 
important neutrophil associated genes were chosen based on several authoritative 
reviews [Borregaard et al., 2007; Kobayashi, 2008; Theilgaard-Mönch et al., 2005]. Analysis of 
the gene expression profiles demonstrated that 14 genes were differentially expressed 
in GC-naïve NP versus controls. Ten genes were up-regulated (CXCL6, CXCL12, 
IFNAR1, LGALS8, ITGB2, CEACAM6, MMP7, MMP9, SERPINA1, and DEFB1) 
while 4 genes were down-regulated (CXCL2, CRISP3, CEACAM1, and PTX3) in 
GC-naïve samples (Table 6.7). Among those 14 genes, only MMP7, MMP9 and 









Table 6.7 Microarray expression profiles of neutrophil associated genes in GC-naïve 
NP as compared to control 





CXCR4; CCR1; CCR2; CCR3; 
CCR6; IL1β; IL8; CXCL1; 
CXCL3; CXCL5; CXCL10; CCL2; 
CCL3; CCL4; CCL19; CCL20; 
IFNGR1; IFNGR2; IL8RA; IL8RB; 
IL4R; IL6R; IL10RB; IL13RA1; 
IL17RA; TNFRSF1A; TNFRSF1B; 
TGFBR2; LILRB1; LILRA2; 












BPI; CST3; CTSG; CYBB; 
SNAP23; STOM; MPO; ELA2; 
DEFA1; DEFA4; PRTN3; AZU1; 
LCN2; MMP8; CAMP; 
CEACAM1; CEACAM8; LTF; 
ITGAM; PGLYRP1; CFP; VAMP2; 
VTI1B; PLAUR; HP; SLPI; 









Genes in bold and underlines style were found significant changes after GC treated. 
*: Significant change in microarray analysis. 
 
6.1.9.3 Edema associated genes 
(1) Bioelectric genes 
Normal airway epithelium maintains the homeostasis of water transport across the 
epithelial tissues via regulating anion secretion and cation absortion. In NP and other 
airway disorders, dysregulation of the ion channels is thought to result in airway 
tissue edema [Boucher, 1994].  
 
In our study, we looked for the ion channel genes based on the literature reports 
[Bernstein 1997; Boucher, 1994; Yasuda et al., 2007a; Yasuda et al., 2007b]. One family of 
sodium channels, sodium channel nonvoltage-gated (SCNN) (also known as 
amiloride-sensitive epithelial sodium channel, ENaC), was uniformly up-regulated in 
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GC-naïve NP as compared to controls: SCNN1A (1.96-fold), SCNN1B (4.93-fold), 
and SCNN1G (5.65-fold). Another family of chloride channels, chloride intracellular 
channels (CLICs), was up-regulated in GC-naïve NP: CLIC3 (2.03-fold), CLIC5 
(1.85-fold), and CLIC6 (3.57-fold). With regard to the molecules which maintain the 
homeostasis of intracellular Na+ levels, ATP1A2 (ATPase, Na+/K+ transporting, alpha 
2) was down-regulated in GC-naïve NP at 2.96-fold. Although these bioelectric 
markers were differentially expressed in NP versus controls, none of them was altered 
after GC treatment. 
 
(2) Angiogenesis related genes 
In NP tissues, small vessels have been observed in the stroma, suggesting 
angiogenesis activity in NP. Angiogenesis in NP has been considered to be associated 
with vascular permeability, leading to tissue edema [Coste et al., 2000]. Several 
angiogenesis related genes have been reviewed. One important angiogenesis gene 
family, so called angiopoientins (ANGPTs), was identified in the NP disease gene list. 
Angiopoientins as well as its functional receptor (TEK) were down-regulated in 
GC-naïve NP as compared to controls: angiopoietin 1 (ANGPT1), 3.66-fold; 
angiopoietin 2 (ANGPT2), 2.94-fold; TEK, 3.19-fold. 
 
6.1.9.4 Genes related to tissue damage 
Airway tissues are susceptible to injury by various stimuli and environmental factors. 
Atmospheric oxygen species and free radicals have been thought to result in tissue 
damage of both upper and lower airways, such as asthma, chronic obstructive 
pulmonary disease and NP [Rahman et al., 2006]. Based on searching for gene ontology 
information related to oxygen species metabolism by online database 
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(http://www.geneontology.org/), we found that the expression of a number of 
oxidant/antioxidant related genes was significantly changed in GC-naïve NP 
compared to the control. Those enzymes which promote oxidative stress were 
uniformly up-regulated in GC-naïve NP: NOS2A, 3.96-fold; NOX4, 3.03-fold; 
DUOX1, 6.67-fold. However, some common antioxidant related enzymes were 
differentially expressed in GC-naïve NP: down-regulation of SOD3 (2.56-fold), 
GPX3 (2.59-fold), OXR1 (2.37-fold), and LPO (35.7-fold); while up-regulation of 
GCLM (3.65-fold), TXN (1.64-fold), PRDX1 (1.62-fold), and PRDX5 (1.79-fold). 
Among these oxidant/antioxidant markers, only GPX3 was up-regulated at 1.59-fold 
in NP after GC treatment.  
 
6.1.9.5 Genes with mucus hypersecretion 
Mucus hyper-secretion is a feature of several airways diseases such as chronic 
rhinosinusitis, asthma, and cystic fibrosis. Our histological results showed that 
submucosal glands in NP were dilated in pathological condition, leading to an 
increase of mucus production (Figure 6.1). Mucins are the major components of 
mucus. Our results showed that several mucin genes were altered in GC-naïve NP 
compared to control: up-regulation of MUC4 (5.47-fold), MUC16 (11.12-fold), and 
MUC20 (4.51-fold), but down-regulation of MUC7 (41.67-fold). However, none of 
these mucins responded to GC treatment in NP.  
 
6.1.10 Target genes validation by quantitative PCR 
To verify the findings from the microarray analysis, the same starting materials for the 
microarray study were used for subsequent quantitative PCR measurements. Several 
target genes deemed biologically interesting because of their differential expression in 
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GC-naïve NP versus control and/or in GC-treated versus GC-naïve NP were selected 
for validation. Selection of verified genes was based on the following criteria: (i) the 
key genes in the top ranking GC-responsive gene network; (ii) the important 
pro-/anti-inflammatory genes among GC-responsive genes; (iii) those NP associated 
genes which respond to GC treatment; (iv) the key genes in NP related Canonical 
Pathways; and (v) some important eosinophil related genes in NP. Appropriate 
TaqMan™ assays for genes of interest and GAPDH were purchased (Table 3.3). PCR 
data of validated genes were comparable to the results generated from microarray 
experiments (Figure 6.17). The rank order and magnitude of gene expression profile 
derived from quantitative PCR were in accordance with the microarray data. 
(A)                                    (B) 
 
Figure 6.17 Correlation of gene expression levels between Real-time RT PCR and microarray assays. 
Fold changes of each gene between GC-naïve NP and control (A), and between GC-treated and 
GC-naïve NP (B), were determined by means of real-time PCR and microarray. Twenty-nine validated 
genes in (A) include AREG, C3, CCL11, CD69, c-Fos, c-Jun, COX-2, CXCL2, DUSP1, DUSP2, 
DUSP6, EGR1, FosB, HBEGF, IL-18, IL5Ra, IL-6, JunB, MMP7, NFKBIA, NFKBIZ, NR4A1, 
NR4A2, SOCS3, SPRY1, SPRY2, SPRY4, THBD, and ZFP36. Twenty-nine validated genes in (B) 
include ANXA1, AREG, CD69, c-Fos, c-Jun, COX-2, CXCL2, CXCL9, CXCL11, DUSP1, DUSP2, 
DUSP6, EGR1, FosB, HBEGF, IL-6, JunB, MMP7, MMP9, NFKBIZ, NR4A1, NR4A2, SCGB1A, 
SOCS3, SPRY1, SPRY2, SPRY4, THBD, and ZFP36. Scale of X and Y axis is logarithmic (base 10) 
transformed.  
 
Due to the importance of the AP-1 network in GC-responsive genes, the correlation 







































between gene expression in AP-1 and AP-1 related genes was further evaluated based 
on fold change by PCR measurement. c-Jun mRNA is positively correlated with c-Fos 
and JunB mRNA (Spearman, r = 0.924, p < 0.001 and r = 0.827, p = 0.003, 
respectively; Figure 6.18). Similarly, c-Jun gene expression is positively correlated 
with AP-1 related genes (COX-2, IL-6 and EGR1) in GC-treated NP tissues (COX-2, 
r = 0.827, p = 0.003; IL-6, r = 0.662, p = 0.03 and EGR1, r = 0.893, p = 0.001; Figure 
6.18). Although the expression levels of the other two AP-1 related genes (AREG and 
HBEGF) were not significantly correlated, their correlation coefficients range from 
medium to large (AREG, r = 0.558; HBEGF, r = 0.426).  
 
Two glucocorticoid receptor (GR) isoforms were also measured by quantitative PCR 
(Appendix II, Page 268). GRα mRNA was significantly decreased in patients with NP, 
either with or without GC treatment, when compared to control tissues. Compared with 















6.1.11 Protein expression evaluated by immunohistochemistry 
Since two AP-1 components (c-Jun and c-Fos) are the core genes among those 
GC-responsive genes, protein expression levels of these AP-1 genes were further 
evaluated by immunohistochemistry. c-Jun was present predominantly in epithelium 
of both NP tissues and nasal mucosal controls (Figure 6.19). c-Jun protein was 
Figure 6.18 Relationship between mRNA 
level (by real-time PCR) of AP-1 genes 
versus AP-1 related genes. Correlation 
between mRNA level of c-Jun versus c-Fos 
(A), JunB (B), COX-2 (C), IL-6 (D), and 
EGR1 (E) was illustrated.  ∆, fold change of 
the indicated gene in individual patient prior 
to versus after GC treatment. Fold changes 
were determined by PCR. 
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markedly lower in 6 of 10 GC-naïve NP tissues, but significantly elevated in 
GC-treated NP, suggesting usage of GC contributed to the increase of c-Jun 
expression (Table 6.8). In turbinate control tissues, the intensity of c-Jun staining in 
epithelial cells was similar to that in GC-treated NP tissues (Figure 6.19). 
 
c-Fos protein was expressed among various cell types such as epithelial cells, 
glandular cells, vascular endothelial cells, lymphocytes, granulocytes and monocytes. 
Interestingly, the expression of c-Fos was similar among GC-naïve, GC-treated and 
control tissues (Figure 6.19), suggesting that GC treatment does not alter the protein 
expression of c-Fos in NP. 
 
Because the current study showed that one of the major effects of GCs in NP was to 
improve epithelial structure (Table 6.1, Page 90) and the functions of the AP-1 gene 
network are involved in cellular development, growth, and proliferation, we intended 
to evaluate the relationship between c-Jun protein expression and epithelial 
improvement by GCs. Interestingly, the results showed that c-Jun expression was 
positively related to the epithelial integrity in both GC-naïve and GC-treated NP 













Figure 6.19 Expression of c-Jun and c-Fos protein in nasal tissues. Protein levels of c-Jun and c-Fos 
were determined by means of immunohistochemistry in the nasal mucosa of 2 representative NP 
patients and 2 controls:  plates A, B, G and H are from patient NP9 and plates D, E, I and J are from 
patient NP7 while plates C and K are from control IT5, and plates F and L are from control IT3.  
Plates A and B represent c-Jun staining in patient NP4 prior to versus after GC treatment and plates G 
and H are stains with isotype control antibody prior to versus after GC treatment. Similarly, plates D 
and E represent c-Fos staining in patient NP5 prior to versus GC treatment while plates I and J are 
stains with isotype control antibody prior to versus GC treatment. Plate C represents c-Jun staining in 
control IT5, while plate K is the corresponding isotype control. Plate F represents c-Fos staining in 
control IT3, while plate L is the corresponding isotype control. Original magnification: 200x.   
 153
Table 6.8 Comparisons of c-Jun immunohistochemistry in  
NP epithelium from GC naïve and GC treated subjects 
 Evaluation of c-Jun staining * 
Group 
Weak     Strong     p value # 
GC naïve NP 6 4 0.01 
GC treated NP 0 10  
Damaged Epithelium † 6 4 0.01 
Intact Epithelium † 0 10  
 
* Referring to c-Jun staining in Table 6.1: overall score of ≥ 6 defined as “strong” expression, and < 6 
as “weak” expression. 
† Referring to epithelium damage in Table 6.1: Grade 0 defined as intact epithelium; Grade 1 and 2 
defined as damaged epithelium.  
# p value obtained by fisher’s exact test. 
 
Part II Discussion 
Gene profiling technologies have demonstrated considerable power in the generation of 
cell and tissue molecular signatures, identification of disease-associated gene, 
determination of candidate genes in response to drug effects and exploration of 
molecular signaling pathways. DNA microarray technology consists of a matrix with 
attached sequences that allow simultaneous analysis of expression of panels of human 
genes. Comparison of gene expression profiles in disease versus healthy tissues or in 
drug effects often highlights the involvement of both expected and unsuspected 
pathologic pathways. 
 
Inflammatory processes within the mucosa of the upper respiratory tract are believed to 
play an important role in the development of NP. Infiltration of eosinophils and 
epithelial damage followed by abnormal remodeling are the most characteristic features 
of NP. Some of the mediators that participate in the NP formation have been already 
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identified in previous studies (See Chapter 1.4.6, Page 15). However, considerable 
doubt remains concerning the role of each molecule in this complex and dynamic 
process. In addition, the molecular mechanisms underlying the ameliorative response 
of NP to GCs are poorly understood. Therefore, based on increasing recognition that a 
systems approach is necessary to view the overall molecular events responsible for NP 
and GC effects on NP, we have combined large-scale analysis of gene expression 
profile with knowledge-based and relevance network analyses.  
 
In our study, DNA microarrays with 38,500 human genes were used to screen for those 
in which expression was altered in GC-naïve NP versus control and GC-treated versus 
GC-naïve NP. This strategy identified both up-regulated and down-regulated genes. 
Most importantly, complex networks involved in inflammation, cellular infiltration and 
tissue development were mapped and subsequently explored in the context of genes 
deemed important in NP development as well as its response to GC treatment by 
inferential statistics for a refined molecular pathway picture. The candidate genes for 
GC effects on NP have been subsequently suggested.  
 
In the following sections, the important findings of the current microarray study will 
be highlighted and discussed: (i) indication of the general microarray analysis 
(including PCA/cluster analysis and functional network analysis); (ii) the major 
molecular events underlying the GC effects on NP; (iii) the important molecular 
mechanisms underlying the pathological patterns of NP. 
 
6.2.1 Indication of microarray analysis 
Microarray analyses describe the general expression profiles (by PCA/cluster 
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analysis), and the functions as well as molecular interaction networks among the gene 
sets. These analyses themselves reveal some interesting indications.  
 
6.2.1.1 Indication of PCA/cluster analysis 
Based on these significantly different genes, advanced computational methods 
(PCA/cluster analysis) were applied to study the relationships among the nasal 
samples according to similarity in pattern of gene expression. The PCA and cluster 
analysis were consistent with each other, and they demonstrated a near-perfect 
separation of three sample groups (GC-naïve NP, GC-treated NP, and control), 
indicating there were prominent underlying differences in gene expression associated 
with the development of NP, as well as the GC effects on NP (Figure 6.10, Page 111; 
Figure 6.11, Page 113). However, one to two NP samples were not contained within 
their corresponding clusters. They did not cluster tightly with the majority of the other 
NP samples in cluster and PCA analyses likely because they have distinct gene 
expression patterns at least with respect to the dataset of the significant genes used in 
these analyses.  
 
In the comparisons between GC-naïve NP and controls, NP6 was clustered opposite to 
the NP samples. This observation may be attributed to the distinct histological pattern 
of NP6 compared to the other GC-naïve NP samples. NP6 was the only polyp sample 
highly infiltrated with lymphocytes but without eosinophil infiltration. Considering 
the comparison of GC-treated vs. GC-naïve NP, NP7 (GC-naïve polyp) and NP4R 
(GC-treated polyp) were not clustered in the corresponding groups. This observation 
could also be explained by the different histological patterns of these NP samples 
from the others. In the studied NP samples, most GC-naïve NP represent high 
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infiltration of eosinophils and severe edema, while most GC-treated NP represent low 
infiltration of eosinophils and absence of edema (Table 6.1, Page 90). NP7 was the 
only NP sample which simultaneously showed little eosinophil infiltration and edema 
among the GC-naïve NP group, so that the histological characters of NP7 were close 
to those of GC-treated NP tissues. As far as the similarity between NP4 and NP4R are 
concerned, the histological changes among this pair of NP were not obvious: 
eosinophil infiltration was not significantly reduced in NP4R compared to NP4, and 
both NP4 and NP4R were not edematous polyps. Therefore, the close cluster of NP4 
and NP4R may indicate the limited effects of GCs on change of histopathologic 
profiles (eosinophils and edema) in NP4 patient. 
 
In summary, these analyses suggest that varied histological features of NP may have a 
basis in distinct gene expression patterns and this observation is consistent with the 
great biological variability observed in vivo as manifested in patient clinical behavior 
and the heterogeneous features of NP.  
 
6.2.1.2 Indication of functional analysis 
In Chapter 6.1.6 (Page 114), we described and compared the most significant 
functional groups in three datasets (GC-naïve NP versus control, GC-treated versus 
GC-naïve NP, and GC-treated NP versus control). The significant functions were 
classified into three categories (i.e., at disease, tissue, and molecular/cellular levels). 
The most significant functions related to NP and the response of NP to GCs were in 
agreement with each other, including inflammatory/immunological diseases, cancer, 
tissue development, cellular development, growth, proliferation, and death. Indeed, 
these functions may contribute to the pathogenesis of NP at different levels (i.e. from 
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tissue to cell to molecule). These results could explain that NP is a chronic 
inflammatory disease with abnormal tissue development process in epithelium and 
stroma area, which are attributed to dysregulation of cellular activation and infiltration. 
Furthermore, these functions are also considered to be the underlying mechanism for 
the potent anti-inflammatory and tissue repair effects of GCs.  
 
One interesting finding of the functional analysis is that the top significant disease 
related to NP associated genes is cancer. Although NP has not been considered a 
cancer-prone lesion, the hyperplastic features and high recurrence rate of NP raise 
attention to whether NP could share some pathological mechanisms with those 
malignant (e.g. nasopharyngeal carcinoma) and benign (e.g. inverted papilloma) 
neoplasms in upper respiratory tissues, or whether NP could serve a link between 
neoplasia and inflammation. This suggests that some cancer related 
genes/mechanisms could be considered alternative approaches to study NP 
pathogenesis. 
 
6.2.1.3 Indication of functional network analysis 
The effect of GC treatment on NP is attributed to the complex interaction among those 
functional related genes, so that we have identified distinct molecular networks 
implicated in the mechanism of GCs. These networks include both directed and 
undirected interactions. Directed interactions are characterized by a well-defined 
information flow (e.g., from a transcription factor to the gene it regulates). Undirected 
interactions do not have an assigned direction (e.g., mutual binding relationships). 
The ability to rank the networks based on their relevance to the GC-responsive gene 
set allowed for rapid prioritization of networks with highest importance. The 
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top-scoring network, AP-1 network is related to cellular development, growth, and 
proliferation; while the 2nd ranking network is associated with inflammatory disease. 
These results are consistent with those in functional analysis and could represent the 
molecular evidence of GCs, at least in our studied NP samples. 
 
Another important application of network analysis in the current study is to identify 
the core/candidate genes among the GC-responsive genes. This is based on the 
searching of most prominent interaction partners within the merged networks. Other 
than those previous microarray studies in NP which focused on the top 
over-expressed/under-expressed genes [Fritz et al., 2003; Benson et al., 2004; Liu et al., 2004; 
Lee et al., 2006; Bolger et al., 2007; Figueiredo et al., 2007], network analysis identifies the 
most functional interacting genes which may represent the molecular candidates in 
response to GC treatment. The identified candidates, AP-1 genes (c-Jun and c-Fos) are 
critical factors which govern the transcription status of numerous growth related 
genes, mapping the central position among the GC-responsive gene network. Again, 
these results are also in agreement with those significant functions related to the gene 
sets. 
 
6.2.2 Summary of the functional network pathways 
Based on the network analysis (Chapter 6.1.7, Page 118) and Canonical Pathway 
analysis (Chapter 6.1.8, Page 126), the present microarray study reveals several 
important molecular signaling pathways which contribute to the pathogenesis of NP 
and its response to GC treatment. Network analysis suggests that AP-1 network and 
the network composed of pro-/anti-inflammatory genes would underlie the GC effects 
on NP. The Canonical Pathways suggests that apoptosis signaling, complement 
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system, EGF/EGFR signaling, eicosanoid signaling, ERK/MAPK signaling, IL-6 
signaling, and NF-kappaB signaling would be associated with NP pathogenesis. Table 
6.9 summarized the relevant roles of these signaling pathways in NP before and after 
GC treatment based on the evaluation of the expression levels of the key genes. Note 
that some genes identified in Canonical Pathways are also determined in 
GC-regulated network pathways. The Canonical Pathways are discussed in this 
section; while those GC-responsive pathways will be discussed in a latter section (See 
Chapter 6.2.3, Page 169; Chapter 6.2.4, Page 179). 
 
Table 6.9 Summary of the functional network pathways in NP 
Response to GC therapy‡ Pathway Relevant 
biological/immunolog
ical functions† Before After 




process Down Up 
Caspase-mediated 
apoptosis signaling# 
Epithelial damage Up NS 
Complement system# Eosinophil infiltration Up NS 
EGF/EGFR 
signaling# 
Epithelial restitution Down Up 
Leukotriene 
signaling#  
Eosinophil infiltration Up NS 
Prostaglandin E2 
signaling# 




process Up Down 




process Up Down 
* Networks generated from GC-regulated genes. 
# Networks generated from NP disease associated genes. 
† Only list the most relevant function of the indicated pathway based on the results of current study. 
‡ Response of indicated network is evaluated by the expression levels of the involved key genes. 
NS, not significant change. 
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6.2.2.1 Apoptosis signaling in NP 
Apoptosis, a form of cell death characterized by cell shrinkage, membrane blebbing, 
nuclear breakdown, and DNA fragmentation, is essential for development, 
maintenance of tissue homeostasis and elimination of harmful cells in metazoan 
organisms [Nagata, 1997]. Caspases, a group of cysteine proteases that cleave protein 
substrates after aspartic acids, play a central role in the regulation and execution of 
apoptosis [Cryns et al. 1998]. Canonical Pathway of apoptosis described the 
caspase-mediated apoptosis cascade in GC-naïve NP (Figure 6.15B, Page 129). 
 
There is less information about the apoptotic factors in NP, and only one recent report 
showed that down-regulation of cIAP1 (apoptosis inhibitor 1) may contribute to the 
increase of cellular infiltrates in NP [Cho et al., 2008]. Our results showed that, although 
GCs did not change expression level of the apoptotic factors in NP, two critical 
downstream caspase genes (CASP3 and CASP7) as well as Bid and AIF were 
constituently expressed higher in GC-naïve NP. The previous study also reported that 
CASP3 was only expressed in the epithelial region in NP, but not in subepithelial 
constituents [Cho et al., 2008]. Since epithelium damage was detected in GC-naïve NP 
in our study, it suggests that the caspase pathway may not be an important 
pro-apoptotic mechanism in the stromal cellular infiltration, but may be essential in 
epithelial damage/remodeling in NP. In addition, up-regulation of pro-apoptotic genes 
may also indicate the heterogeneity of apoptotic environment in NP, i.e., the 





6.2.2.2 Complement components in NP 
The complement system is perceived as a central constituent of innate immunity, 
defending the host against pathogens, coordinating various events during 
inflammation, and bridging innate and adaptive immune responses [Markiewski & 
Lambris, 2007]. However, disturbance in this defense system leads to inflammatory 
disorders. The Canonical Pathway of complement system showed the activation 
cascades of complement components in GC-naïve NP (Figure 6.15C, Page 131).  
 
The roles of complement in asthma are considered to promote migration of 
inflammatory cells, resulting in the rapid degranulation of mast cells [Guo et al., 2005; 
DiScipio et al., 2007]. However, the effects of complement signaling in NP inflammation 
have been rarely reported. Only two studies have reported the findings of complement 
levels in NP, but the results were controversial since both up- and down-regulated 
production of complement was found [Zídková et al., 1993; Baruah et al., 2007].  
 
Our results showed that the key complement component C3 was associated with 
eosinophil infiltration (Table 6.6, Page 142) and other components such as C4a and 
C1QB were also up-regulated in GC-naïve NP. Moreover, C3 has also been 
recognized as a potent mediator for the induction of Th2-induced allergic asthma 
[Drouin et al., 2001]. Therefore, the increase of complement components in NP may 
reflect the ongoing inflammatory response (e.g. recruitment of leukocytes and 
up-regulation of inflammatory cytokines) in exposure to microbes in nasal mucosa, 




6.2.2.3 EGF/EGFR signaling in NP 
The EGF/EGFR signaling is important to regulate cell proliferation, migration and 
differentiation on target cells (Figure 6.15D, Page 132). The EGF/EGFR signaling 
has been suggested to play a critical role in tissue repair/remodeling in both healthy 
airway tissues and airway inflammatory disorders (e.g., asthma) [Davies et al., 1999; 
Holgate, 2000; Watelet et al., 2006]. Most importantly, the localization of EGF genes and 
EGFR in nasal epithelium from healthy inferior turbinate indicates that they have an 
essential role in epithelial development and repair [Polosa et al., 2000]. However, its 
function in NP has been less documented. Our results showed that both EGFR ligands 
(e.g., AREG, EGF, HBEGF and NRG3) and EGF receptors (e.g., ERBB4) were 
down-regulated in GC-naïve NP as compared to controls, suggesting the 
dysregulation of EGF/EGFR mediated proliferation signaling in NP, especially in NP 
the epithelial region. Furthermore, an increase of AREG and HBEGF in response to 
GC treatment suggests the epithelial repair function of GCs (more detail in Chapter 
6.2.3, Page 169). 
 
6.2.2.4 Eicosanoid signaling in NP 
Abnormal regulation of both leukotriene (LT) and prostaglandin (PG) pathways 
appear to be involved in the chronic inflammation of NP [Picado et al., 1999; Mullol et al., 
2002; Pérez-Novo et al., 2005; Pérez-Novo et al., 2006; Adamjee et al., 2006; Hyo et al., 2007]. The 
Canonical Pathway picture showed the interactions of the molecules involved in the 
eicosanoid signaling network (Figure 6.15E, Page 134).  
 
The enzymes (PLA2, ALOX5AP, and LTA4H) in the LT synthesis pathway as well as 
the LT receptors (LTB4R and CYSTLR1) were up-regulated in GC-naïve NP and 
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up-regulation of these LT related markers were significantly correlated with an 
increased infiltration of eosinophils in nasal samples (Table 6.6, Page 142; Figure 
6.16, Page 143). These data are in line with the previous studies showing that 
eosinophils are one of the most important sources of LT receptors in inflamed upper 
airways [Sousa et al., 2002]; and that an LT signaling pathway may be involved in 
eosinophil migration and survival [Holgate et al., 2003; Saito et al., 2004].  
 
As far as in the PG pathway, we found that the key enzyme (COX-2) for PGE2 
production and the PGE2 receptors (PTGER2 and PTGER3) were changed in 
GC-naïve NP as compared to controls and only COX-2 expression responded to GC 
treatment in NP. The anti-inflammatory roles of COX-2/ PGE2 in NP have been 
documented. Previous studies reported that the imbalance of AA/PGE2 metabolism in 
aspirin-intolerant/aspirin-tolerant NP patients could be due to down-regulation of 
COX-2 [Picado et al., 1999; Mullol et al., 2002; Pujols et al., 2004]. Another important role of 
COX-2/PGE2 is considered to be associated with epithelial repair and it will be 
discussed in Chapter 6.2.3 (Page 169). The complexities of PGE2-mediated effects 
may be attributed to the diversified properties of PGE2 receptors [Funk, 2001; Tilley et al., 
2001]. PGE2 promotes vasodilatation by activation of cAMP-coupled PTGER2 on 
vascular smooth muscle and increase of vascular permeability by enhancing the 
release of histamine and other mediators from leukocytes. Regarding PTGER3, a 
previous study showed that the prevalence of a certain haplotype in PTGER3 was 
significantly higher in mild asthmatics than in moderate and severe asthmatics, 
suggesting that genetic variations in PTGER3 may play an important role in asthma 
severity [Park et al., 2007]. PTGER3 action was mediated by an increase of intracellular 
cAMP signaling, which is associated with an inhibition of leukocyte activation in 
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inflamed tissues [Gerlo et al., 2004]. Therefore, up-regulation of PTGER2, but 
down-regulation of PTGER3 may promote the chronic inflammation of NP. 
 
In summary, mRNA patterns of the genes involved in LT and PG pathways are 
different between NP and control. Up-regulation of the markers related to LT 
synthesis/activation would contribute to eosinophil infiltration in NP. In contrast to the 
effects of LT signaling, PGE2 pathway (COX-2 – PTGERs) may have diverse 
modulatory roles in the development of NP and up-regulation of COX-2 may 
represent the beneficial effects of GCs in NP inflammation. In addition, our results 
also indicate that to determine the role of PGE2 in a given inflammatory response, one 
should keep in mind not only knowledge of the lipid mediators (PGs) presented in the 
tissues, but also the PG receptor profile and its corresponding biochemical signaling 
on immune cells.  
 
6.2.2.5 ERK/MAPK signaling in NP 
The ERK/MAPK signaling pathway has an important role in cellular processes, such 
as proliferation, stress responses, apoptosis, and inflammation. MAPK pathways are 
activated through a cascade of sequential phosphorylation events. Activated MAPKs 
can phosphorylate a wide array of downstream targets, including protein kinases and 
transcription factors (e.g. ATF/CREB and AP-1 family) that facilitate the transcription 
of pro-inflammatory genes [Johnson et al., 2007]. Meanwhile, activation of the MAPK 
signaling cascade also triggers negative-feedback mechanisms, which can restrain and 
terminate the inflammatory response [Lang et al., 2006]. The ERK/MAPK Canonical 
Pathway (Figure 6.15F, Page 136) revealed altered expression of two major negative 
regulators of MAPK signaling pathway in NP, including dual specificity phosphatases 
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(DUSPs) and sprouty homologys (SPRYs), which control the signaling cascade at 
different activation/phosphorylation levels. Moreover, most of the DUSPs and SPRYs 
responded to GC treatment in NP, which were also identified in the GC-responsive 
gene networks. 
 
In many cases, the expression of DUSPs is regulated by MAPKs and the participation 
of DUSPs in feedback regulation of MAPK activity is thought to be critical to the 
dynamic regulation of MAPK responses. GCs have been shown to inhibit the activity 
of different MAPK members [González et al., 1999; González et al., 2000; Lasa et al., 2002]. 
However, the response of most DUSP members to GCs is poorly understood; only 
induction of DUSP1 was found in several cell types by GC treatment and it has been 
regarded as one potential anti-inflammatory mechanism of GCs [González et al., 1999]. 
Furthermore, DUSP1 is the founding member of the MAPK phosphatase family and 
is expressed as an immediate-early gene in response to serum, growth factors, or 
cellular stresses [Sun et al., 1993; Zheng et al., 1993].  
 
Sprouty homology family represents a major class of ligand-inducible inhibitors of 
receptor tyrosine kinase (RTK)-dependent signaling pathways, particularly the 
RTK-RAS-RAF-ERK/MAPK signaling cascade [Mason et al., 2006]. Expression of 
SPRY proteins is induced by various growth factor signals, including fibroblast 
growth factors (FGFs) [Hanafusa et al., 2002] and epidermal growth factor (EGF) [Reich 
et al., 1999]. The inhibitory activity of SPRY is exerted upstream of ERK/MAPK and 
downstream of the RTK, but the precise point at which SPRY intercepts 
RTK-ERK/MAPK signaling varies depending on the biological context. For example, 
in mouse fibroblasts, SPRY1 and SPRY2 interfere with ERK/MAPK signaling at the 
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level of Ras activation [Gross et al., 2001], while in human epithelial cells, SPRY2 and 
SPRY4 functions at the level of RAF activation [Yusoff et al., 2002]. 
 
Although the knowledge of MAPK signaling pathway in inflammation is well 
established, the mechanism of MAPKs in NP has been rarely reported. Only the 
induction of RANTES [Yamada et al., 20001], MUC5AC [Young et al., 2004], MUC8 [Cho 
et al., 2005], and CCL2 [Lin et al., 2007] was involved in MAPK mediated inflammatory 
pathways. In addition, no report has described the expression and function of the 
MAPK negative regulators (DUSPs and SPRYs) in NP. Our study found that five 
main DUSPs (DUSP1, DUSP2, DUSP4, DUSP5, and DUSP6) and three major 
SPRYs (SPRY1, SPRY2, and SPRY4) were expressed lower in GC-naïve NP, 
indicating the negative regulation process on MAPK was inadequate in NP. Therefore, 
the response of DUSP1, DUSP2, DUSP6, SPRY1, SPRY2, and SPRY4 to GC 
treatment in NP suggests the anti-inflammatory effects of GCs on ERK/MAPK 
signaling pathways. 
 
6.2.2.6 IL-6 signaling in NP 
As shown in Figure 6.15G (Page 138), IL-6 signaling is mediated by IL-6 signal 
transducer (IL6ST, or known as gp130), which leads to Jak activation, receptor 
phosphorylation, and consequently activation of the transcription factor STAT3 [Bravo 
et al., 2000; Schmitz et al., 2000]. Upon phosphorylation, STAT3 forms homodimer and 
translocates into the nucleus, where it activates transcription of target genes, such as 
Bcl-2, cyclin D1, cyclin E1, CDKN1A, MYC, c-Jun, and c-Fos [Alvarez et al., 2004]. To 
control the IL-6 mediated proliferation signal, gp130 can recruit the key feedback 
inhibitor, suppressor of cytokine signaling 3 (SOCS3) by interacting with the Y759 
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motif of gp130 [Starr et al., 1997; Nicholson et al., 2000]. SOCS3 is induced by IL-6 and has 
an important role in the regulation of IL-6 signaling pathway [Croker et al., 2003]. 
 
The expression of IL-6 in NP has been reported controversially, and both up- and 
down-regulated alteration has been found [Bachert et al., 1997; Scavuzzo et al., 2005; 
Danielsen et al., 2006], indicating IL-6 may participate in both pro- and 
anti-inflammatory actions. Since all the key markers (including IL-6, gp130, STAT3, 
and SOCS3) were down-regulated in NP, IL-6 signaling may be defected in GC-naïve 
NP samples (Figure 6.15G, Page 138). Reduction of IL-6 signaling may reflect the 
damage of epithelium and low growth potential of epithelial cells in NP. So that the 
increase of IL-6 expression in NP after GC treatment suggests the promotion of 
epithelial restitution by GCs; while the simultaneous up-regulation of SOCS3 by GCs 
may indicate the homeostatic effect of GCs on IL-6 mediated proliferation signaling. 
 
6.2.2.7 NF-kappaB signaling in NP 
NF-kappaB acts on genes for proinflammatory cytokines, chemokines, enzymes that 
generate mediators of inflammation, immune receptors, and adhesion molecules that 
play a key part in the initial recruitment of leukocytes to sites of inflammation [Hayden 
et al., 2004]. The activated form of NF-kappaB is a heterodimer, which usually consists 
of two proteins, a p65 subunit and a p50 subunit. In unstimulated cells, NF-kappa B is 
found in cytoplasm and is bound to inhibitors of NF-kappaB (IkappaB), which 
prevent it from entering the nuclei [Baldwin, 1996]. NF-kappaB Canonical Pathway 
revealed that two important inhibitors (NFKBIA and NFKBIZ) of NF-kappaB 
signaling were decreased in GC-naïve NP (Figure 6.15H, Page 140).  
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There are six IkappaB family members, including IkappaB-α (NFKBIA), IkappaB-β 
(NFKBIB), IkappaB-γ, IkappaB-ε (NFKBIE), BCL3, and IkappaB-ζ (NFKBIZ), 
which are characterized by the presence of five to seven ankyrin repeats that assemble 
into elongated cylinders that bind the dimerization domain of NF-kappaB dimmers. 
Various members of the IkappaB family target different NF-kappaB complexes, for 
example, NFKBIA and NFKBIB interact preferentially with p65/p50 heterodimers 
[Thompson et al., 1995], while NFKBIZ preferentially associates with the NF-kappaB 
subunit p50 rather than p65 [Yamazaki et al., 2001].  
 
Previous studies showed that an increase of NF-kappaB activity and expression has 
been found in NP, which was accompanied with up-regulation of pro-inflammatory 
genes (such as GM-CSF, IL-5, IL-8, and eotaxin) [Takeno et al., 2002; Valera et al., 2008]. 
Direct interactions between the glucocorticoid receptor and NF-kappaB account for 
the inhibitory effects of GCs on NF-kappaB signaling [McKay et al., 1999]. However, 
glucocorticoid response element (GRE) was found in IkappaB genes, and GCs are 
able to induce expression of IkappaB, indicating another way by which GCs inhibit 
NF-kappaB activity [Auphan et al., 1995]. Therefore, the lower expression of NFKBIA 
and NFKBIZ suggest that the control mechanism of NF-kappaB is insufficient, 
contributing to the chronic inflammatory milieu in NP. Although we did not find the 
change of expression in NF-kappaB factors in NP, the results of up-regulation of 
NFKBIZ are in line with the concept that GCs can inhibit activation of NF-kappaB by 
promoting IkappaB expression [Scheinman et al., 1995]. 
 
6.2.2.8 Conclusion of Canonical Pathways in NP 
Systemic pathway analysis reveals the well-established signaling pathways which 
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contribute to the NP pathogenesis. Referring to the histopathological findings of the 
current study, we suggest that the dysfunction of NP epithelium would be associated 
with the alteration of caspase-mediated apoptosis signaling, EGF/EGFR signaling, 
PGE2 signaling, and IL-6 signaling, while the increase of eosinophil infiltration and 
inflammatory process in NP would be related to the enhanced activity of complement 
system, LT signaling, ERK/MAPK signaling, and NF-kappaB signaling (Table 6.9, 
Page 159). Most of the Canonical Pathways responded to GC treatment (except 
apoptosis signaling, complement system, and LT signaling), indicating the potential 
effects of GCs on NP could be epithelial repair and anti-inflammation (Table 6.9, 
Page 159). These two major beneficial effects will be discussed in detail in the 
following two sections (Chapter 6.2.3 & 6.2.4). 
 
6.2.3 Epithelial repair effect of GCs in NP 
In the current study, the advanced functional and network analyses were used to 
identify the key networks and candidates in response to GC treatment. This is the first 
in vivo study deciphering the role of the AP-1 gene network and epithelial remodeling 
in NP. The major findings are: (i) epithelial damage is an important feature of NP and 
a remarkable epithelial restitution is observed after GC treatment; (ii) AP-1 and its 
related genes appear to be a key molecular network underlying the wound healing in 
NP; (iii) epithelial c-Jun protein expression is up-regulated by oral GC therapy and is 
positively correlated with epithelium restitution in NP tissues. 
 
6.2.3.1 Background information of epithelial repair in airway tissues  
The epithelial repair process is a highly organized and well coordinated process, 
which is generally categorized into three steps: the inflammatory, proliferative, and 
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remodeling phases. During inflammation, various inflammatory cells (including 
neutrophils, lymphocytes and macrophages) infiltrated the wounded epithelium, and 
secrete pro-inflammatory mediators (e.g. cytokines and growth factors) which are 
vital for pushing the wound healing process into the proliferative phase. After the 
inflammatory stage, fibroblasts begin to enter the wound site, marking the onset of the 
proliferative phase. During this period, epithelial cells migrate across the new tissue to 
form a barrier between the wound and the environment. Finally, tissue remodeling 
occurs, including re-epithelialization and matrix deposition.  
 
The human nasal epithelium represents the first line of defense against a number of 
toxic substances, allergens and infectious agents. In order to maintain its integrity, the 
nasal epithelium has the capacity to repair itself in response to the chronic exposure of 
damaging agents. However, the feature of mucosal inflammation in NP is epithelial 
damage followed by abnormal tissue repair and remodeling [Holgate, 2000; Watelet et al., 
2006]. The NP epithelium is “passively” under attack by the infiltrating eosinophils 
and inflammatory mediators, leading to damage of epithelium [Uneri et al., 2005; Cheng et 
al., 2006]. Consequently, the epithelial damage of NP causes the release of 
pro-inflammatory signals which pass down into the submucosa and also removes 
some anti-inflammatory mediators such as PGE2, leading to uncontrolled remodeling. 
Hence, under chronic inflammatory conditions, the epithelial repair process may 
become inadequate in NP, resulting in abnormal tissue repair and remodeling. In this 
context, rapid repair of damaged epithelium without causing uncontrolled 
re-epithelialization process is critical to the resolution of NP inflammation.  
 
GC treatment is considered the most effective pharmacological therapy for chronic 
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upper airway inflammation including NP and asthma [Fokkens et al., 2007; Bateman et al., 
2008]. The predominant effects of GCs are to switch off multiple inflammatory genes 
that have been activated during the inflammatory process and to promote tissue repair, 
such as immunoregulatory and remodeling effects by induction of TGF-β in NP 
[Mastruzzo et al., 2003], and by activation of EGF/EGFR signaling in the asthma model 
[Wadsworth et al., 2006]. However, the previous studies only specify selected known 
markers, while a systematic approach is necessary to view the overall molecular 
events responsible for GC therapy and their effects on epithelial repair in NP. 
 
6.2.3.2 Histolgoical findings regarding epithelial repair by GCs in the current 
study 
On the basis of a grading system that we used to quantify epithelial integrity, the 
epithelium of most GC naïve NP samples was substantially damaged, while 
remarkable epithelial restitution with no abnormal remodeling was observed after oral 
GC treatment (Table 6.1, Page 90). Moreover, improvement was evident in GC-naïve 
NP tissues with areas of squamous epithelium (NP3 and NP10), and GC-treated NP3 
and NP10 presented pseudostratiried columnar epithelium without aberrant 
hyperplasia, indicating the regulatory effects of GCs. Our findings are consistent with 
those reports which demonstrate improvement in the structure of airway epithelium 
after GC treatment [Mastruzzo et al., 2003; Wadsworth et al., 2006]. Note that the previous 
studies focused on the effect of topical GC treatment, while our study observed that 
short course (3-5 days) of oral GC treatment indeed had a tissue repair effect on NP in 
vivo.  
 
6.2.3.3 Molecular events underlying the wound healing effects of GCs in NP 
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Histological evaluation has confirmed the epithelial change at the tissue level, while 
microarray analyses explored the molecular evidence underlying this healing process 
of GCs. In this context, the top-scoring network (AP-1 network) and the involved GC 
candidate genes (AP-1 molecules) as well as their major interacting genes are of 
particularly interest. The functions of AP-1 network and AP-1 genes/AP-1 related 
genes are associated with cellular development, growth, and proliferation, which are 
considered to contribute to the histological change of NP epithelium. The discussion 
of AP-1 and AP-1 related genes is described in the following paragraphs. 
 
(1) Background information of AP-1 
AP-1 regulates a wide range of cellular processes by induction of various 
pro-/anti-inflammatory molecules, including inflammation, cell migration, 
proliferation, death, survival and differentiation [Shaulian et al., 2002]. AP-1 is formed 
by dimerization of members of Jun (c-Jun, JUNB and JUND) and Fos (c-Fos, FOSB, 
FOSL1 and FOSL2) proto-oncogene families, while the most abundant AP-1 
heterodimer is c-Fos:c-Jun [Karin et al., 1997]. c-Jun is the central component of all 
AP-1 proteins and the key factor for AP-1 activity, due to its wide range of 
dimerization with other AP-1 members and regulation (e.g. phosphorylation) by 
various mediators [Karin et al., 1997]. The Fos proteins, which cannot homodimerize, 
form stable heterdomiers with Jun proteins and thereby enhance their DNA binding 
activity.  
 
AP-1 activity is regulated by a broad range of extracellular stimuli including 
physiological agents (mitogens, growth factors, hormones, extracellular matrix and 
inflammatory cytokines), bacterial and viral infections, pharmacological compounds 
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(anisomycin, phorbol esters, and okadaic acid) and cellular stress (ultraviolet or 
ionizing radiation) [Karin et al., 1997]. Many of these stimuli activate the 
mitogen-activated protein kinase (MAPK) cascades [mostly p38, JUN N-terminal 
kinases (JNKs) and extracellular signal-related kinases (ERKs)], leading to the 
phosphorylation of c-Jun [Karin, 1995]. In turn, phosphorylated JUN heterodimers bind 
DNA sequences (AP-1 response elements) and induce the transcription of downstream 
genes which are most involved in cellular development, growth and proliferation. 
AP-1 induces a variety of growth related genes (e.g. EGF protein family) [Grose, 2003], 
cytokines (e.g. IL-6) [Gallucci et al., 2000], and enzymes (e.g. COX-2) [Yamaguchi et al., 
2005]. Moreover, AP-1 can also interact with other transcription factors (e.g., EGR1), 
which enhance AP-1 activity [Levkovitz & Baraban, 2001]. 
 
Regulation of AP-1 gene expression in response to GCs is highly complex and may be 
cell-type-specific. Subramaniam et al. demonstrated that dexamethasone (Dex) 
up-regulated the mRNA levels of c-Jun and c-Fos in human osteoblasts [Subramaniam et 
al., 1992]. Zhou et al. showed that both c-Jun mRNA and protein, but not other 
members of the AP-1 family (c-Fos, JUNB, JUND, FOSB), were induced by Dex in 
human leukemic lymphoblasts [Zhou et al., 1996]. Boudreau et al. reported that both the 
mRNA and protein of c-Jun, c-Fos, and JUNB were increased in intestinal epithelial 
cells by Dex treatment [Boudreau et al., 1999]. However, Lee et al. reported that the 
expression of c-Jun was repressed by Dex in fibroblasts [Lee et al., 1991]. In addition, 
c-Jun transcription was directly stimulated by its own gene product [Angel et al., 1988].  
 
(2) AP-1 gene expression in nasal tissues 
We determined the expression of two main components of AP-1 (c-Jun & c-Fos) in 
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NP as well as in nasal mucosal control at mRNA and protein level. A deficiency in 
both c-Jun and c-Fos mRNA expression in NP tissues was evident. A restoration of 
both c-Jun mRNA and protein was found after GC therapy in NP tissues. With regard 
to c-Fos, its mRNA was up-regulated in GC-treated NP, but immunohistochemical 
staining suggests that GC treatment did not improve c-fos protein level in extracted 
NP tissues. 
 
Our results are in disagreement with a previous report in which elevated c-Fos protein 
was detected in NP tissue and GC decreased c-Fos protein, but did not affect c-Fos 
mRNA level in NP tissues [Baraniuk et al., 1998]. In that study, mRNA expression of 
c-Fos was measured by RT-PCR that is considered as qualitative but not quantitative 
measurement. Furthermore, determination of c-Fos mRNA level was normalized by 
β-actin intensity band, which is not a reliable internal control for GC-treated nasal 
samples [Bolger et al., 2007]. c-Fos mRNA and protein expression may also be affected 
by broad alterations in post-transcriptional processes: (i) increased turnover of c-Fos 
protein may not be detectable by immunohistochemistry [Kruijer et al., 1984]; (ii) c-Fos 
or AP-1 may negatively auto-regulate c-Fos protein translation [Sassone-Corsi et al., 
1988]; (iii) binding of activated GR and c-Fos may lead to the mutual inactivation and 
proteolytic degradation and then hamper the c-Fos production [Yang-Yen et al., 1990]. 
Other plausible explanations for such a conflicting result are due to variable factors 
such as choice of different subjects (same patient versus different patient before and 
after treatment), dosage and type of GC treatment (oral versus topical GC), and 
different experimental protocols (e.g. different RNA detection method, different 
immunohistochemistry methods). Nevertheless, the role of c-Fos protein in NP and its 
response to GC treatment needs to be further clarified, and trying to minimize 
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confounding factors in detecting c-Fos is recommended. 
 
(3) Tissue repair role of c-Jun/AP-1 and its related genes in nasal polyp epithelium 
Circumstantial evidence suggests a critical role of AP-1 (especially c-Jun) and its 
related genes in the maintenance and repair of epithelial tissues and reduction of AP-1 
expression may interrupt a critical autocrine/paracrine pathway of signaling to the 
epithelial restitution [Grose, 2003; Li et al., 2003; Shaulian et al., 2002]. In our results, 
elevated expression of c-Jun in GC-treated NP tissues was associated with the 
significant improvement in NP epithelial structure (Figure 6.19, Page 152; Table 6.8, 
Page 153), indicating that GCs may perform the tissue repair effect via regulating 
c-Jun expression.  
 
c-Jun/AP-1 is a transcription factor, which induces many mRNAs for cytokines and 
growth factors (AP-1 downstream genes), while c-Jun/AP-1 itself is also regulated by 
various growth related factors (AP-1 upstream genes). Therefore, these c-Jun/AP-1 
related genes (both downstream and upstream) indeed participate in the epithelial 
repair function of c-Jun/AP-1. The integrated analysis of multi-dimensional 
microarray data has proved informative. Our network analyses have identified a 
number of AP-1 related genes (COX-2, IL-6, AREG, HBEGF, and EGR1) which 
appear to modulate airway epithelial remodeling and are GC dependent. 
 
AP-1 induces transcription of COX-2 which is the key enzyme required for the 
conversion of arachidonic acid into prostaglandins (PGs) [Yamaguchi et al., 2005]. 
COX-2/PGE2 plays an important role in the homeostasis of epithelial remodeling 
process in airway tissues [Savla et al., 2001]. Decreased expression of COX-2 and 
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diminished PGE2 production seem to be an important feature of untreated NP tissues, 
especially those with aspirin intolerance [Picado et al., 1999; Mullol et al., 2002]. We found 
an up-regulation of COX-2 mRNA in NP tissues after oral GC treatment, which is in 
line with the report by Dworski et al., who found that treatment with prednisone 
resulted in a significant increase in COX-2 mRNA and protein in atopic subjects in 
vivo [Dworski et al., 1997]. 
 
In our study, up-regulation of c-Jun/AP-1 is associated with IL-6. c-Jun/AP-1 was 
shown to induce IL-6 expression through the CRE binding region [Franchimont et al., 
1999], while IL-6 mediated signal pathway could increase expression of c-Jun 
[Solis-Herruzo et al., 1999]. IL-6 is a pleiotropic cytokine that exerts both pro- and 
anti-inflammatory activities, as well as cellular proliferation. GCs were found to 
enhance the induction of IL-6 mRNA in human bronchial epithelial cells, indicating 
the host defense activity of GCs [Homma et al., 2004]. In addition, IL-6 together with 
growth related factors (e.g. EGF and COX-2) are important to protect epithelium from 
injury in a variety of tissues, including skin [Gallucci et al., 2000], gastrointestinal tract 
[Tebbutt et al., 2002], and kidney [Nechemia-Arbely et al., 2008].  
 
This study shows evidence of an up-regulation of two EGFR ligands (AREG and 
HBEGF) in response to GC treatment. The EGF protein family is thought to be the 
primary cytokines in the process of epithelium healing [Holgate, 2000; Watelet et al., 2006]. 
The GC mediated wound healing process in airway epithelium requires the activation 
of the EGF/EGFR signaling pathway [Wadsworth et al. 2006]. The response of EGF 
genes is clearly linked to AP-1 transcription factor activity, since both the EGFR and 
its known ligands are direct AP-1 target genes [Fu et al., 1999; Johnson et al., 2000]; and 
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activation of EGF/EGFR signaling also leads to the induction of AP-1 [Grose 2003; Li et 
al., 2003].  
 
In this study, we found an increase of EGR1 that has been regarded to induce c-Jun 
expression and trigger c-Jun/AP-1 activation [Levkovitz et al., 2001]. EGR1 functions as 
a transcriptional regulator and is an example of an “immediate early response protein” 
because it is rapidly induced by numerous cytokines, growth factors, injurious stimuli, 
stress, and GC hormone [Liu et al., 2000; Revest et al., 2005]. EGR1 is also involved in the 
tissue repair process mediated by AP-1/EGF signaling [Warburton et al., 2005] and 
activated GC receptors could increase the levels of both EGR1 mRNA and protein 
[Revest et al., 2005]. 
 
6.2.3.4 Conclusion of the epithelial repair effect of GCs 
Our results indicate the epithelial repair effect of GCs on NP from histological to 
molecular levels. AP-1 (especially c-Jun) and its related genes are all involved in the 
top function network composed of GC-regulated genes in NP (Figure 6.13, Page 122). 
The network analysis has revealed an extended pathway map potentially underlying 
the epithelial healing process in NP in response to GC treatment. c-Jun/AP-1 has been 
considered the core gene in this network, while the interactive positive feedback loop 
between c-Jun/AP-1 and its related genes (including AREG, HBEGF, COX-2, IL-6, 
and EGR1) will contribute to the epithelial repair effects of GCs on NP. The 
interaction among c-Jun/AP-1 and its related genes are summarized in Figure 6.20 
(Page 179): (i) expression level of c-Jun/AP-1, EGF molecules (AREG & HBEGF), 
COX-2, IL-6 and EGR1 in GC-naïve NP may be too low to perform their normal 
physiological process (e.g. wound healing), resulting in epithelial damage; (ii) 
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inadequate expression of AREG, HBEGF, COX-2, and IL-6 in NP may contribute to 
the lower expression of c-Jun/AP-1; (iii) since these growth related genes are 
c-Jun/AP-1 target genes, it may further potentiate the reduction of AREG, HBEGF, 
COX-2, and IL-6; (iv) after GC treatment, GR may directly/indirectly induce the 
expression of c-Jun/AP-1, AREG, HBEGF, COX-2, IL-6, and EGR1 in NP, and the 
positive feedback loop among these factors is activated, resulting in the promotion of 







Figure 6.20 Schematic diagram of AP-1 and AP-1 related genes in epithelial repair in NP after GC 
treatment. AREG, HBEGF, COX-2, and IL-6 are both AP-1 upstream activators and AP-1 downstream 
target genes; and EGR1 is the co-activator of AP-1. Before GC treatment, AP-1 and AP-1 related genes 
are expressed at a low level in NP; while after GC treatment, all these genes are up-regulated and then 
the positive loop of epithelial cell proliferation is activated, leading to enhance of epithelial restitution. 
GR, glucocorticoid receptor.  
 
6.2.4 Anti-inflammatory effect of GCs in NP  
In previous paragraphs, we suggested that GCs may promote re-epithelization during 
the tissue repair process. Indeed, the anti-inflammatory action of GCs is widely 
accepted, and this effect is mediated by glucocorticoid receptor (GR), which migrates 
from the cytoplasm to the nucleus upon binding of ligand and exerts both positive and 
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negative effects upon transcription [Newton, 2000]. In our study, the network analysis 
identified several important pro- and anti-inflammatory genes involved in the GC 
gene networks (Chapter 6.1.7, Page 118). We suggest that GR modulates the 
expression of anti-inflammatory genes (e.g., inhibitors of NF-kappaB, inhibitors of 
MAPKs, SOCS3, ANXA1, SCGB1A1, ZFP36 and THBD) in a positive way, either 
directly or indirectly [Castro-Caldas et al., 2003; Usmani et al., 2005; Ishaq et al., 2007]; while it 
modulates the expression of some pro-inflammatory genes (e.g., MMP7, MMP9, and 
chemokines) in a negative regulation way. 
 
6.2.4.1 Glucocorticoid receptor 
Two human isoforms of glucocorticoid receptor (GR), GRα and GRβ, have been 
identified, which originate from the same gene by alternative splicing of the GR 
primary transcript [Encío et al., 1991]. GRα is the predominant isoform of the receptor 
and has GC-binding activity [Pujols et al., 2004]. In contrast, GRβ does not show 
ligand-binding activity, but may act as a dominant negative inhibitor of GRα activity 
[Pujols et al., 2004]. Moreover, recent evidence suggests that increased expression of 
GRβ may be associated with GC resistant asthma and NP [Hamid et al., 1999].  
 
Our results showed a decrease of GRα mRNA in GC-naïve NP compared to controls, 
which is in line with previous reports [Pujols et al., 2008]. It has been reported that most 
of the eosinophils in NP were stained slightly with GR [Pujols et al., 2008], and GR 
expression was prominent in airway epithelial cells [Adcock et al., 1996]. These findings 
indicate that the local inflammatory milieu (high infiltration of eosinophils) of NP 
may be related to the down-regulation of GRα. In contrast to our results, Choi et al. 
 181
reported the higher level of GRα mRNA in NP than in control nasal mucosa [Choi et al., 
2006]. These controversial results may be attributed to the cellular complexity of the 
NP tissues, heterogeneity of patient background and different detection methods. In 
agreement with previous data, expression of GRβ mRNA was too low to be detected 
in both NP and control tissues by real-time RT PCR.  
 
GC resistance in asthma may result from the elevated level of GRβ expression and 
deficiency of GRα [Leung et al., 1997]. Although GRβ expression is considered a 
marker of GC resistance in NP [Hamilos et al., 2001], GRα expression level appears to 
have no effect on those NP patients who is resistant to the GC treatment [Choi et al., 
2006]. Our results confirmed no detection of GRβ in GC-naïve NP, indicating that no 
GC resistance occurs in the studied samples. In addition, down-regulation of GRα in 
GC-naïve NP also appears not to be associated with the GC insensitivity in NP 
patients, since GCs could alter the expression of many GC responsive genes in the 
current NP samples. 
 
There was no significant difference in GRα expression in NP before and after GC 
treatment. These results contrast with the data showing down-regulation of the GR 
after in vitro treatment of different airway cell types with GCs [Pujols et al., 2001; Pujols 
et al., 2004]. In keeping with our results, Henriksson et al. reported that NP did not 
respond with down-regulation of GR mRNA following GC treatment in vivo 
[Henriksson et al., 2001]. The conflicting findings may be attributed to the different 
experimental designs (in vitro vs. in vivo). 
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6.2.4.2 Anti-inflammatory molecules regulated by GCs 
The inhibitors of pro-inflammatory signaling pathways including NFKBIZ, DUSPs, 
SPRYs, and SOCS3 were discussed in Chapter 6.2.2 (Page 158). Moreover, some 
other important anti-inflammatory genes were also identified by network analysis, 
such as ANXA1, SCGB1A1, ZFP36, and THBD. 
 
(1) Annexin A1 
Annexin A1 (ANXA1) belongs to a family of Ca2+-dependent phospholipid binding 
proteins and has phospholipase A2 (PLA2) inhibitory activity. Since PLA2 is required 
for the biosynthesis of the potent mediators of inflammation, such as prostaglandins, 
and leukotrienes. ANXA1 may have potential anti-inflammatory activity in 
inflammatory response [Wallner et al., 1986]. Besides the inhibition of arachidonic acid 
metabolism, ANXA1 also contributes to a variety of anti-inflammatory pathways, 
including inhibition of iNOS expression [Wu et al., 1995], stimulation of IL-10 release 
[Ferlazzo et al., 2003], inhibition of leukocyte migration [Perretti et al., 1996], and induction 
of apoptosis of inflammatory cells [Solito et al., 2001]. Regulation of ANXA1 by GCs 
has been well established and ANXA1 is able to mimic the anti-inflammatory effects 
of GCs in several experimental models of inflammation both in vivo and in vitro 
[Flower et al., 1988]. Our study showed that expression of ANXA1 was not different 
between NP and controls, but augmented ANXA1 expression was found in NP after 
GC treatment. These results are in agreement with the previous study [Sena et al., 2006], 
indicating that up-regulation of ANXA1 in NP may be attributed to the feedback 
response of the immune system to chronic inflammation, while GCs may enhance 
such anti-inflammatory action. 
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(2) Secretoglobin, family 1A, member 1 
Secretoglobin, family 1A, member 1 (SCGB1A1; also know as uteroglobin), is an 
important GC-induced anti-inflammatory gene, which was originally found to inhibit 
PLA2 activity [Mukherjee et al., 2007]. It is the founding member of a newly designated 
Secretoglobin superfamily of proteins [Klug et al., 2000], constitutively expressed by the 
epithelial lining of all organs that communicate with the external environment. It has a 
broad range of anti-inflammatory effects [Mukherjee et al., 2007], including the inhibition 
of PLA2, leukocyte chemotaxis, and pro-inflammatory cytokines. Furthermore, 
peptides derived from SCGB1A1 are among the most potent anti-inflammatory agents 
identified to date [Miele, 2003]. Our study found that SCGB1A1 was expressed at a 
similar level between GC-naïve NP and control, but it was up-regulated at 5.19-fold in 
NP in response to GC treatment. The result is consistent with the previous NP 
microarray study, which revealed that SCGB1A1 was increased most in NP after GC 
treatment [Benson et al., 2004].  
 
(3) Zinc finger protein 36 
Zinc finger protein 36 (ZFP36; also known as tristertraprolin, TTP) is an 
immediate-early gene induced by various stimuli (e.g. LPS, TNF-α, p38 MAPK, 
IFN-γ) [Sauer et al., 2006], and destabilizes several pro-inflammatory cytokine mRNAs 
by binding to AU-rich elements with their 3’ untranslated regions, targeting 
degradation [Carballo et al., 1998]. Moreover, dexamethasone treatment was found to 
inhibit TNF-α expression by sustained induction of the ZFP36 mRNA level in lung 
epithelial cells [Smoak et al., 2006]. This evidence suggests that ZFP36 performs its 
anti-inflammation activity by a negative feedback loop which is induced by 
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inflammatory signalings. Although GCs can induce ZFP36 and control the post 
transcription of pro-inflammatory genes, the role of ZFP36 in airway inflammation 
(e.g. NP and asthma) as well as its response to GC treatment has not been investigated 
as well. Our results demonstrated that ZFP36 was expressed lower in GC-naïve NP, 
but up-regulated in NP after GC treatment, suggesting the degradation effect of GCs 
on pro-inflammatory gene mRNA. 
 
(4) Thrombomodulin 
Ample evidence has suggested the cross-talk between inflammation and coagulation, 
i.e. inflammation leads to the activation of coagulation, meanwhile coagulation also 
significantly affects inflammatory activity, moreover, several anti-coagulant 
molecules are supposed to modulate inflammation [Levi et al., 2004]. Thrombomodulin 
(THBD) is an important anticoagulant factor. It plays an indirect role in modulating 
inflammation by inhibiting thrombin mediated inflammatory and remodeling 
processes [Van de Wouwer et al., 2004]. For example, the C-type lectin-like N-terminal 
domain of THBD could suppress activation of the MAPK cascade and prevent 
expression of leukocyte adhesion molecules, consequently interfering with the 
leukocyte migration to inflammatory tissues [Conway et al., 2002]. However, the roles of 
THBD in NP and its response to GC treatment have not yet been studied. Our study 
found down-regulation of THBD in GC-naïve NP, while it was increased in NP after 
GC treatment, indicating the effect of GCs on the coagulation system mediated 
inflammation and remodeling process in NP. 
 
6.2.4.3 Pro-inflammatory molecules regulated by GCs 
In addition to the positive effect on anti-inflammatory genes, GCs also suppress the 
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expression of those pro-inflammatory genes, such as Matrix metalloproteinase and 
CXC-chemokines. 
 
(1) Matrix metalloproteinase (MMP) 
Among the GC-responsive genes, two pro-inflammatory genes, MMP7 and MMP9 
were down-regulated in GC-treated NP. MMP7 and MMP9 belong to the matrix 
metalloproteinase (MMP) family, which is capable to cleave a diverse array of 
extracellular matrix (ECM), thereby modulating cellular infiltration and tissue 
structure during both health and disease stages. Substantial evidence suggests that 
MMP is an important modulator of the inflammatory and remodeling processes. 
Increased or mis-regulated levels of MMPs have been observed in many inflammation 
associated diseases [Malemud, 2006]. The natural inhibitors of MMPs, so called tissue 
inhibitors of metalloproteinases (TIMPs), were used as anti-inflammatory drugs in 
inflammatory conditions such as arthritis [Burrage et al., 2007]. Steorids have been found 
to reduce expression of MMPs in airway tissues [Hoshino et al., 1999; Profita et al., 2004]. 
 
MMPs was found to be involved in tissue remodeling and eosinophil migration in NP 
due to the property of ECM degradation [Lechapt-Zalcman et al., 2001; Watelet et al., 2004; 
Kostamo et al., 2007; Can et al., 2008]. There is evidence that eosinophils are a source of 
MMP9 in NP and asthmatic tissues [Ohno et al., 1997]. In agreement with the previous 
studies, we found the up-regulation of MMP7 and MMP9 in GC-naïve NP, and 
increase of MMP9 was associated with eosinophil/neutrophil infiltration in NP, while 
MMP7 was only associated with a neutrophil influx. Increase of MMP9 and MMP7 
production could degrade components of endothelial basement membrane and then 
enhance microvascular permeability, leading to eosinophil or neutrophil 
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transmigration [Lechapt-Zalcman et al., 2001; Yoon et al., 2007; Can et al., 2008; Swee et al., 2008]. 
Hence, after GC treatment, decrease of MMP7 and MMP9 may not only contribute to 
the suppression of leukocyte migration, but also maintain the homeostasis of tissue 
remodeling in NP. 
 
(2) CXC-chemokines 
Two CXC-chemokines, CXCL9 and CXCL11 were down-regulated in NP in response 
to GC treatment. CXCL9 and CXCL11 genes are closely located to each other on 
human chromosome 4. Both of them are considered T-cell chemoattractants, which 
interact with the T-cell surface receptor CXCR3. Since gene expression of CXCL9 
and CXCL11 is strongly induced by IFN-gamma and CXCR3 is primarily expressed 
on activated Th1 cells, CXCL9 and CXCL11 are associated with Th1 response [Cole et 
al., 1998]. In addition, CXCL9 and CXCL11 are commonly produced by local cells in 
inflammatory lesions, suggesting that CXCR3 and its chemokines ligands participate 
in the recruitment of inflammatory cells. With regard to the response of GCs, CXCL9 
and CXCL11 which were induced by IFN-gamma were found to be decreased after 
GC treatment [Egesten et al., 2007; Widney et al., 2000]. 
 
Although CXCL9 and CXCL11 have not been reported in any NP studies, their role in 
allergic rhinitis is regarded to suppress Th2 response [Sun et al., 2007]. Our results 
showed that before GC treatment, expression of CXCL9 and CXCL11 was not 
significantly different between NP and control. However, they were expressed at a 
high level in one NP sample (NP6) which was prominently infiltrated by lymphocytes 
(data not shown). These results are consistent with the histological patterns of these 
studied NP samples, most of which are eosinophil dominant. The decrease of CXCL9 
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and CXCL11 by GCs suggests that GC attenuation of CXCL9 and CXCL11 
expression may contribute to the anti-inflammatory effects of GCs in Th1-dependent 
processes [Goleva et al., 2004].   
 
6.2.4.4 Conclusion of the anti-inflammatory effects of NP 
Our observation suggests that the anti-inflammatory effects of GCs in NP may not 
only be due to transrepression of pro-inflammatory genes by the GR, as indicated in 
previous studies [De Bosscher et al., 2003], but also involves positive regulation of 
anti-inflammatory genes. This finding is in agreement with the new concept of 
“non-transrepression” anti-inflammatory actions of GCs, i.e., activated GR initiates a 
signaling cascade with an induction of anti-inflammatory genes [Limbourg & Liao, 2003; 
Hayashi et al., 2004]. Most importantly, the identified anti-inflammatory genes are all 
involved in the negative feedback loops of the inflammatory signaling pathways. For 
example, NFKBIZ inhibit NF-kappaB activation, DUSPs, SPRYs, ZFP36, THBD 
inhibit MAPK cascade activation, SOCS3 inhibit IL-6 activity, ANXA1 and 
SCGB1A1 antagonize arachidonic acid mediated inflammatory response. 
Nevertheless, those pro-inflammatory markers such as MMP7, MMP9, CXCL9, and 
CXCL11 were also attenuated by GCs. These findings emphasize the diverse 
anti-inflammatory functions of GCs in modulating cellular signaling events in NP. 
 
6.2.5 Hypothesis of the GC beneficial effects on NP 
With regard to the GC effects on NP, we discussed two major findings: epithelial 
repair and anti-inflammatory function. AP-1 and AP-1 related genes respond to the 
growth effect on damaged NP epithelium and they are mainly involved in MAPK, 
IL-6, and arachidonic acid signaling pathways; however, most identified 
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anti-inflammatory genes negatively regulate this growth related signaling. Although 
these two effects seem opposite, they may represent a regulatory effect of GCs on the 
epithelial repair process. This is because wound healing itself is a process that 
involves both inflammation and the resolution of the inflammatory response, which 
culminates in remodeling.  
 
Figure 6.21 summarizes the epithelial repair process under physiological and 
pathological conditions: the increase of pro-inflammatory signaling markers (like 
AP-1 and AP-1 related genes) in response to epithelial damage results in epithelial 
restitution, while if these growth signals are not controlled, it will cause chronic 
inflammation and then potentiate the epithelial injury, leading to abnormal epithelial 
remodeling. In this scenario, the increase of the inhibitors (like DUSPs, SPRYs, 
SOCS3, etc.) of these inflammatory signaling pathways would be considered to 
control the aberrant remodeling. Indeed, the histological evaluation of NP epithelium 
was concordant to the effects of these genes, and showed improvement of epithelial 
structure but without severe remodeling (e.g., squamous metaplasia).  
 
Based on these observations, we hypothesize that the beneficial effects of GCs on 
epithelial healing may be at least in part, mediated by the induction of c-Jun/AP-1 and 
its related genes; and the promotion of anti-inflammatory effects of GCs could control 
the remodeling process of epithelium in a proper situation. Therefore, regulation of 
these gene markers would be useful in the resolution of NP inflammation, suggesting 




Figure 6.21 Schematic representation of the epithelial repair process as well as its 





6.2.6 Combination of eosinophil- and neutrophil-infiltration in NP  
The general histopathological classification of NP is eosinophil-dominated 
inflammation (65-90%), which appears to be a hallmark of Caucasian NP [Fokkens et al., 
2007]. However, in the Caucasian population, neutrophilic NP may only account for 
15% to 20% of the studied cases [Bachert et al., 2003]. In contrast to the studies in 
Caucasians, recent studies reported a lower incidence of eosinophil-dominated 
inflammation in Asian population with tissue infiltration of neutrophils was as high as 
40% [Jareoncharsri et al., 2002]. We have investigated the type of cellular inflammation in 
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Singaporean Chinese patients with NP. Our results indicated a combined cell 
infiltration with eosinophil, neutrophils and CD4+/CD8+ T lymphocytes [Hao et al., 
2006]. Our recent findings lead to the following intriguing theory. Besides 
well-recognized eosinophil-dominated inflammation in Caucasian studies, 
predominant infiltration of other types of cells, especially neutrophils, could be also a 
key component underlying the pathogenesis of NP in Asian populations. 
 
The current study confirmed that infiltration of eosinophils and neutrophils was 
evident in Chinese patients with NP. The concept that NP in Chinese population may 
be a separate entity from those NP in Caucasian population is an interesting 
postulation. However, it is also possible that NP in Chinese population may represent 
a whole constellation of disease states with differing etiologies that converge upon a 
common final pathway of clinical manifestation as those NP in Caucasian populations. 
The current knowledge about the pathogenesis of NP is insufficient to test this 
hypothesis as some Chinese patients may undergo medical management for their 
disease after it has been present for a long period of time, making it difficult to 
determine what the inciting factors may have been. We postulated that a specific cell 
type-associated genetic analysis of differential gene expression could be a relevant 
indicator of difference or similarities among various disease states in NP. The 
questions to be addressed in this research, therefore, were whether eosinophil- or 
neutrophil-associated gene expression differs in NP patients and, if so, how it differs. 
 
6.2.6.1 Eosinophil-related genes in NP 
In rhinosinusitis, with or without NP, eosinophils have accumulated in the nasal or 
paranasal sinuses and caused profound clinical effects. Important immunoregulatory 
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genes influence the function of eosinophils. By using the microarray approach, we 
were able to assess the gene expression levels of most candidate genes (n=60) which 
are associated with eosinophil biology from published reviews [Lampinen et al., 2004; 
Rothenberg, 1998; Rothenberg, 2006], as well as their response to GC treatment in the same 
study. Among those 60 important eosinophil-associated genes, expression levels of 31 
genes were different in NP patients versus controls. Aberrant expression of those 31 
genes has been associated with the migration and survival of eosinophils. Ten out of 
these 31 eosinophil-associated genes were down-regulated while 21 genes were 
up-regulated in NP when compared to controls (Table 6.6, Page 142). In addition, it is 
not surprising that we did not find any genes related to eosinophil development due to 
the tissue specificity of our study samples. 
 
Hierarchical clustering indicates the relationships among samples (NP and control) 
with different histological patterns dependent on the expression of those 31 
eosinophil-associated genes. The expression profile of eosinophil-associated markers 
was distinct between NP and control nasal mucosa due to their different patterns of 
eosinophil infiltration, (Figure 6.16, Page 143). In addition, two NP samples (NP6 
and NP7) with weak eosinophil infiltration were not clustered tightly with the 
majority of NP, suggesting the expression profile may also be different between 
eosinophilic and non-eosinophilic NP. Note that the histological feature of NP6 
represented edema with highly infiltrated lymphocytes, while the feature of NP7 
represented increased number of glands without edema. These results suggest the 




Among those 31 eosinophil-associated genes, differential expression of 12 genes 
(MMP9, IL5RA, ITGB2, SELPLG, CCL11, LGALS9, LTA4H, ALOX5AP, 
PLA2G4A, CYSLTR1, LTB4R and NOS2A) in NP subjects versus controls have been 
reported previously [Chen et al., 2007; Gevaert et al., 2003; Hebestreit et al., 1998; Matsumoto et 
al., 2002; McNulty et al., 1999; Olze et al., 2006; Parnes, 2002; Ponath et al., 1996; Sousa et al., 2002; 
Woltmann et al., 2000]. As far as we are concerned, this is the first study suggesting that 
aberrant expressions of 19 eosinophil-associated genes are important aspects 
conditioning the severity and prognosis of NP. Perturbations of these 19 genes 
(ADAM8, CCL15, IL-18, C3, SCG2, CXCL12, IL13RA2, NR4A1, NR4A2, NR4A3, 
CD69, CD86, LYN, MIF, NFKBIA, DUSP1, CCL28, CD9 and CD40) have been 
implicated in many diseases associated with eosinophila, such as asthma [Adachi et al., 
1999; DiScipio et al., 2007; Foerster et al., 2002; Hashida et al., 2007; Kobayashi et al., 2006; Matsuno 
et al., 2008; Yasunaga et al., 2003], allergic rhinitis [Korsgren et al., 2003; Sebelova et al., 2007], 
and atopic dermatitis [Kagaya et al., 2005]. These 19 genes exert critical role in 
regulating migration and survival of eosinophils. It has been shown that up-regulation 
of ADAM8, CCL15, IL-18, C3, SCG2 and down-regulation of CXCL12, IL13RA2 
promote eosinophil migration into inflammatory tissues [DiScipio et al, 2007; Pardigol et 
al., 1998; Matsuno et al., 2008; Yasunaga et al., 2003]; while down-regulation of NR4A1, 
NR4A2, NR4A3, and CD69 suppress eosinophil apoptosis [Foerster et al., 2002; Hashida 
et al., 2007]. Moreover, up-regulation of CD86, LYN, MIF and down-regulation of 
NFKBIA, DUSP1 may facilitate activation signals in eosinophils [Adachi et al., 1999; 
Fujihara et al., 2005; Kobayashi et al., 2006]. Up-regulation of CD9, CD40, and CCL28 
genes promotes migration and survival of eosinophils [John et al., 2005; Rothenberg et al., 
2006].  
 
IL-5 and CCL11 (eotaxin) have been frequently reported as the molecular markers for 
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eosinophils in NP [Hamilos et al. 1998; Olze et al., 2006]. IL-5 gene expression was 
undetectable in all samples in this study. However, IL-5Rα mRNA was significantly 
higher (9.85-fold by real-time PCR) in untreated NP as compared to controls, while it 
was not altered by GCs. Our result is in agreement with a recent study in which 
soluble IL-5Rα protein expression level was found to be dramatically higher (up to 
1,200 times) than IL-5 concentrations in NP [Gevaert et al., 2003]. It has been found that 
the expression level of soluble form IL-5RA was associated with eosinophil 
infiltration and the concentrations of ECP and IL-5, indicating IL5RA levels were 
related to the disease severity [Gevaert et al. 2003]. Moreover, the expression level of 
IL5RA is important in relation to the sensitivity of anti-IL-5 treatment [Gevaert et al. 
2003]. With regard to CCL11, its mRNA was significantly up-regulated in NP samples 
(14.9-fold) in comparison with the controls but it remained unchanged after oral GC 
therapy. It seems that the expression profiles of these two best-known gene markers of 
eosinophils are not in concordance to the reduction of eosinophils in NP after GC 
therapy, indicating other eosinophil-associated genes may respond to GCs. 
 
6.2.6.2 Eosinophil-related genes in response to GC treatment in NP 
GC is the most effective and the current standard treatment for NP [Fokkens et al., 2007]. 
Our data confirm that a 3-5 day oral GC treatment (30mg prednisone daily) could 
eventually reduce infiltration of eosinophils and tissue edema in NP. A total of 5 
eosinophil-associated genes (MMP9, NR4A1, NR4A2, CD69 and DUSP1) were 
responsive to GC therapy (Appendix II, Page 268). These molecular changes 
correlate well with histological findings, such as reduced severity of tissue edema and 
eosinophil count in NP tissues, after oral GC treatment. In addition, a short-term oral 
GC therapy appears to be sufficient to normalize the expression of those genes. 
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In the literature, a number of research data have already confirmed the biological 
functions of these five genes in relation to eosinophils. MMP9 is a matrix 
metalloproteinase that promotes eosinophil migration and tissue edema in airway 
inflammation which was discussed in Chapter 6.2.4.3 (Page 184). DUSP1 potently 
inhibits MAPK mediated inflammatory signal pathways in activated eosinophils [Lasa 
et al. 2002; Wong et al. 2002], and the role of DUSP1 was also discussed in Chapter 
6.2.2.5 (Page 165). 
 
NR4A nuclear receptor members are immediate-early genes, which have been shown 
to play a key role in regulating expression of various genes related to inflammation 
[Winoto et al., 2002]. Recent review suggested that the NR4A receptor family was 
important in causing eosinophil apoptosis, because CD30 stimulation which induced 
eosinophil-specific apoptosis, enhanced expression of NR4A1, NR4A2 and NR4A3 
[Hashida et al., 2007]. We showed that NR4A1 and NR4A2 expression was increased 
after GC treatment in NPs, but NR4A3 expression was too low to detect in all NP 
samples. Hence, it indicates that transcription of NR4A1 and NR4A2 may be 
controlled by external stimuli (e.g. GCs) and it may participate in the GC-induced 
apoptosis of eosinophils in NP.  
 
Although the expression of CD69 was induced by pro-inflammatory cytokines (e.g. 
IL-3, IL-5 and GM-CSF) [Hartnell et al., 1993] in activated eosinophils, the function of 
CD69 is to transduce a death signal, leading to eosinophil apoptosis [Foerster et al., 
2002]. Our results showed that CD69 was up-regulated in response to GC treatment in 




As discussed above, GCs may perform the effects on eosinophils by regulating the 
expression of some genes which related to eosinophil migration and survival. 
Although most of the other eosinophil-related markers we found did not respond to 
GC treatment, it does not exclude the potential effects of GCs on these markers, since 
the reduction of eosinophil density itself would confuse the detection of 
eosinophil-related genes.  
 
6.2.6.3 Genes related to neutrophil infiltration in NP 
Recently, neutrophils were detected in the tissue of NP but their pathophysiological 
relevance is unclear. We have reported that a combination of eosinophils, neutrophils 
and CD4+/CD8+ T lymphocytes is a common feature of NP and adjacent middle 
turbinate mucosa in Asian patients [Hao et al., 2006]. In the current study, we have 
assessed the expression level of important neutrophil-associated genes, together with 
its cellular count in NP. Our results demonstrate that: (1) infiltration of neutrophils is 
common (66.6%) in NP patients; (2) among the 76 important neutrophil-associated 
genes [Borregaard et al., 2007; Kobayashi et al., 2006; Theilgaard et al., 2005], the expression 
level of 14 genes (10 up-regulated and 4 down-regulated) were different in NP 
patients versus controls (Table 6.7, Page 145). Among those 13 differentially 
expressed neutrophil-associated genes, 4 genes (MMP7, MMP9, ITGB2, DEFB1 and 
PTX3) have been shown to promote neutrophil infiltration in NP [Baruah et al., 2007; Can 
et al., 2008; Chen et al., 2007; Lee et al., 2002; McNulty et al., 1999]. In addition, the 
up-regulation of CXCL2, CXCL6, IFNAR1, LGALS8, ITGB2 and down-regulation 
of CXCL12 have been suggested to promote neutrophil migration [Borregaard et al., 2007; 
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Kobayashi et al., 2008; Nishi et al., 2003]. The up-regulation of SERPINA1, CEACAM1, 
CEACAM6, MMP7 and MMP9 may facilitate neutrophil adhesion and degranulation 
[Borregaard et al., 2007; Kobayashi et al., 2008; Swee et al., 2008; Theilgaard et al., 2005]; DEFB1 
promotes neutrophil survival [Borregaard et al., 2007]; and CRISP3 and PTX3 are 
associated with neutrophil-mediated innate immune defense [Baruah et al., 2007; 
Borregaard et al., 2007]. There is little effect of GCs on neutrophil-associated gene 
expression. Oral prednisone was only effective in modulating expression levels of 3 
neutrophil-associated genes (MMP7, MMP9 and CXCL2) and had no significant 
effect on neutrophil recruitment.  
 
6.2.6.4 Relationship between eosinophil and neutrophil infiltration in NP 
Our results suggest that infiltration of eosinophils and neutrophils is a common 
feature in Chinese patients with NP. However, the pathophysiological interactions 
between eosinophils and neutrophils in NP are not fully understood. Recent results 
suggest that eosinophils and neutrophils may share similar pathobiological processes 
in inflammatory tissues and may cross-talk to facilitate the recruitment of one to the 
others. Neutrophil-mediated pro-inflammatory cytokines such as IL-8, IL-1β, and 
TNF-α may contribute to allergic inflammation by inducing the influx and 
degranulation of eosinophils [Borregaard et al., 2007; Kobayashi et al., 2008; Lamblin et al., 
1998]. Neutrophils were suggested as a carrier of eosinophil cationic protein (ECP) 
and correlated with ECP level [Sur et al., 1998]. In addition, some reported 
eosinophil-associated genes (e.g., SELPLG, ITGB2, ADAM8, MMP9, CCL11, 
LTB4R, CYSLTR1, LTA4H, ALOX5AP, PLA2G4A, C3, CXCL12, NOS2A, MIF, 
LYN, CD69, DUSP1, NFKBIA, CD40) have also been reported to be effective on 
neutrophil migration and survival [Asberg et al., 2008; Corry et al., 2004; Fazal et al., 2002; 
 197
Gabbay et al., 1999; Khan et al., 2006; Kobayashi et al., 2006; Symon et al., 1996; Matsuno et al., 2008; 
McNulty et al., 1999; Nopp et al., 2002; Sampson, 2000; Wang et al., 2007; Ward et al., 1999]. In the 
future, it may be necessary to combine these two cell types in studies of inflammatory 
disorders (especially in NP), which have a predominant infiltration of these cells. 
   
With a combined assessment of both cell types, our results suggest that GCs are 
effective in inhibiting eosinophil infiltration and decreasing the size of polyps and 
edema but their effect on neutrophils is not established. Our results are consistent with 
several independent studies in which GCs induce apoptosis in eosinophils, but have 
no effect on neutrophil recruitment [Burgel et al., 2004; Meagher et al., 1996; Meltzer et al., 
1994; Sampson, 2000]. It raises an interesting question as to whether these unchanged 
expression levels of most neutrophil-associated genes underlie such phenomenon or 
whether neutrophils could counteract the beneficial effects of GC therapy on allergic 
inflammation [Benson et al., 2000]. It is an important area of research as there are quite a 
substantial number of NP patients who appears to be refractory to GC therapy; and 
therefore, the roles of those neutrophil-associated genes are worth further 
investigation. 
 
6.2.6.5 Conclusion of eosinophil- and neutrophil- assocaited genes in NP 
In summary, we have profiled eosinophil- and neutrophil-associated genes and their 
response to GC treatment in Chinese patients with NP. Clustering of a longitudinally 
derived data set provided a detailed picture of the gene expression patterns induced 
and/or suppressed in the nasal tissues during various stages of NP. In particular, the 
changes in expression profiles of MMP9, NR4A1, NR4A2, CD69 and DUSP1 appear 
to be correlated to the short-term oral GC therapy and are associated with reduction of 
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local tissue infiltration of eosinophils and edema in NP. This is the early step in 
learning the molecular events of inflammatory cell infiltrations in NP. Subsequent 
work is needed to localize these gene expression levels in specific cell types (e.g., 
eosinophils and neutrophils) and to determine their relationship with the 
bio-physiological functions of these infiltrating cell types.  
 
6.2.7 Other gene families associated with pathogenesis of NP 
In addition to the eosinophil/neutrophil-associated genes, the present microarray study 
also observed a variety of gene families which potentially contribute to the 
pathogenesis of NP by literature reviews. These gene families include the 
oxidant/antioxidant-related genes, edema-related genes, and mucin genes.  
 
6.2.7.1 Oxidant/antioxidant-related genes in NP  
Airways are exposed to high levels of environmental oxidants, yet they also have 
enriched extracellular antioxidants. Airways disease such as asthma, cysitic fibrosis, 
and chronic obstructive pulmonary disease have evidence of increased oxidative stress, 
suggesting that reactive oxygen (ROS) and nitrogen species (RNS) may overwhelm 
antioxidant defenses in these diseases. ROS include superoxide, hydrogen peroxide, 
and hydroxyl radical; while RNS include nitric oxide (NO) and its derivates such as 
nitrogen dioxide and peroxynitrite. Some key enzymes underlie the mechanisms of 
generation of ROS and RNS, including myeloperoxidase, NADPH oxidase, and nitric 
oxide synthases. While in response to oxidative stress, antioxidants are synthesized by 
their related enzymes including the families of superoxide dismutases (SODs), 
catalase, glutathione peroxidases (GPXs), glutathione S-transferasaes (GSTs), 
thioredoxins (TXN) and peroxiredoxins (PRDXs).  
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An imbalance of oxidants (e.g. ROS & RNS) and antioxidants has been regarded to 
play a role in the pathogenesis of NP. Eosinophils, neutrophils, macrophages, and 
lymphocytes are highly infiltrated in NP tissue and these inflammatory cells are 
considered to produce extensive ROS/RNS, which cause cellular and tissue damage 
[Dogru et al., 2001; Kang et al., 2004]. Dagli et al. reported a significant negative 
correlation between free radical-mediated peroxidation products and antioxidants in 
NP, suggesting high free-radical levels in NP can be related to reduced antioxidant 
levels or consumption of antioxidants by excess free radicals [Dagli et al., 2004]. Several 
oxidant/antioxidant related enzymes were found to change in GC-naïve NP as 
compared to controls in the current study. 
 
(1) Oxidant-related enzymes 
Our results showed up-regulation of some common oxidant-related enzymes (NOS2A, 
NOX4, and DUO1) in GC-naïve NP (Appendix II, Page 268). As discussed before 
(Chapter 6.2.6, Page 189), NO induced by NOS2A could disrupt Fas 
receptor-mediated apoptosis in eosinophils in NP [Hebestreit et al., 1998]. NADPH 
oxidase 4 (NOX4) and Dual oxidase 1 (DUO1) are the major NADPH oxidases 
expressed in airway epithelium and also in eosinophils/neutrophils. The principal 
function of NOX4/DUO1 is to catalyze transmembrane transfer of electrons form the 
cytosolic electron donor NADPH to the electron acceptor – O2, leading to the 
production of O2- [Geiszt et al., 2004]. O2- has a very short half-life due to its rapid 
reaction with other radical species and its spontaneous formation of hydrogen 
peroxide (H2O2). Therefore, increases of NADPH oxidases can increase the release of 
ROS from epithelial cells and eosinophils/neutrophils, leading to damage of nasal 
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epithelium. In addition, NADPH oxidase enzymes are also involved in inflammatory 
signaling in airway diseases. For example, the Th2 cytokines could induce epithelial 
expression of DUOX1 in allergic asthma [Harper et al., 2005], and DUOX1 was 
associated with airway acidification [Schwarzer et al., 2004]. Both NOX4 and DUO1 
have been suggested to induce overexpression of mucin 5AC (MUC5AC) in chronic 
inflammatory airway diseases with mucus hypersecretion [Kim et al., 2008; Shao et al., 
2005].   
 
(2) Antioxidant-related enzymes 
Several antioxidant-related genes including oxidation resistance 1 (OXR1), 
superoxide dismutase 3 (SOD3), glutathione peroxidases 3 (GPX3) and 
lactoperoxidase (LPO) were down-regulated in GC-naïve NP (Appendix II, Page 
268). OXR1 localizes to the mitochondria, and can prevent and repair oxidative DNA 
damage by detoxification of ROS, leading to protection against spontaneous 
mutagenesis and cell death [Volkert et al., 2000].  
 
SOD3 belongs to the superoxide dismutases (SODs) family, which potently 
counteract against superoxide radicals. SODs not only catalyzes the dismutation of 
two superoxide radicals into H2O2 and O2 [Zelko et al., 2002], but also modulates nitric 
oxide-mediated signaling associated with bronchodilation [Jonsson et al., 2002]. SOD3 is 
distributed in extracelluar regions, and abundant in airway epithelium [Su et al., 1997]. 
Thus, SOD3 can protect airway tissues from oxidative stress and lead to reduction of 
airway hyper-responsiveness [Assa'ad et al., 1998]. Decreased expression and activity of 
SOD3 was found in asthma and NP, indicating the excessive ROS/RNS injury in these 
airway diseases [Cannady et al., 2007; Comhair et al., 2005;]. 
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Following SODs dismutase two superoxide radicals into H2O2, the glutathione system 
can decompose organic and inorganic hydroperoxides. GPX3 belongs to the GPX 
enzyme family which requires reduced glutathione to serve as the electron donor 
[Comhair et al., 2002]. GPX3 is the plasma GPX that has been detected in the epithelial 
lining fluid of the human lung [Comhair et al., 2001]. GPXs not only reduce ROS (e.g., 
H2O2 and O2-), but also protect against nitric oxide-mediated protein oxidation by 
regulation of RNS (e.g., peroxynitrite) levels in airway inflammatory diseases 
[Comhair et al., 2002].  
 
LPO is another major contributor to H2O2 consumption. LPO uses H2O2 to oxidize the 
anion thiocyanate to an antibiotic compound (hypothiocyanate) that prevents growth 
of bacteria, fungi, and viruses in airway tissues. Unlike other members of this 
peroxidase group, including myeloperoxidase (MPO) (present in neutrophil and 
monocytes) and eosinophil peroxidase (EPO), LPO is mainly present in epithelial 
cells. Most importantly, LPO generated hypothiocyanate is a weak oxidizing agent 
and is not as toxic as the hypochlorite species produced by MPO and EPO. Hence, it 
may provide less damaging antimicrobial activity than the recruitment of granulocytes 
to prevent the airway mucosa from infection.  
 
However, some antioxidant enzymes were up-regulated in GC-naïve NP, including 
GCLM, TXN, PRDX1, and PRDX5. The increase of these antioxidant enzymes in NP 
could be a compensatory mechanism to prevent tissue damage. However, 
up-regulation of only these four enzymes may not be sufficient to scavenge the 
increased ROS/RNS in NP as it may not compensate for the decreased levels of other 
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antioxidant enzymes (OXR1, SOD3, GPX3, and LPO) and increased levels of 
oxidases (NOS2A, DUO1, and NOX4). 
 
(3) Oxidant/antioxidant-related enzymes in response to GC treatment 
GCs appear to affect both antioxidant and oxidant levels during airway inflammation 
[De Raeve HR et al., 1997; Dweik et al., 1997; Rocksén et al., 2000]. However, our results 
demonstrated that only GPX3 responded to GC therapy, indicating the important roles 
of the glutathione system on prevention of oxidative stress in NP, leading to reduction 
of tissue damage. Whether GCs have beneficial effects on antioxidants in NP remain 
to be further investigated. Nevertheless, our study reviewed groups of 
oxidant/antioxidant related enzymes in NP, indicating the imbalance of oxidant and 
antioxidant levels may increase the oxidative burden in NP and then contribute to 
epithelial damage in NP.  
 
6.2.7.2 Genes related to edema in NP 
Stromal edema is the typical histopathological feature of NP. Two gene families were 
found to be associated with edema formation in NP, including bioelectric genes and 
angiogenesis-related genes. 
 
(1) Bioelectric genes 
Airway epithelial cells maintain the volume and composition of airway surface liquid 
via regulation of transepithelial ion transport [Boucher, 1994], i.e., water transport 
across the epithelial tissues (secretion and absorption) is regulated by anion (Cl⎯) 
secretion and/or cation (Na+) absorption. The permeability of Cl⎯ is regulated by 
chloride channels and their regulators; while Na+ enters the epithelial cells via sodium 
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channels in the apical surface, and then it is “pumped out” via the basolateral surface 
by Na-K-ATPase.  
 
As introduced in Chapter 1.4.7 (Page 23), deregulation of fluid and electrolyte 
transport has been considered as one hypothesis of edema formation in NP [Bernstein et 
al., 1997]. Our results showed an up-regulation of the nonvoltage-gated sodium channel 
(SCNN1A, SCNN1B, and SCNN1G) and chloride intracellular channels (CLIC3, 
CLIC5, and CLIC6), but down-regulation of Na-K-ATPase in NP compared to 
controls. The sodium channels (SCNNs) were reported to be expressed higher in NP 
as compared to paranasal sinus mucosa and the correlation of the Na+ absorption with 
mRNA expression of sodium channels was significant [Yasuda et al., 2007a]. An increase 
of activation of CCLs in NP would enhance anion (Cl-) influx and consequently this 
hyperpolarization would increase the Na+ absorption [Yasuda et al., 2007b]. The sodium 
pump (Na-K-ATPase) located on the basolateral surface of the epithelial cell 
transports ions by consuming ATP and pumping Na+ out of the cell in exchange for K+ 
influx to maintain Na+ and K+ gradients [Stern et al., 2000]. The expression patterns of 
these ion channels/enzymes suggest that the increase in sodium absorption and 
chloride permeability across the cells in NP would allow water to be absorbed through 
the epithelium into the interstitial space and may account for the edema in NP.  
 
Although GC treatment significantly reduced the edema in NP samples, we did not 
find the expression of these ion channel-related genes was changed by GCs. It is 
possible that GCs may indirectly regulate the ion channel/enzyme activity instead of 




(2) Angiogenesis-related genes 
Angiogenesis is the result of a highly orchestrated series of molecular and cellular 
events, resulting in the migration, proliferation, and differentiation of endothelial cells 
into newly formed capillaries that can subsequently develop into more mature vessels. 
Angiogenesis-related genes are not only associated with vascular development, but 
are also involved in the formation of edema in airway inflammatory diseases (such as 
asthma and NP) [Jones, 2003]. For example, an increase of VEGF was found to be 
associated with microvascular permeability in asthma and NP [Gosepath et al., 2005; Lee 
et al., 2008; Muluk et al., 2007]. Our results found there was a down-regulation of several 
angiogenesis-related genes in GC-naïve NP, including ANGPT1 and ANGPT2 (from 
angiopoietin family) and their receptor (TEK).  
 
The angiopoietin family and its related receptor (TEK) are essential in regulating 
vascular development and maintenance of vascular integrity [Jones, 2003]. More 
interestingly, the ANGPTs/TEK signaling pathway plays an important role in 
modifying the inflammatory response in airway inflammation, especially inhibition of 
vascular permeability [Fiedler & Augustin., 2006; Kanazawa et al., 2007]. To reduce vascular 
permeability, ANGPTs/TEK interacts with integrins to stabilize tight cell-cell 
adhesion among endothelial cells and counteracts vascular endothelial growth factor 
(VEGF)-mediated leakage effects [McDonald, 2001]. Although GCs significantly relieve 
edema in NP, none of these angiogenesis associated genes were altered after GC 
treatment. Whether the GC effects on vascular permeability in NP was related to 
alteration of the angiogenesis genes needs to be further clarified. Nevertheless, 
reduction of ANGPTs/TEK may contribute to the increase of vessel leakage, leading 
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to mucosal edema in NP. 
 
6.2.7.3 Mucin genes in NP 
Mucus is the layer that covers, protects, and lubricates the luminal surfaces of 
epithelial respiratory, gastrointestinal, and reproductive tracts. Airway mucus is 
composed of water, ions, lung secretions, serum protein transduates, anti-microbial 
proteins and mucus glycoproteins (mucins). The viscoelastic properties of mucus are 
mainly determined by the presence of mucins that are high molecular weight proteins 
extensively synthesized and secreted by submucosal glands and epithelial goblet cells 
[Rose et al., 2001]. Genes encoding for 19 human mucin proteins and the mucins have 
been categorized in two distinct families [Moniaux et al., 2001]: (i) secreted mucins (e.g. 
MUC2, MUC5AC, MUC5B, and MUC7); (ii) membrane-bound (surface) mucins (e.g. 
MUC3, MUC4, MUC16, and MUC20).  
 
Mucus hypersecretion as well as mucus obstruction is one of the main symptoms of 
NP. Several mucin genes such as MUC4 and MUC5 which have been studied in NP 
and submucosal glands have been considered to play a major role in mucin gene 
expression in NP [Ali et al., 2005; Ali and Pearson, 2007; Martínez-Antón et al., 2006]. In our 
study, we found three cell surface-associated mucin genes (MUC4, MUC16, and 
MUC20) were up-regulated, but one secreted mucin gene (MUC7) was 
down-regulated in GC-naïve NP compared to controls.  
 
MUC4 is commonly expressed in airway epithelium from both healthy and diseased 
tissues [Ali et al., 2005; Martínez-Antón et al., 2006]. However, Ali et al. showed that MUC4 
was rarely expressed in submucosal glands from control nasal mucosa, but was 
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extensively expressed in enlarged glands from NP [Ali et al., 2005]. MUC16 has been 
well known in epithelial origin cancer (such as ovarian carcinoma) [Yin and Lloyd, 2001] 
and been found to be expressed in tracheal surface epithelium and submucosal glands 
in the bronchial epithelial cells [Hattrup and Gendler, 2008]. MUC20 is a novel mucin 
marker and up-regulation of MUC20 was involved in renal injuries [Higuchi et al., 2004]. 
Our H&E staining results showed clearly different patterns of gland structure between 
NP (dilated glands) and controls (small branched glands) (Figure 6.1, Page 91) and 
thus increase of MUC4, MUC16, and MUC20 expression may be attributed to this 
histological difference.  
 
In contrast to those membrane-bound mucins, MUC7 is an unusually small secretory 
mucin, sharing no homology with other MUC proteins [Bobek et al., 1993]. Previous 
studies reported that MUC7 was exclusively detected in submucosal glands from 
healthy nasal mucosa but not from NP. MUC7 was not expressed in the epithelial 
region of airway tissues [Ali et al., 2005; Martínez-Antón et al., 2006]. Therefore, the 
reduced MUC7 content in NP may be associated with the increase of mucin secretion, 
indicating the enhancement of mucus in the lumen of hypersecretion glands.  
 
Although GCs significantly suppress eosinophil infiltration in NP and effectively 
decrease polyp size, we did not find that GCs have any effect on mucin expression. 
Our results are in line with the previous study which also found no response of 
MUC5AC to GCs in NP [Burgel et al., 2004]. We found that the extent of submucosal 
glands was not significantly different in NP before and after GC treatment, indicating 
GCs may not inhibit mucus hypersecretion in NP. Therefore, the unchanged 




Part III Conclusion 
We have explored the molecular mechanisms underlying the pathogenesis of NP and 
its response to GC treatment. Utilizing the pathway analysis, down-regulation of the 
AP-1 network, anti-inflammatory gene network, EGF/EGFR signaling, PGE2 
signaling, IL-6 signaling, up-regulation of apoptosis signaling, complement system, 
leukotriene signaling, ERK/MAPK signaling, and NF-kappaB signaling have been 
considered to contribute to NP pathogenesis. 
 
Our data suggest that AP-1 (especially c-Jun) and its related gene network are central 
molecular effectors of epithelial damage and repair in NP, which can be modulated by 
GC treatment. Moreover, the anti-inflammatory effect of GCs is considered to 
up-regulate the expression level of negative regulators among the inflammatory 
signaling pathways and down-regulate the pro-inflammatory genes in NP. The 
interaction and relation between AP-1/AP-1 related genes and 
anti-inflammation-related genes are documented. The dramatic modulatory effects of 
GCs on NP epithelium could also be readily demonstrated in histological observation. 
Hence, we provided in vivo evidence to support the notion that the beneficial effects 
of GCs in NP may be related to its ability to promote epithelial repair without 
uncontrolled remodeling (i.e., anti-inflammatory function), potentially via its 
regulation of the AP-1 gene network. 
 
Combined infiltration of esoinophils and neutrophils as well as edema is prominent in 
the stroma of NP from Chinese patients. GCs potently suppress eosinophils and 
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edema in NP, but have no effect on neutrophil infiltration. We have profiled 
eosinophil- and neutrophil-associated genes based on reports in the literature. 
Although only a few of these genes responded to GC treatment, their expression 
patterns are thought to be associated with eosinophil- and neutrophil-infiltration in NP. 
In addition, the cross-relationship of these genes in eosinophil and neutrophil 
biological process indicates the potential interaction of these two common 
inflammatory cell types in NP. Other gene families such as 
oxidant/antioxidant-related genes, edema-related genes, and mucin genes have also 
been reviewed in this study. These genes are regarded to be associated with some 

















Chapter 7. Conclusions and Suggested Future Studies 
7.1 Summary of important findings 
This thesis studies the molecular mechanisms underlying the pathogenesis of NP and 
its response to GC treatment. Although negative results which were not anticipated 
initially came out in the superantigen and methylation studies, they eventually 
provided valuable information as to the pathogenesis of NP. The presence of S. aureus 
as well as its superantigens may not be significant in Asian NP, indicating the 
different pathological profiles underlying Asian and Caucasian NP. Our study 
demonstrates for the first time that methylation of common TSGs can be detected in 
NP as well as control nasal mucosa, indicating that the role of methylation of these 
TSGs in nasal mucosal inflammation appears to be minimal. 
 
The most significant findings in this thesis are the identification of NP associated 
genes and the GC responsive genes as well as their related network pathways in NP 
based on the advanced microarray analysis methods. As far as we know, it is the first 
study to investigate the gene expression profiles and their interactive networks in NP 
before and after oral GC treatment and to systemically explore the NP associated 
genes in Chinese NP in a genome-wide manner. There are two main approaches to 
identify the interested genes, the IPA pathway analysis and literature review. 
 
Pathway analysis revealed that down-regulation of AP-1 network, anti-inflammatory 
gene network, EGF/EGFR signaling, PGE2 signaling, and IL-6 signaling and 
up-regulation of apoptosis signaling, complement system, leukotriene signaling, 
ERK/MAPK signaling, and NF-kappaB signaling would be involved in NP 
pathogenesis. GCs are considered to perform two major beneficial effects in NP: 
 210
epithelial repair and anti-inflammatory function, leading to a proper epithelial 
restitution. AP-1/AP-1 related genes are supposed to promote epithelial remodeling 
from the damaged NP epithelium; while the regulation of inflammatory related genes 
(especially the negative regulators of inflammatory signaling) are supposed to control 
aberrant epithelial remodeling. So these two types of the genes would contribute to 
the regulatory effect of GCs on epithelial repair. AP-1 (especially c-Jun) is considered 
the core gene underlying these GC-mediated beneficial effects. Although the actual 
role of these genes and gene interactions in the pathway picture requires careful 
functional evaluation, the network may contribute to understanding the key biological 
functions and pathways that are altered during GC treatment in NP. 
 
Based on the literature review, eosinophil- and neutrophil-associated genes were 
applicable to differentiate eosinophilia and neutrophilia in nasal samples, and were 
proposed to participate in the biological process of these two major inflammatory cell 
types in Chinese NP. In addition, the histopathological features of NP are also 
attributed to the change of other genes/gene families in NP, such as 
oxidant/antioxidant related genes, edema related genes, and mucin genes. Therefore, 
these disease-related genes supply a comprehensive molecular profile for Chinese NP, 
and such information will ultimately prove useful for researchers in providing new 
insight into the pathogenesis and treatment of NP.  
 
7.2 Limitation of the current study 
Although we tried to reduce the potential confounding/variation factors during the 
experiment, there are several limitations to this thesis that could be rectified in future 
investigations. We have recruited a relative small number of NP and control subjects 
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in this gene expression study. Subsequent follow-up studies using a large pool of 
patients are needed to verify the important findings. Another potential shortcoming is 
the analysis of NP versus nasal mucosal control. Since there are various cell types in 
NP but not in control tissues, some of the findings may reflect the differences in the 
cellular makeup of the tissues. Such limitation can be improved by using the advanced 
microdissection technique to isolate the cell type of interest. An additional limitation 
of the current study is that the functional networks and their essential gene-gene 
interaction is deduced by an array modeling approach, which is based on a 
predetermined database knowledge and can only be considered as source of 
hypotheses. Therefore, functional testing will be needed for the rigorous evaluation of 
individual molecular interactions inferred by our database approach.  
 
7.3 Suggestions for the future work  
Our gene expression study provided a large amount of valuable information 
potentially associated with NP pathogenesis and the response of NP to GC treatment. 
Considering that the current study is a descriptive observation, future studies 
(especially functional studies) should be used to follow up this project. 
 
7.3.1 Future study for gene expression profiles in NP in response to nasal GCs 
Nasal (topical) GC is recommended the first-line treatment of NP [Fokkens et al., 2007]. 
Data generated from this study (with oral GCs) provide reference information for the 
evaluation of the effect of nasal GCs in the treatment of NP. Therefore, a study with 
similar design using nasal GCs will be performed in future. The comparison of the 
gene expression profile between oral and nasal GCs in NP treatment will give useful 
information to identify drug target genes. 
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7.3.2 Future study for AP-1 and AP-1 gene network 
Our study identified AP-1 and its gene network as the central effectors underlying the 
GC effects on NP, which mainly contribute to proper epithelial repair. To specifically 
target the epithelial cells, epithelium of NP could be microdissected from histological 
sections. Then expression of AP-1/AP-1 genes could be determined in a cell specific 
manner. In vitro functional study is also worth carrying out regarding the response of 
AP-1 and its mediated network to GC treatment. Epithelial cells can be isolated from 
fresh NP tissues and then treated with GCs; consequently expression of AP-1 genes 
can be determined at different time points. Moreover, those known AP-1 upstream 
activators/inhibitors and AP-1 downstream target genes along the AP-1 signaling 
pathways can be also evaluated. Factors related to epithelial repair (e.g., cell 
proliferation and migration) are evaluated. If the correlation between epithelial cell 
and AP-1/AP-1 related genes is confirmed, RNA interference technique can be 
applied to specifically knock down the expression of AP-1 genes and confirm the 
necessary roles of AP-1 in epithelial biological process. 
 
7.3.3 Future study for the anti-inflammatory genes in NP 
In response to GC treatment, a group of negative regulators (e.g., DUSPs, SPRYs, 
IKappaB, SOCS3, ANXA1, ZFP36, and SCGB1A1) of the inflammatory signaling 
pathways have been identified in our array study. This finding indicates one important 
mechanism of GCs in controlling the inflammatory response in NP. Again, a future 
study could target on this epithelial region. Epithelium can be microdissected from NP 
and expression level of these anti-inflammatory genes can be determined. Epithelial 
cells also can be isolated from NP for in vitro functional analysis. Epithelial cells can 
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be treated with GCs and the expression levels (both RNA and protein level) of these 
genes can be detected. Moreover, the expression and activity (or say phosphorylation 
status) of those inflammatory signaling factors (such as MAPKs, NFkappaB) can also 
be evaluated. Therefore, the activators and regulators in these major inflammatory 
pathways in response to GC treatment can be profiled in an in vitro cell model. 
 
7.3.4 Future study for eosinophil- and neutrophil-associated genes 
Our study reviewed series of eosinophil- and neutrophil-associated genes in NP. Some 
of them have not been reported in previous NP study. We will confirm the protein 
expression level of these genes first and try to localize these genes in specific cell 
types (e.g., eosinophils and neutrophils). In in vitro analysis, the cells can be isolated 
from NP tissues and the expression levels (both RNA and protein) can be assessed. 
Among the eosinophil- and neutrophil-associated genes of interest, specific gene 
knock-down methods (e.g., RNAi) for the over-expressed ones or gene induction 
methods for the under-expressed ones in NP can be performed in the cell model. 
Consequently, correlation analysis can be applied to evaluate the relation between 
eosinophil/neutrophil amount and the change of gene expression level in a functional 
manner. 
 
7.3.5 Future study for cancer-related genes in NP  
In the functional analysis by IPA, the most significant disease associated with NP 
related genes is cancer. Since some of the clinical characters of NP (e.g., high 
recurrence rate) is similar to tumor growth, whether NP is a benign neoplasm or only 
an inflammatory lesion has been discussed for a long time. Therefore, the observation 
of numerous cancer-related genes in NP in our current study indicates there could be 
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some potential link between the NP and tumor with regard to their pathogenesis. To 
study some cancer related mechanism in NP, methylation of TSGs is considered an 
interesting area to start. This is because we already found methylation of some TSGs 
in NP. In future work, we will focus on the epithelial region due to two reasons: (i) 
hyperplasia of NP epithelium (e.g., squamous metaplasia) may have some similar 
properties to the epithelium from tumors; (ii) epithelial cells are available to 
microdissect for downstream analysis in a cell-specific manner. In this case, DNA can 
be extracted from the microdissected epithelial cells, and the methylation profile of 
cancer-related genes can be assessed by using an array-based platform. The genes 
with different methylation status in NP as compared to controls are selected. The 
expression level of these interested genes is consequently evaluated. If the negative 
correlation between expression level and methylation status of the indicated gene is 
determined, this gene is regarded as a methylation candidate in NP. Furthermore, the 
relation between these methylation candidates and histopathological features or even 
prognosis (such as recurrence rate) of NP can be evaluated. 
 
In summary, the follow-up studies proposed here will open a new area in investigating 
NP pathogenesis and its response to GC treatment. It is ultimately useful to 
understand the beneficial roles of GCs in NP and develop some novel therapeutic 
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Appendix I Significant functions of the datasets  
 






Diseases & Disorders 
Cancer 2.82E-25 to 1.26E-03 554 
Developmental Disorder 2.08E-11 to 3.46E-04 135 
Inflammatory Disease 1.30E-09 to 1.26E-03 188 
Connective Tissue Disorders 3.59E-09 to 8.06E-04 168 
Cardiovascular Disease 1.51E-08 to 1.26E-03 130 
Immunological Disease 6.29E-06 to 1.21E-03 152 
Respiratory Disease 1.47E-05 to 1.26E-03 112 
Organismal Injury and Abnormalities 4.73E-05 to 8.01E-04 61 
Genetic Disorder 4.86E-05 to 1.26E-03  160  
Physiological System Development & Function   
Tissue Development 2.59E-15 to 1.26E-03 270 
Organismal Development 3.70E-12 to 5.66E-04 210 
Cardiovascular System Development and Function 6.97E-12 to 1.26E-03 154 
Tissue Morphology 4.39E-08 to 1.26E-03 227 
Organismal Survival   1.51E-06 to 5.82E-06 140  
Organ Development   8.95E-06 to 7.63E-04 145  
Tumor Morphology   1.47E-05 to 1.26E-03 66 
Immune Response 2.20E-05 to 9.57E-04   106 
Connective Tissue Development and Function 2.96E-05 to 1.26E-03 142 
Organismal Functions  2.45E-04 to 2.45E-04 19 
Molecular & Cellular Functions   
Cellular Movement 6.51E-15 to 8.89E-04 282 
Cellular Growth & Proliferation 9.88E-13 to 1.24E-03 456 
Cell Death 6.74E-12 to 1.19E-03 411 
Cellular Development 1.41E-10 to 1.26E-03 336 
Cell morphology 1.56E-08 to 1.26E-03 230 
Cell Cycle 4.14E-09 to 1.26E-03 197 
Cellular Assembly and Organization 9.50E-08 to 1.26E-03 155 
Gene Expression 1.80E-06 to 1.26E-03 268 
Cell-to-Cell Signaling and Interaction 1.94E-06 to 6.87E-04 122 











Diseases & Disorders 
Cancer 2.14E-12 to 1.38E-02 317 
Developmental Disorder 2.83E-11 to 9.51E-03 98 
Cardiovascular Disease 8.28E-06 to 1.20E-02 72 
Genetic Disorder 4.57E-05 to 1.38E-02 120 
Respiratory Disease 3.36E-04 to 1.38E-02 60 
Organismal Injury and Abnormalities 1.27E-03 to 1.38E-02 30 
Inflammatory Disease 4.73E-03 to 1.00E-02 101 
Immunological Disease 5.18E-03 to 5.18E-03 4 
Physiological System Development & Function   
Tissue Morphology 1.03E-08 to 1.18E-02 75 
Tissue Development 1.07E-06 to 1.38E-02 165 
Cardiovascular System Development and Function 1.03E-04 to 1.38E-02 91 
Organismal Development 1.23E-04 to 1.29E-02 122 
Organ Development 2.22E-04 to 1.38E-02 132 
Immune Response 3.03E-04 to 1.38E-02 65 
Immune and Lymphatic System Development 3.03E-04 to 1.38E-02 75 
Organ Morphology 7.93E-04 to 1.38E-02 48 
Connective Tissue Development and Function 1.01E-03 to 1.18E-02 64 
Tumor Morphology 1.55E-03 to 1.33E-02 22  
Molecular & Cellular Functions   
Cellular Movement 6.23E-08 to 1.38E-02 176 
Cell Morphology 8.00E-06 to 1.38E-02 151 
Cellular Assembly and Organization 2.92E-05 to 1.38E-02 112 
Cell Signaling 3.38E-05 to 1.38E-02 73 
Cellular Growth & Proliferation 5.00E-05 to 1.38E-02 266 
Cellular Development 6.93E-05 to 1.38E-02 190 
Cell-to-Cell Signaling and Interaction 7.56E-05 to 1.38E-02 101 
Lipid Metabolism 1.1E-04 to 9.51E-03 15 
Small Molecule Biochemistry 1.1E-04 to 1.38E-02 64 
















Diseases & Disorders 
Inflammatory Disease 5.43E-15 to 1.86E-04 33 
Cancer 1.24E-12 to 2.58E-04 51 
Cardiovascular Disease 2.37E-12 to 1.73E-05 23 
Connective Tissue Disorders 8.03E-12 to 1.86E-04 33 
Immunological Disease 1.78E-10 to 1.23E-04 29 
Organismal Injury and Abnormalities 1.47E-08 to 2.39E-04 16 
Genetic Disorder 9.19E-07 to 9.19E-07 7 
Respiratory Disease 3.44E-05 to 1.15E-04 6 
Developmental Disorder 1.10E-04 to 1.10E-04 14 
Physiological System Development & Function   
Organismal Functions  6.90E-10 to 1.27E-05 9 
Tissue Morphology 9.30E-10 to 2.28E-04 26 
Tissue Development 2.24E-08 to 2.32E-04 34 
Immune Response 3.54E-08 to 1.55E-04 29 
Organismal Development 6.69E-08 to 2.77E-05 25 
Tumor Morphology 2.67E-07 to 2.28E-04 11 
Organ Morphology 9.54E-07 to 8.06E-05 8 
Connective Tissue Development and Function 1.09E-06 to 2.46E-04 23 
Organ Development 1.13E-06 to 1.13E-06 18 
Cardiovascular System Development and Function 1.20E-06 to 2.52E-04 19 
Molecular & Cellular Functions   
Cell Death 1.83E-14 to2.15E-04 47 
Cellular Growth & Proliferation 1.08E-13 to 2.41E-04 53 
Cellular Development 9.50E-13 to 2.46E-04 41 
Cellular Movement 1.59E-12 to 2.52E-04 37 
Cell Cycle 3.63E-09 to 2.58E-04 25 
Gene Expression 3.94E-09 to 2.58E-04 31 
Cell-to-Cell Signaling and Interaction 2.15E-08 to 2.28E-04 27 
DNA Replication, Recombination, and Repair 1.38E-06 to 1.38E-06 13 
Cell Morphology 1.68E-06 to 1.82E-04 22 
Cellular Function and Maintenance 3.84E-05 to 2.28E-04 5 






Appendix II Fold change of interested genes in three datasets (measured by 
microarray and quantitative PCR) 
 
Fold difference assessed by means 
of microarray 






















ADAM8 1.61 NS NS N.A. N.A. N.A. 
ALOX5AP 2.61 NS NS N.A. N.A. N.A. 
ANGPT1 0.27 0.29 NS N.A. N.A. N.A. 
ANGPT2 0.34 0.36 NS N.A. N.A. N.A. 
ANXA1 NS NS 5.91 N.A. N.A. 4.55 
AREG 0.22 NS 6.47 0.01 NS 6.7 
ATP1A2 0.34 0.35 NS N.A. N.A. N.A. 
Bid 1.65 NS NS N.A. N.A. N.A. 
C1QB 4.73 2.67 NS N.A. N.A. N.A. 
C3 2.64 2.21 NS 5.75 N.A. N.A. 
C4A 5.54 3.97 NS N.A. N.A. N.A. 
CASP3 1.73 1.60 NS N.A. N.A. N.A. 
CASP7 1.85 1.70 NS N.A. N.A. N.A. 
CCL11 3.87 NS NS 14.92 NS N.A. 
CCL15 4.68 3.76 NS N.A. N.A. N.A. 
CCL28 0.18 0.22 NS N.A. N.A. N.A. 
CD40 0.51 NS NS N.A. N.A. N.A. 
CD69 0.41 NS 2.99 0.05 NS 4 
CD86 3.39 2.38 NS N.A. N.A. N.A. 
CD9 0.51 NS NS N.A. N.A. N.A. 
CEACAM1 0.57 NS NS N.A. N.A. N.A. 
CEACAM6 6.06 4.68 NS N.A. N.A. N.A. 
CFH 0.49 NS NS N.A. N.A. N.A. 
c-Fos 0.08 NS 14.85 0.02 NS 14.2 
c-Jun 0.29 NS 3.39 0.06 NS 4.9 
CLIC3 2.03 NS NS N.A. N.A. N.A. 
CLIC5 1.85 NS NS N.A. N.A. N.A. 
CLIC6 3.57 4.41 NS N.A. N.A. N.A. 
COX-2 0.38 NS 3.47 0.17 NS 5.51 
CRISP3 0.01 0.14 NS N.A. N.A. N.A. 
CXCL11 NS NS 0.4 N.A. N.A. 0.35 
CXCL12 0.34 0.32 NS N.A. N.A. N.A. 
CXCL2 0.61 NS 5.42 0.14 NS 7.45 
CXCL6 7.65 6.09 NS N.A. N.A. N.A. 
CXCL9 NS NS 0.4 N.A. N.A. 0.4 
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Fold difference assessed by means 
of microarray 






















CYSLTR1 2.92 3.05 NS N.A. N.A. N.A. 
DEFB1 3.93 2.53 NS N.A. N.A. N.A. 
DUOX1 6.67 2.56 NS N.A. N.A. N.A. 
DUSP1 0.1 NS 4.98 0.12 NS 8.35 
DUSP2 0.18 NS 3.19 0.06 NS 2.8 
DUSP4 0.21 0.32 NS N.A. N.A. N.A. 
DUSP5 0.22 NS NS N.A. N.A. N.A. 
DUSP6 0.34 NS 2.08 0.16 NS 2.5 
EGF 0.25 NS NS N.A. N.A. N.A. 
EGR1 0.08 0.36 7.81 0.01 0.12 12.3 
ERBB4 0.47 NS NS N.A. N.A. N.A. 
FosB 0.05 NS 16.67 0.01 NS 15.3 
GCLM 3.65 3.3 NS N.A. N.A. N.A. 
GPX3 0.38 NS 1.59 N.A. N.A. N.A. 
GRα   N.A. N.A. N.A. 0.31 0.34 1.2 
GRβ  N.A. N.A. N.A. UDab UDab UDab 
HBEGF 0.21 NS 5.45 0.06 NS 5.05 
IFNAR1 1.56 NS NS N.A. N.A. N.A. 
IL13RA2 0.49 NS NS UDa N.A. N.A. 
IL18 3.03 2.9 NS 4.37 N.A. N.A. 
IL5Ra 1.58 NS NS 9.85 NS N.A. 
IL-6 0.16 0.42 7.87 0.01 0.2 9.85 
IL6ST 0.59 NS NS N.A. N.A. N.A. 
ITGB2 2.62 NS NS N.A. N.A. N.A. 
JunB 0.24 0.37 3.37 0.06 0.15 3.15 
LGALS8 1.64 NS NS N.A. N.A. N.A. 
LGALS9 1.69 NS NS N.A. N.A. N.A. 
LPO 0.03 0.23 NS N.A. N.A. N.A. 
LTA4H 1.53 NS NS N.A. N.A. N.A. 
LTB4R 1.66 2.35 NS N.A. N.A. N.A. 
LYN 1.97 NS NS N.A. N.A. N.A. 
MIF 1.75 NS NS N.A. N.A. N.A. 
MMP7 6.43 2.48 0.47 8.62 4.05 0.5 
MMP9 3.48 NS 0.44 UDb UDb 0.45 
MUC16 11.12 11.21 NS N.A. N.A. N.A. 
MUC20 4.51 3.58 NS N.A. N.A. N.A. 
MUC4 5.47 5.48 NS N.A. N.A. N.A. 
MUC7 0.02 0.06 NS N.A. N.A. N.A. 
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Fold difference assessed by means 
of microarray 






















NFKBIA 0.65 NS NS 0.45 N.A. N.A. 
NFKBIZ 0.46 NS 2.22 0.23 NS 2.2 
NOS2A 3.96 6.76 NS N.A. N.A. N.A. 
NOX4 3.03 NS NS N.A. N.A. N.A. 
NR4A1 0.14 NS 4.36 0.03 NS 9.15 
NR4A2 0.11 NS 7.02 0.08 NS 6.25 
NR4A3 0.11 0.28 NS N.A. N.A. N.A. 
NRG3 0.23 0.29 NS N.A. N.A. N.A. 
OXR1 0.42 0.39 NS N.A. N.A. N.A. 
PLA2G10 2.51 2.53 NS N.A. N.A. N.A. 
PLA2G4A 2.61 3.28 NS N.A. N.A. N.A. 
PRDX1 1.62 NS NS N.A. N.A. N.A. 
PRDX5 1.79 NS NS N.A. N.A. N.A. 
PTGER2 1.99 NS NS N.A. N.A. N.A. 
PTGER3 0.15 0.29 NS N.A. N.A. N.A. 
PTGIS 0.26 0.25 NS N.A. N.A. N.A. 
PTX3 0.12 NS NS N.A. N.A. N.A. 
SCGB1A1 NS NS 5.51 N.A. N.A. 4.9 
SCNN1A 1.96 2.11 NS N.A. N.A. N.A. 
SCNN1B 4.93 6.04 NS N.A. N.A. N.A. 
SCNN1G 5.65 7.34 NS N.A. N.A. N.A. 
SELPLG 2.04 NS NS N.A. N.A. N.A. 
SERPINA1 3.18 3.48 NS N.A. N.A. N.A. 
SOCS3 0.31 NS 4.2 0.21 NS 3.8 
SOD3 0.39 0.47 NS N.A. N.A. N.A. 
SPRY1 0.33 NS 2.49 0.19 NS 2.1 
SPRY2 0.62 NS 2.11 0.51 NS 2.21 
SPRY4 0.62 NS 2.13 0.42 NS 2.03 
STAT3 0.58 NS NS N.A. N.A. N.A. 
TEK 0.31 0.41 NS N.A. N.A. N.A. 
THBD 0.22 NS 2.63 0.09 NS 2.7 
TXN 1.64 NS NS N.A. N.A. N.A. 
ZFP36 0.17 NS 3.77 0.11 NS 5.35 
z NS, No statistical difference; 
z UDa, Undetectable in NP (either GC-naïve or GC-treated);  
z Udb, Undectable in control;  
z Udab, Undectable in both NP and control; 
z N.A., Not applicable. 
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   Appendix III Relative expression level of selected genes by real-time RT PCR 








ANXA1 5.45 3.50 N.A. 
AREG 12.85 8.98 6.59 
C3 2.15 N.A. 4.68 
CCL11 5.56 N.A. 9.52 
CD69 11.94 9.46 7.59 
c-Fos 5.74 0.97 0.13 
c-Jun 7.67 5.26 3.6 
COX-2 9.26 6.8 6.72 
CXCL11 8.53 9.8 N.A. 
CXCL2 8.75 6.35 5.67 
CXCL9 5.45 6.32 N.A. 
DUSP1 4.52 1.00 1.47 
DUSP2 11.98 9.92 7.97 
DUSP6 5.75 4.57 3.06 
EGR1 5.31 1.86 -0.56 
FosB 10.59 5.31 4.52 
GRα  8.10 7.97 6.41 
GRβ  UD UD UD 
HBEGF 8.45 5.66 4.61 
IFNAR1 N.A. N.A. N.A. 
IL13RA2 UD UD UD 
IL18 10.37 N.A. 12.36 
IL5Ra 9.67 N.A. 12.22 
IL-6 13.24 9.12 6.82 
JunB 5.19 3.98 1.01 
MMP7 6.41 7.51 9.18 
MMP9 5.89 7.33 UD 
NFKBIA 3.40 N.A. 2.18 
NFKBIZ 7.85 6.23 5.67 
NR4A1 7.43 3.26 2.19 
NR4A2 7.82 5.19 4.09 
SCGB1A1 11.72 9.29 11.99 
SOCS3 5.68 4.05 3.40 
SPRY1 9.79 9.15 7.47 
THBD 8.45 7.09 5.05 
ZFP36 5.09 3.21 1.88 
z UD, Undetectable  
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